Highlights
Updated Nov 12, 2026, 10:15 PM ET- Nvidia is in crisis after CEO Jensen Huang’s admitted affairs and alleged ties to a Chinese spy, triggering FBI/DOJ/national security probes, Democratic and Republican congressional inquiries, class-action litigation, and scrutiny of Megaspeed chip exports and large China-related deals; Huang has resigned as CEO and director, Colette Kress is interim CEO, Harvey Jones is chair, and Nvidia stock is down roughly 30–34% from its high with single-day drops of 5–11% and >$300B in market cap lost, while rivals AMD and Broadcom gain and Chinese GPU makers rally.
- Kalshi odds put only a 30% chance on Huang remaining as CEO amid succession concerns and heavy Wall Street focus on the stability of Nvidia’s $164.5B+ in funding commitments and $750B+ deal pipeline.
- Northwestern Polytechnical University and other Chinese institutions are reportedly acquiring or renting restricted Nvidia H200 chips despite U.S. export controls, intensifying U.S. political pressure on Nvidia.
- Nebius cut its 2026 revenue outlook to $3B due to delays and fines at a New Jersey Microsoft-linked site, sending shares down 17%, but raised 2027 revenue guidance to $12–13B while planning $40B of 2027 capex; Microsoft has tightened oversight of late third‑party projects.
- CoreWeave posted Q3 revenue of $3.66B, up 168% YoY, but a $709M net loss; it is financing a $132.5B backlog via contract-backed loans instead of expensive unsecured debt, has raised prices ~35%, and now charges >$40M per MW annually on short-term contracts; despite Bernstein’s capacity-risk warning, strong results drove a 20% share surge and lifted peers like Nebius and Nvidia.
- Fractile raised $720M in a Series C at a $7B+ valuation to develop UK-based AI chips, targeting first shipments next year to secure domestic compute for the UK economy.
- OpenAI generated $10B in Q3 revenue, up 50% QoQ, but still has a deeply negative adjusted margin of -109%; Anthropic reported much larger Q3 revenue of $17B with an $81B annual run rate versus OpenAI’s $50B, while both face intense competition from major tech platforms and open-source labs.
- Anthropic has filed for a Nasdaq IPO under ANT, offering 825M shares at $70–78 for a $57.8–64.4B valuation and total proceeds of $84.6–93.7B including $26B of concurrent private sales to AMD, Broadcom, Google, Nvidia and others; a separate narrative pegs an aspirational $1.4T valuation and shows founders collectively selling shares worth $236–264M while retaining 51.1% voting power via Class F stock, and Reed Hastings committing $300M.
- OpenAI launched a beta Business Hub to let verified firms build specialized agents and track limited engagement metrics, positioning ChatGPT more as a discovery platform than a direct commerce hub; it also quietly acq-hired AI travel startup Odessia after the latter raised $6M from Sequoia and shut down.
- Anthropic introduced Claude Meetings, Whiteboards, Sheets and Claude Data for enterprise collaboration and analytics, embedding AI into calls, visual workspaces and data warehouses for Team and Enterprise customers.
- Meta’s Muse AI agent now has over 10M U.S. users, is available on Apple Watch, Wear OS and iPad, supports voice/text/video chat and avatar-based interactions, and offers a paid plan at $20/month for 500M tokens weekly; it is expanding to business calls for paid users and will add email creation for free users.
- Google upgraded Search to Gemini 4 Hydrogen, a faster (2.5x vs Gemini 3.8 Flash) multi-level reasoning model rolled out globally across consumer and developer surfaces including AI Studio, API and Pro/Ultra tiers.
- Google unveiled TPU 8tx (co-developed with AMD) and TPU 8i Max to reduce reliance on external chipmakers, adding on-the-fly training, enhanced security, and doubled memory/power, further deepening its AI infrastructure moat.
- AWS released AWS Emulator, a Rust-based local tool that emulates AWS APIs so developers can test workloads and agents without cloud charges, supporting multiple services and deployment modes via Linux packages and Docker.
- Databricks launched Genie, an AI agent aimed at companies with 150+ employees that executes multi-step tasks using custom ontologies and Unity Gateway for cost control, positioning Databricks as a horizontal AI-workflow layer.
- AI agents remain unreliable for complex unsupervised tasks; Plurai raised $13M seed to use synthetic data and digital twins to post-train small open-weight models, targeting cheaper, more robust agent behavior.
- Fireworks AI disclosed a second cyber breach in two months, exposing billing data, datasets and chat transcripts via a compromised cloud provider, with attackers apparently trying to monetize stolen LLM tokens.
- N-able temporarily disabled its N-Central product to patch zero-day vulnerabilities (Able2Shell) that allowed root access; though it reports no successful exploitation, the disclosure highlights enterprise software security risk.
- A coalition including Public Citizen sued Anthropic, Google, Meta, OpenAI and SpaceX in San Francisco seeking to halt AI development under California unfair-competition law, citing public health and extinction risks, adding legal overhang to the sector.
- New York’s RAISE Act requires AI firms with >$500M revenue to register by Jan 1, 2027, publish safety frameworks and report incidents within 72 hours, with fines up to $3M; California and Illinois have similar regimes, raising compliance costs for large AI players.
- Irene Solaiman warns that open AI platforms are increasingly targeted by hackers, with recent attacks on OpenCode, OpenAI and Fireworks prompting security tightening by Hugging Face and GitHub while they try to preserve researcher access.
- Matter’s Sundrop app uses on-device Apple Vision/Core ML to create baby-photo recaps without cloud or generative AI, charging $39.99/year, reflecting consumer demand for private, subscription-based AI utilities.
- a16z-backed Phota Labs raised $5.6M seed for an AI photo-enhancement app that personalizes styles while preserving authenticity via invisible watermarks and plans a freemium model and Android expansion.
- Helix, founded in 2025, raised $6M to build on-device voice identity tech for CAPTCHA replacement and distress detection; it explicitly cannot reliably detect lies or AI agents, limiting some high-risk use cases.
- Kora Systems is developing a new Linux OS with integrated AI and autonomous agents, targeting 50M users by 2027 and monetizing through subscriptions to its Cortex AI engine and agentic services.
- Adobe and Google expanded their strategic partnership: Acrobat will be embedded into Google Workspace, Gemini models will power AI features in Acrobat and Photoshop, and Google’s imaging/video models will feed Adobe’s Firefly, Premiere and Express, deepening cross-platform lock-in.
- Adobe’s MAX updates added Firefly Builder (beta), Model Context Protocol integration with ChatGPT, third-party model support, and new AI capabilities in Photoshop, Premiere and Topaz Labs plug‑ins, strengthening its AI-enabled creative suite.
- X introduced a video clipping tool that lets users cut and repost segments with source attribution and monetization via Original Content Rewards, boosting creator engagement and ad inventory.
- Spotify enhanced its AI DJ for 94M+ Premium users with multiple English and Spanish voices and less commentary, rolling out to 95 markets and reinforcing stickiness among paid subscribers.
- Reddit launched AI-powered Reviews for 10k products across platforms, aggregating community content into structured shopping guidance with abuse controls, likely improving ad and affiliate monetization ahead of the holidays.
- Google launched the Pixel Tag at $29.99, an item tracker using Bluetooth and UWB, with IP67 rating, loud speaker and replaceable battery, targeting Android users and competing with Apple’s AirTag.
- Amazon’s Ring created Ring Robotics with two AI-enabled devices: a $270 indoor Drone Cam (Jan 27) and a $1,000 Rover Cam for business patrols (Dec 16), using AI Pilot navigation to expand Ring’s hardware and subscription ecosystem.
- Cosm is partnering with Disney for immersive Star Wars dome films on 87-foot 12K screens in March to coincide with the franchise’s 50th anniversary, building on prior Hollywood collaborations to drive venue traffic and content revenues.
- X launched an enhanced live-streaming and creator ecosystem earlier in the year (long-form video, paywalled threads, live-streaming studio grants), now adding clipping and reward structures to deepen engagement and revenue.
- Nebius, CoreWeave, Fractile and broader AI-infrastructure investment underscore that AI data-center capex is surging, with much of the physical buildout funded through long-dated contracts and leveraged balance sheets, creating both growth optionality and leverage risk.
- AI-sector commentary highlights uncertainty about long-term profitability, potential commoditization of models, heavy infrastructure needs, and regulatory/tax risks, even as current leaders like Nvidia and TSMC enjoy outsized near-term economics.
- MIT’s use of Anthropic’s Fable 5.2 to prove the Aaronson‑Ambainis conjecture demonstrates AI’s growing role in frontier research, with PSI working to commercialize theoretical advances, potentially expanding AI’s scientific TAM.
- Nine Korean deep-tech startups, including AI brain-health winner Voinosis, pitched at DETO 2026 for TechCrunch’s Startup Battlefield, signaling a pipeline of new AI and robotics entrants aiming at the U.S. market.
- Kunal Shah plans to simplify WhatsApp via AI features such as summaries and bill-payment tools, pairing growth in financial services with a strong privacy stance to protect its 3B‑user base.
- Kora, Matter, Phota, Helix and similar startups show a trend toward on-device, privacy-focused AI products monetized via subscriptions rather than pure ad models.
News Briefs
- NVDADemocrats launch inquiry into Trump admin Nvidia China sales after CEO Jensen Huang resigns amid spy allegations. Neal & Wyden seek records on Megaspeed routing & $26M donation to Trump projects. Republican groups demanded Huang testify before resignation. TechCrunch · 6h ago
- METAMeta's AI agent Muse now places business calls for paid subscribers, serving over 10M users. Plans start at $20/month for 500M tokens weekly. The feature avoids long hold times though some businesses reject AI voices. Email creation for free users is coming soon. TechCrunch · 6h ago
- MSFTNebius slashed 2026 rev to $3B despite $40B 2027 capex plan. Shares fell 17% after NJ Microsoft site delays caused by fines & generator issues. Microsoft tightened oversight on late 3rd-party projects. 2027 rev forecast raised to $12B-$13B. TechCrunch · 7h ago
- NVDANvidia founder Jensen Huang stepped down as CEO & board member amid reports of an affair with VP Kimberley Powell. CFO Colette Kress is interim CEO. Huang will testify before Congress regarding national security implications. TechCrunch · 8h ago
- GOOGLGoogle Search now uses Gemini 4 Hydrogen for complex queries. It runs 2.5x faster than Gemini 3.8 Flash, breaks prompts into subqueries, & offers 4 thinking levels including new xhigh tier. The model rolls out globally to all users, AI Studio, API, App, Pro, Ultra, & Antigravity. TechCrunch · 9h ago
- METANectar launched a Creator Agent to automate influencer marketing across 300M profiles for Instagram & TikTok. The tool raised $30M Series A in May as US creator ad spending is projected to hit $44B by 2026. TechCrunch · 10h ago
- MSFTMicrosoft Outlook is down globally due to elevated infrastructure load, forcing traffic redistribution. The admin center is unreachable. No specific cause given. Last major outage was in September. TechCrunch · 10h ago
- NVDANvidia CEO Jensen Huang stepped down amid affair allegations involving an alleged Chinese spy. Colette Kress is interim CEO. Huang supported OpenAI & pushed back on export controls. Nvidia agreed to pay $6B for Poolside tech & hasn't finalized a $13B Hugging Face deal. TechCrunch · 10h ago
- NVDAHugging Face CEO calls Nvidia's proposed $12.9B acquisition a sad day. DOJ inquiries began in October. Deal scheduled to close in H1 2027. Nvidia pledged to preserve open support & recently expanded its Nemotron open-weight models. TechCrunch · 11h ago
- UALUnited Airlines bans unauthorized AI agents for booking flights citing cybersecurity risks & federal regulation violations. Sharing credentials exposes sensitive info & breaches human check-in rules. Policies now prohibit AI use on platforms & via travel agencies. TechCrunch · 12h ago
- 9984.TSoftBank invested $30B in OpenAI $33B in a gas plant yet lost $7.1B due to overordering turbines to secure supply. CEO cites $3B price discovery for avoiding shortages as data centers seek energy security. TechCrunch · 12h ago
- a16z-backed Phota Labs uses AI to enhance photos while preserving authenticity. Features include style customization, preference learning & invisible watermarks. Launched with $5.6M seed round. Future plans include Android support & a freemium model. TechCrunch · 12h ago
- NVDAEx-Nvidia CEO Jensen Huang agreed to testify before the House Foreign Affairs Committee behind closed doors by Thanksgiving after threats of subpoena from Republicans Brian Mast, John Moolenaar, & Rick Crawford. TechCrunch · 12h ago
- NVDANvidia CEO Huang ousted amid affair, spy ties & smuggling reports. Republicans seek security testimony while Democrats probe $25M donation. $750B deals face scrutiny as Wall Street fears crash. Company enters post-founder era. TechCrunch · 12h ago
- NVDANvidia CEO Jensen Huang resigned Nov 12, 2026. Trump suggested Tim Cook as replacement after Cook stepped down from Apple in September 2026. Cook now serves as Apple's Executive Chairman. TechCrunch · 13h ago
- GOOGLWhoop launches Humans social network for data sharing. Features include FDA-cleared health tools, Medicare program, & Ulta retail expansion. 1,200 employees, 70% growth, 4M members projected. No data selling. CEO confirms future IPO plans. TechCrunch · 13h ago
- NVDAJensen Huang resigned as Nvidia CEO amid allegations of affairs with a Chinese spy and direct report. CFO Colette Kress assumed interim role. Kress, 59, with $1.2B net worth, commits to AI growth. Nvidia reports earnings Tuesday. TechCrunch · 13h ago
- WFCNorwest, backed by Wells Fargo, raised $4B for its 18th fund. It targets AI startups in US, India & Israel across consumer, healthcare & tech. Focus includes physical AI, voice AI, agentic cybersecurity & aerospace. Since its 17th fund, Norwest made 87 investments. TechCrunch · 14h ago
- Fireworks AI confirms cyberattack exposed billing info, datasets & chat transcripts after cloud provider breach. Systems disconnected Nov 3. Hackers appear financially motivated to sell LLM tokens. This marks Fireworks' second breach in two months. TechCrunch · 14h ago
- NVDAJensen Huang resigned as Nvidia CEO Nov 12 after admitting affairs with Kim Powell & spy Alice Huang. Board named Colette Kress interim CEO & Harvey Jones chair. Shares slid 5% amid national security probes into Megaspeed chip transfers to China. TechCrunch · 14h ago
- NVDAJensen Huang resigned as Nvidia CEO after admitting to an affair with an alleged Chinese spy. Collete Kress serves as interim CEO. Shares fell 11% as market cap dropped over $300B. Harvey C. Jones appointed first-ever board chair. Nvidia thanked Huang for contributions. TechCrunch · 15h ago
- DISCosm partners w/ Disney for Star Wars dome films in March, coinciding w/ the franchise's 50th anniversary. The experience features 87ft 12k screens, immersive backgrounds & a themed menu. This marks Cosm's sixth Hollywood collab, following Warner Bros. & Universal. CNBC · 15h ago
- 005930.KSNine Korean deep tech startups pitched at DETO 2026 for 200 Startup Battlefield spots. Voinosis won with an AI brain health tool. Others include Awesome Lab, Crosshub, DeepFusion AI, EFLOW, Otiton Medical, Riibotics, Ternell & Testbank. All target U.S. market entry. TechCrunch · 15h ago
- VOW3Scout Motors has 212k reservations for its Terra pickup & Traveler SUV, nearing completion of a $2B SC plant. Full production starts next year with deliveries in 2028. CEO Keogh expects orders to double, with 87% for EREV models & 75% for SUVs. CNBC · 17h ago
- NVDAKalshi gives Jensen Huang 30% chance to stay CEO amid admitted affair. Nvidia lacks succession plan. Potential candidates include Lisa Su, Eric Schmidt, Lip-Bu Tan, Bret Taylor, Ian Buck, Andrew Bell, Colette Kress, or wife Lori Huang. Board may keep him as chairman. TechCrunch · 1d ago
- NVDAJensen Huang admitted cheating on his wife with Alice Huang, a spy suspect. Nvidia board plans to oust him amid national security concerns & Megaspeed chip smuggling probe. Shares slid over 5%. Trump supports Huang. TechCrunch · 1d ago
- NVDANvidia's board meets Wednesday to decide CEO Jensen Huang's fate after he admitted an affair with a Chinese spy. Stock dropped 8% in after-hours trading and is down 11% in five days. Huang has 60 direct reports with no clear successor. TechCrunch · 1d ago
- NVDANvidia CEO Jensen Huang faces investigation for an affair with a woman accused of being a Chinese spy & a second alleged affair with VP Kimberly Powell. The board is looking into ousting Huang, while House Republicans plan to subpoena him regarding spy allegations. TechCrunch · 1d ago
- GILDUS accuses CANARX of illegal drug imports 2017-2026. Treasurer John Thomas Howard arrested Sunday; president Bob Howard at large. Company sources meds from Canada, UK, Australia, NZ. Gilead sues over HIV meds; FDA seized shipments in 2023. CNBC · 1d ago
- METAMeta's Santosh Janardhan steps down as head of infrastructure, replaced by ex-Amazon VP Dave Brown. Janardhan transitions to an advisory role on Meta Compute before leaving next year. The move comes as Meta boosts infrastructure investment to compete in the AI race. TechCrunch · 1d ago
- Firms with 4th+ funds captured 88.2% of US VC dollars in 2026 Q1-Q3 while first-time funds got 4.5%. Just 81 first-time funds closed, making 2026 the worst year in a decade. Yet small funds between $1M-$10M consistently outperform larger ones. TechCrunch · 1d ago
- MSFTCoreWeave Q3 revenue hit $3.66B, up 168% YoY, but net loss was $709M. To fund $132.5B backlog, it uses contract-backed loans, avoiding unsecured debt at yields over 15%. Prices rose 35% total, with short-term contracts exceeding $40M per megawatt annually. TechCrunch · 1d ago
- FTSEFractile raised $720M Series C led by Thrive, Founders Fund, Lightspeed & Redpoint, with backing from Britain's Sovereign AI Fund. Valued over $7B, the UK startup aims to ship AI chips next year to secure domestic hardware for its future economy. TechCrunch · 1d ago
- NVDAHouse Republicans plan to subpoena Nvidia CEO Jensen Huang over alleged China spy ties. Reps Mast, Moolenaar & Crawford seek a closed-door briefing. Moolenaar demands a response by end of day or face subpoena. Nvidia did not immediately comment. TechCrunch · 1d ago
- AALAmerican Airlines reintroduces fresh first class bites on NY-Chicago flights this month, including prosciutto & melon or Thai noodle salad. This marks the return of fresh food since 2019 as the carrier seeks to compete with Delta & United through premium upgrades. CNBC · 1d ago
- NVDAAI sector faces espionage beyond Nvidia scandal. Heron CEO Nate Singer cites execs crossing lines with state actors via jet incidents & 3+ cases. Semis are frequent trade secret theft targets. Sexual elements rarely public. Singer claims many condone activities. TechCrunch · 1d ago
- METAOpenAI Q3 revenue hit $10B, a 50% jump from Q2. Adjusted margin improved to -109%. Anthropic reported $17B Q3 revenue with an $81B annual run rate vs OpenAI's $50B. Both face competition from Meta, Amazon, Microsoft, Google, & open-source labs. TechCrunch · 1d ago
- TCKRHelix, a 2025 startup by Oberg, Dorofiyenko & Hall, raised $6M for on-device voice identity tech. Backed by Chicago Ventures & Siri's Kittlaus, it pilots CAPTCHA replacement & distress detection. CEO Oberg notes it cannot detect lies or AI agents reliably. TechCrunch · 1d ago
- JBLUJetBlue denies bankruptcy & restructuring plans as shares surged 40%. CEO Geraghty confirmed no layoffs. New BlueFirst seats launch next month. Targets operating profit next year & $1 EPS by 2028. Debt stands at $8.4B. Deutsche Bank upgraded stock citing conservative growth. CNBC · 1d ago
- Databricks unveiled Genie, an AI agent for firms with 150+ employees. It executes multi-step tasks via custom ontologies & Unity Gateway for cost control. CEO Ali Ghodsi demonstrated real-time advice & analysis of unvarnished feedback without external tools. TechCrunch · 1d ago
- NVDAAI agents lack reliability for complex unsupervised work. Startup Plurai uses synthetic data & digital twins to fix edge cases. Founders Ilan Kadar & Elad Levi secured $13M seed funding from Team8 to post-train small open-weight models for lower costs. TechCrunch · 1d ago
- NVDANvidia shares fell 9.5% in two days after CEO Huang admitted to an affair & suspected spying for China. The board hired Wachtell Lipton to investigate violations. A class action alleges securities fraud while experts criticize lack of succession planning & family employment. TechCrunch · 1d ago
- GOOGLX launched a new video clipping tool. Users can edit & post directly. "Clip from" links to sources. Creators earn via Original Content Rewards. This follows 2022 long-form updates, March paywalled threads, & July's $1M live-streaming studio grant. TechCrunch · 2d ago
- FOSLFossil Group hit Q3 profitability with $25.3M op income & $11.7M net. Sales up 0.4% to $271.2M, fueled by 15.1% Asia growth. Raised FY guidance to $980-$985M, expects positive free cash flow by year-end, & plans smaller retail base for 2027. CNBC · 2d ago
- EXPEOpenAI quietly acq-hired Odessia, a 1-year-old AI travel agent founded by Francis Davidson. Odessia raised $6M from Sequoia before shutting down after helping users plan millions in travel. This follows OpenAI's July 2025 mention of travel as a key AI assistant use case. TechCrunch · 2d ago
- NY opened AI registration for firms >$500M revenue by Jan 1, 2027 under RAISE Act. Firms must publish safety frameworks & report incidents within 72 hours. Violations face fines up to $3M. Gov Hochul launched $55M AI safety center. CA & IL have similar laws. TechCrunch · 2d ago
- ROGSahir Raoof raised $27.5M for Proximal Ventures targeting AI drug development at pre-seed & seed stages with $500K-$1.5M checks. Backed six startups incl. ChronicleBio. LPs include SignalFire, Kleiner Perkins & former FDA official Amy Abernethy. TechCrunch · 2d ago
- DOWX-energy gained US approval for four Xe-100 reactors at a Dow Texas plant, marking the first advanced nuclear permit for an industrial site. Amazon invested $500M and pledged 5GW capacity. Critics question safety. Shares trade below IPO price despite 2030s start. TechCrunch · 2d ago
- GOOGLAnthropic plans IPO valuing firm at $1.4T with shares priced $70-$78. Seven co-founders leave OpenAI in 2021 to prioritize AI safety. Each founder sells 3.4M shares for $236M-$264M. Founders retain 51.1% voting power via Class F stock. Reed Hastings buys $300M shares. TechCrunch · 2d ago
- Oura acquires Counsel Health for $625M after IPO delay. Counsel's CEO & 70 staff join to expand care. Deal closes by end of 2027. Oura hit $1.75B FY2026 revenue, up 92% YoY. TechCrunch · 2d ago
Research Briefs
- FREU.S. existing home sales fell 5.5% in October to a seasonally adjusted annual rate of 3.75 million units, marking the lowest level since August 2010. The median sales price for all existing homes dropped 0.4% to $416,700, while unsold inventory rose 1.3% to 1.59 million units, representing a 5.1-month supply. High mortgage rates, which reached 7.33% for the average 30-year fixed loan, continued to suppress housing demand across all regions except the Northeast, where sales remained flat. Haver Analytics · 1d ago
- Global economic momentum has softened as the world faces cheaper energy and dearer money. Brent crude prices fell from over $135 to around $91 per barrel due to growing hopes of a Middle East settlement, while US Treasury yields rose back toward 5 percent following stronger-than-expected core inflation. China's export growth is increasingly driven by technology sectors like semiconductors, whereas US corporate profits recovery relies heavily on finance and information industries. Forecasters have raised interest rate projections for 2027 more than inflation expectations, indicating that central banks may maintain restrictive policies for longer. Haver Analytics · 1d ago
- United Kingdom manufacturing output has increased for three consecutive months, driving three-month growth to an annual rate of 9.1%. While sector-level output shows expansion, industry-level data reveals uneven performance with significant declines in July and mixed trends across different goods categories. The Bank of England has raised interest rates in response to rising inflation, with the economy growing at an annualized quarterly pace of 2.8% in the third quarter. Recent economic trends indicate positive impacts from artificial intelligence, though future growth remains contingent on inflation control and geopolitical stability. Haver Analytics · 1d ago
- NVDAArtificial intelligence is described as a transformative technology with vast potential, yet its investment landscape is complicated by significant uncertainties regarding its evolution, profitability, and competitive dynamics. Key challenges include the difficulty in predicting which companies will succeed, the risk of commoditization reducing vendor profits, and the substantial infrastructure requirements involving data centers and compute power. While current leaders like Nvidia and TSMC are profiting from chip demand, the long-term outlook involves questions about AI's ethical alignment, regulatory taxation, and the potential for rapid shifts in market dominance. Oaktree Capital · 1d ago
- The buildout of AI data centers has contributed to strong business fixed investment, which now accounts for 17% of GDP, with AI investment representing roughly 1.7% of GDP. However, over 70% of the capital spending on these centers is imported, meaning the direct impact on GDP is largely offset by a widening U.S. trade deficit. Despite the muted direct GDP impact, the AI buildout has fueled a positive wealth effect and boosted consumption by raising profit and stock market expectations. While the pace of new projects may slow, numerous facilities are currently under construction or in planning stages across states including Texas, Virginia, Pennsylvania, Ohio, and Indiana. Haver Analytics · 2d ago
- German inflation metrics show mixed signals, with headline inflation falling in October while core inflation remains elevated. The HICP annual rate has eased to 2.6% over three months, and the domestic CPI excluding energy is at 1.6%. However, diffusion statistics indicate a broadening of price increases over the last three months, with 63.6% of categories showing acceleration. Oil prices, specifically Brent, have surged significantly, introducing uncertainty into future inflation forecasts. Economists suggest central banks should focus on communicating their goals and scenarios rather than making specific forward guidance on volatile variables like oil prices. Haver Analytics · 2d ago
- BACHousing cost pressures have extended across all income cohorts, with nearly one in four lower-income households spending at least half their income on rent. Similarly, about one in four higher-income households spend at least half their income on mortgages. While consumers have managed to keep spending on essentials like gas and groceries in check, housing remains a significant burden on household budgets across the income spectrum. Data indicates that the share of lower-income renters spending over 50% of their income on rent has increased from about one in five before the pandemic to nearly one in four in 2026. BofA Institute — Daily Insights · 2d ago
- GSNet sovereign bond issuance is projected to remain elevated in 2027 across the G4 nations. In the United States, Euro Area, and United Kingdom, net supply to the public is expected to be stable or lower compared to 2026. Japan stands as the only major sovereign bond market where economists anticipate a modest increase in net supply to the public for the coming year. Goldman Sachs Insights · 2d ago
- Japan's Economy Watcher Index slipped in October to a 46.1 diffusion reading from 47.0 in September, indicating a deterioration in the current economic assessment. The future economy watchers index also declined to 46.5 from 47.4, with only three of nine components showing improvement. Despite month-to-month declines, the index shows point-to-point improvement over three and six months, though the year-over-year change remains negative. Haver Analytics · 3d ago
- The NFIB Small Business Optimism Index slipped to 97.8 in October, remaining slightly below its 53-year average of 98.0. The Uncertainty Index fell to 84, the lowest level since December 2025, while expectations for the economy improved for the 24th consecutive month. Labor quality, taxes, and inflation were identified as the top three concerns facing small businesses, with hiring plans rising to 18% and average selling prices increasing to 33%. Haver Analytics · 3d ago
- Japan's Economy Watcher Index slipped in October to a diffusion reading of 46.1, down from 47.0 in September. While the index shows point-to-point improvement over three and six months, the 12-month change remains negative for the headline and most components. The future economy watchers index also declined to 46.5 in October, with year-over-year assessments lower despite modest gains over the last three and six months. Haver Analytics · 3d ago
- Southeast Asia is transitioning from assembling AI hardware to hosting data centers, with Malaysia, Thailand, and Singapore leading the expansion. Malaysia's Johor region has seen significant GDP growth driven by data center investments, though power and water constraints have led to new tariffs and approval caps. Thailand's digital industries captured nearly half of approved foreign direct investment in 2025, prompting a pause on new applications due to resource scarcity in the Eastern Economic Corridor. Singapore experienced a sevenfold rise in operating surplus for data processing but imposed a moratorium from 2019 to 2022 due to resource limits, redirecting some investment to neighboring Johor. Economic gains from these facilities often remain limited for local residents due to foreign ownership, high capital intensity, and low staffing requirements. Haver Analytics · 3d ago
- BACLower-income wage growth reached 4.7% year-over-year in October 2026, surpassing the 3.4% growth rate for higher-income households. This trend, which began earlier in 2026, is attributed to tax withholding impacts from the One Big Beautiful Bill Act and a broadening labor market characterized by increased job-to-job changes and raises. Middle-income households saw wage growth of 3.8% during the same period. The data is derived from aggregated consumer deposit account information provided by Bank of America. BofA Institute — Daily Insights · 3d ago
- The global AI investment boom has created widespread demand for semiconductor exporters, equipment manufacturers, and energy suppliers, with the United States at the center of this cycle. Asian producers supply chips while European and Japanese manufacturers provide sophisticated equipment, creating a tightly linked international supply chain. Political resistance to data center construction in the US and Europe poses a potential constraint that could delay physical investment and slow the expansion of the sector. The financial exposure is global, as pension funds and insurers share risks through equity portfolios, making a market correction a potential macroeconomic issue. Haver Analytics · 3d ago
- The global media rights market grew 41% since 2020, reaching approximately $57.8 billion in 2025 and projected to hit $67 billion in 2026, driven largely by live sports and streaming services. Institutional investment in sports has surged, with private equity transactions rising from 50 in 2018 to 192 in 2025, while the WNBA Valkyries achieved a valuation of $850 million, the highest in the league. A landmark settlement allowing college athletes to monetize their name, image, and likeness has transformed college football into a highly competitive commercial sport, prompting schools to seek new financing models. Investors are increasingly exploring international expansion, women's sports, and emerging leagues like Unrivaled to capture growth equity returns. Goldman Sachs Insights · 3d ago
- U.S. consumer prices rose more than anticipated in October, with the headline Consumer Price Index increasing 0.4% month-over-month and the core index rising 0.3%. Shelter and food prices were the primary drivers of the increase, contributing significantly to the headline rate. The year-over-year headline inflation rate climbed to 4.1%, the highest level since May, while the core rate reached 2.8%. Financial markets reacted strongly to the data, pricing in a near-certain 25 basis point interest rate hike by the Federal Open Market Committee in December. Haver Analytics · 3d ago
- Japan's leading economic index fell sharply in September to 116.4, down from a peak of 118 in August, though it remains marginally higher than readings from May and June. Consumer confidence has shown a mild year-over-year increase of 1.1% since April, despite a negative trend over the preceding 24 months. The Economy Watchers index indicates modest contraction in current conditions and expected future contraction, with both metrics below their historic medians. Despite these cooling indicators, the Bank of Japan is expected to proceed with a rate hike to address inflation, supported by fiscal stimulus. Haver Analytics · 4d ago
- BACThe U.S. equity market is expected to continue a bull market in 2027 following a typical midterm election pattern, with economic growth peaking in 2026 before moderating. China's integration into the World Trade Organization has led to a global convergence where Western nations increasingly adopt state-led industrial policies similar to China's model. Significant capital investment is projected for the Artificial Intelligence sector, with data center developers expected to spend over $1.4 trillion in 2027, raising concerns about financing costs and credit spreads. Market conditions suggest a shift toward higher-quality, less leveraged segments as financial conditions tighten and earnings momentum slows. Bank of America — Private Bank Market Update · 4d ago
- U.S. wholesale inventories increased by 0.7% in September, marking the eighth consecutive month-over-month gain and a 7.6% year-over-year rise, the fastest pace since March 2023. Wholesale sales surged 2.8% month-over-month, driven by strong demand in durable and nondurable goods sectors, while the inventory-to-sales ratio fell to 1.21, its lowest level since May. Durable goods inventories grew 0.6% led by electrical and electronic goods, whereas nondurable goods inventories climbed 0.9% primarily due to a rebound in petroleum products. Haver Analytics · 4d ago
- BACConsumer confidence has declined, leading to a record-high level of consumers trading down to lower spending tiers since 2021. This shift is characterized by households becoming increasingly value-conscious, often substituting premium purchases with standard or value options in categories like apparel, dining, grocery, and travel. The trend suggests that while total spending may remain stable, the composition of spending is moving toward more affordable options as households delay discretionary purchases. Data indicates that this behavior is observed across various income levels, with specific attention paid to how spending patterns are categorized based on merchant tiers. BofA Institute — Daily Insights · 4d ago
- SInvestors are advised to maintain long-term goals during market volatility, as missing the best trading days can result in near-flat cumulative returns. A bear market is defined as a decline of 20% or more from a recent peak, with the S&P 500 experiencing 14 such periods since 1932. Historical data indicates that bull markets have lasted an average of 4.9 years compared to 1.5 years for bear markets, with average returns of 177.6% versus losses of 35.1%. Strategies to navigate these periods include dollar-cost averaging, staying invested to avoid missing rebounds, maintaining asset diversification, and managing emotional reactions to market fluctuations. Stifel Insights · 6d ago
- ARMU.S. equities declined as selling in artificial intelligence-linked stocks outweighed gains elsewhere, with the S&P 500 falling 4.4%, the Dow Jones Industrial Average dropping 3.4%, and the Nasdaq losing 5.5%. Concerns that tighter restrictions on data center construction could slow the AI investment cycle, driven by Democratic victories in midterm elections, served as the dominant catalyst for the market move. While earnings reports from Arm Holdings and Qualcomm added pressure, economic data indicated continued labor market resilience with initial jobless claims falling to 189,000. Non-U.S. markets were mixed, with Germany's DAX falling 0.4% and Japan's Nikkei declining 1.8%, while the 10-year Treasury yield fell to 4.84% and Brent crude rose 4.1%. Stifel Insights · 6d ago
- Quantum computing is projected to become a major technological advancement by 2035, potentially generating $2 trillion in value across finance, materials, life sciences, and mobility. The boundaries between humans and machines are expected to blur through advances in bionics, including artificial limbs and brain chips, while vertical farming aims to ensure food security in growing cities. The U.S. power infrastructure is anticipated to rely more on small modular nuclear reactors to support a digitalized economy, and the space economy is predicted to triple to $1.8 trillion by 2035. Stifel Insights · 6d ago
- SFGlobal GDP is projected to increase by 14% by 2030 due to artificial intelligence, driven by automation and product enhancements. The U.S. faces a fiscal transition with rising debt costs, where household, corporate, and federal debt have increased significantly since the Great Financial Crisis. Inflation and Federal Reserve policy remain central to economic forecasts, with the Fed maintaining a data-dependent approach to interest rates while monitoring labor market strength. Geopolitical tensions, including the Israel-Hamas war and global election cycles, present risks of deglobalization and market volatility. Stifel Insights · 6d ago
- The Stifel NextGen Investor Handbook provides guidance for young adults entering the workforce, covering essential topics such as budgeting, saving, and investing. It outlines strategies for job hunting, including resume preparation and networking, while explaining financial principles like the 50/30/20 rule and the power of compounding. The guide details various investment vehicles including IRAs, 401(k)s, 529 plans, ETFs, and mutual funds, alongside advice on credit management, home buying, and tax planning. It further addresses life events such as marriage, starting a family, estate planning, and helping aging parents, concluding with sections on family mission statements and philanthropy. Stifel Insights · 6d ago
- AAPLU.S. companies are reporting strong third-quarter earnings with net profit margins near 13.1%, the highest since 2009. Major firms have announced approximately $1.5 trillion in multiyear investments for nearshoring and reshoring across technology, pharmaceuticals, and industrials. The artificial intelligence boom is driving a construction surge, with the U.S. hosting over 5,400 data centers, while government incentives like the CHIPS and Science Act accelerate corporate decisions to onshore production. This structural reindustrialization is transforming the workforce by creating higher-skilled, higher-wage manufacturing roles through automation. Stifel Insights · 6d ago
- IBMTechnological innovation is breaking down boundaries between physical, digital, and biological worlds, creating opportunities in data processing, artificial intelligence, and quantum computing. Global population dynamics are shifting, with the senior population expected to reach 1.6 billion by 2050 and the global middle class projected to grow by over 1 billion people by 2030. Companies and governments are prioritizing the development of critical resources, including food, water, energy, and new materials, while reshoring production to reduce foreign dependence. Geopolitical tensions are driving increased investment in defense modernization, space exploration, and the digital economy, with the global space economy potentially reaching $1.8 trillion by 2035. Stifel Insights · 6d ago
- U.S. GDP growth is forecast to range between 1.75% and 2.5% in 2026, with inflation expected to run between 2.25% and 2.75%. The Federal Reserve is anticipated to implement one or two quarter-point rate cuts during the year, while the 10-year Treasury yield is projected to remain between 4.0% and 4.5%. Artificial intelligence is viewed as a dual force driving productivity and capital investment while presenting macro risks if adoption slows. The S&P 500 is forecast to deliver a total return of approximately 10%, driven primarily by earnings growth rather than valuation expansion. Stifel Insights · 6d ago
- SIFThe global economic landscape is shifting from globalization toward increased localization, protectionism, and geopolitical uncertainty. Key risks identified over the next three to five years include intensifying U.S.-China competition, the potential for cyberattacks, and the emergence of competing geopolitical blocs. Specific military conflicts in the South China Sea, the Middle East, and Taiwan are assessed as likely or unlikely, with significant implications for global trade, energy markets, and supply chains. Investment strategies are advised to focus on cybersecurity, defense, energy efficiency, and sectors with strong pricing power to navigate these structural shifts. Stifel Insights · 6d ago
- The U.S. economy expanded at a 2.0% annualized pace in the first quarter of 2026, driven by resilient consumer spending and investment in artificial intelligence. Inflation reached 3.8% year-over-year due to oil supply shocks and geopolitical fragmentation, leading futures markets to price out Federal Reserve rate cuts for the year. U.S. equity markets have rebounded to record highs with S&P 500 earnings tracking toward 28% growth, while the 10-year Treasury yield is expected to remain between 4.0% and 4.5%. Geopolitical tensions involving the U.S., Israel, and Iran have caused temporary spikes in oil prices, though historical data suggests equity markets typically recover as uncertainty fades. Stifel Insights · 6d ago
- GOOGLThe U.S. and Iran are engaged in a conflict with four potential scenarios: a managed off-ramp, shadow war, severe tail, or regime change. The Federal Reserve held rates at 3.50%-3.75% in July 2026, with markets pricing in potential rate hikes through 2027 due to inflation concerns and geopolitical risks. Economic forecasts project 2026 GDP growth at 2.2%, while the Congressional Budget Office estimates a $1.8 trillion deficit pushing total debt over $40 trillion. Major market indices have shown rotation away from previous trends, with the S&P 500 trading at a premium to its 10-year average P/E ratio. Stifel Insights · 6d ago
- The S&P 500 advanced 15.2% in the second quarter of 2026 as markets stabilized following an unsettled start to the year. Under new Federal Reserve Chair Kevin Warsh, the central bank held rates steady at 3.5% to 3.75% while emphasizing price stability and shifting away from forward guidance. Geopolitical tensions eased after the United States and Iran reached a memorandum of understanding to wind down conflict and reopen the Strait of Hormuz. Inflation remained firm with the core PCE price index rising to 3.4% in May, leading to an upward revision of the full-year inflation forecast. Stifel Insights · 6d ago
- SPOTA survey of 150 Stifel summer interns reveals that 56% consider remote work unimportant, though most prefer working from home at least once a week. While 61% are comfortable with robots as restaurant waiters, 91% would not feel comfortable with an AI bot as a primary care doctor. Interns expect significant labor market transformation, with 31.9% predicting 15-20% of current jobs will be replaced by AI by the end of the decade, and 43% believe NVIDIA will be the largest of the Magnificent Seven companies in ten years. Stifel Insights · 6d ago
- GSGoldman Sachs analysts discuss market reactions following the US midterm elections, noting a significant rotation away from high-multiple AI data center stocks which have declined 36% from their year-highs. The discussion highlights a shift toward healthcare as a new defensive sector driven by AI applications in diagnostics and tools, while traditional staples are deemed overvalued due to low earnings yields. Analysts recommend investing in the S&P 500 excluding AI companies to access high-quality balance sheets with lower valuations, while monitoring inflation, employment, and the December 9th FOMC decision for future market direction. Goldman Sachs Insights · 1w ago
- GSNonfarm payrolls rose by 165,000 in October, exceeding forecasts and indicating a solid labor market trend above 100,000 jobs per month. The unemployment rate remained stable between 4.1% and 4.2%, consistent with full employment and subdued wage growth. Goldman Sachs Chief Economist Jan Hatzius projects GDP growth of 2% to 2.5% for the coming year despite tightening financial conditions and geopolitical risks. Additionally, AI adoption is currently reducing employment growth in the technology sector by 10,000 to 15,000 jobs monthly, with broader impacts expected by 2027. Goldman Sachs Insights · 1w ago
- GSFollowing the US midterm elections, the AI data center trade has seen significant corrections with valuations dropping to levels comparable to June lows. Goldman Sachs analysts suggest that traditional defensive sectors like staples are overvalued and recommend shifting focus to quality compounders outside the AI sector. Healthcare is identified as the next leg of the AI trade, offering a defensive play with accelerating growth drivers. Market participants are advised to monitor employment, inflation, and the Federal Open Market Committee decision scheduled for December 9th. Goldman Sachs Insights · 1w ago
- Nonfarm payrolls rose by 165,000 in October, significantly exceeding the expected increase of 65,000. The headline unemployment rate decreased to 4.1%, while the broad unemployment rate (U-6) increased to 7.9%. Average hourly earnings grew by 0.4% in October, resulting in a year-over-year change of 3.1%. Haver Analytics · 1w ago
- GSDavid Schwimmer, CEO of the London Stock Exchange Group (LSEG), discusses market conditions characterized by a shift from rational to irrational complacency due to geopolitical tensions and inflation concerns. Capital flows are experiencing crosscurrents as investors seek to diversify away from US concentration despite recent energy crises favoring US independence. LSEG is leveraging its extensive data assets as a critical component of the AI ecosystem alongside compute and models, while also driving cultural integration following the Refinitiv acquisition. Future market infrastructure is expected to evolve toward digitization and geography-independent capital raising facilitated by AI simplification. Goldman Sachs Insights · 1w ago
- German industrial production increased by 0.7% in September following a 1% rise in August, with consumer goods and capital goods sectors posting strong gains. Capital goods output demonstrated acceleration with an annualized pace of 8% over three months, while intermediate goods output showed contractions across sequential horizons. Survey indicators for the German economy have progressed toward strength over the last three months, though their historic percentile standings remain below the median. In contrast, France, Spain, and Portugal reported output increases in September, but their sequential trends were less positive than Germany's. Haver Analytics · 1w ago
- BACApproximately one-third of family offices are currently invested in sports teams, franchises, or related opportunities, with another 31% expressing interest. Direct ownership of sports teams is more prevalent among offices led by Gen Z or Millennial principals at 27%, compared to 20% for Gen X and 16% for Baby Boomers. A survey of 355 family office decision makers in the U.S. indicates that 79% of offices with a potential next-generation successor believe alternative investments will comprise a larger portion of their portfolios. The study was conducted online in January and February 2026 by Escalent for Bank of America Private Bank. BofA Institute — Daily Insights · 1w ago
- ARMU.S. equities declined as selling in artificial intelligence-linked stocks outweighed gains elsewhere, with the S&P 500 falling 4.4%, the Dow Jones Industrial Average dropping 3.4%, and the Nasdaq losing 5.5%. The primary catalyst was concern that tighter restrictions on data center construction could slow the AI investment cycle following Democratic victories in midterm elections. While earnings from Arm Holdings and Qualcomm provided mixed signals, economic data showed resilience with initial jobless claims falling to 189,000 and third-quarter productivity growing at a 3.6% annual rate. Stifel, Nicolaus & Company maintains a constructive outlook for the U.S. economy, forecasting real GDP growth between 1.75% and 2.5% for the year without predicting a recession. Stifel Insights · 1w ago
- GSEmerging market sovereign and corporate bonds have demonstrated increased stability and resilience despite global shocks such as the Iran war and rising oil prices. The asset class has matured from a monolithic risk trade into a diverse market with over 80 countries offering varied opportunities, supported by stronger fiscal policies and deeper local-currency markets. Corporate bond issuance has grown significantly, featuring globally competitive companies with improved transparency and standardized reporting under International Financial Reporting Standards. Investors are now focusing on credit selection and fundamentals rather than broad market trends, as the constraint of the US dollar on debt servicing has lessened. Goldman Sachs Insights · 1w ago
- BACPayroll growth moderated but remained resilient at 1.2% year-over-year in October 2026, according to Bank of America deposit account data. The number of households receiving unemployment payments fell approximately 5% year-over-year during the same period. Small and mid-sized firms showed strong growth in payments to hiring firms in September, indicating continued hiring plans. These findings suggest a labor market that is directionally consistent with resilience despite a peak in payroll growth over the summer months. BofA Institute — Daily Insights · 1w ago
- Initial unemployment claims in the United States fell by 6,000 to 189,000 for the week ending October 31, 2026. Continuing claims increased by 23,000 to 1.718 million for the week ending October 24, while the insured unemployment rate remained steady at 1.1%. State-level data showed the highest insured unemployment rates in Massachusetts, Washington, and New Jersey, with the lowest rates found in South Dakota, Louisiana, and Florida. These figures represent historically low levels of claims, matching the volume seen in mid-July. Haver Analytics · 1w ago
- German orders have shown a consistent trend toward stronger ground over the long term, though growth rates over the last year and shorter horizons are generally weakening. Domestic orders improved significantly over 12 months but fell sharply in the most recent three-month period, while foreign orders showed modest improvement over three months after degrading over six months. EU industrial confidence metrics for the Big-Four economies—Germany, France, Italy, and Spain—indicate a general progression toward improvement in sequential ratings, despite mixed performance over the last 12 months. Haver Analytics · 1w ago
- GSAI presents an opportunity for music labels and rights holders by enabling streaming providers and tech companies to personalize recommendations and curate content. This technology can transform passive listeners into active creators. Monetization is expected to return to rights holders, disproportionately benefiting higher-end artists whose image, likeness, melodies, or lyrics are used to create AI music. Goldman Sachs Insights · 1w ago
- GSAaru is a startup that uses advanced AI simulations to predict human behavior and population composition for business decision-making. The company fuses large language models with statistical and mathematical models to forecast consumer actions such as product purchases, marketing clicks, and transportation choices. Aaru claims to reduce product innovation cycles from months to weeks by simulating outcomes without processing personally identifiable information. The firm operates globally across over 130 countries and maintains SOC 2 compliance while not training its core models on client data. Goldman Sachs Insights · 1w ago
- The US midterm elections have resulted in Democratic control of both houses of Congress, creating a period of divided government during President Trump's term. This political shift, driven by concerns over living costs and the war with Iran, introduces mixed economic implications including potential limits on tax cuts and complications in budget negotiations. Global markets are facing diverging signals, with US loan demand weakening while lending to non-bank institutions expands, and sovereign bond markets reacting to stretched public finances in countries like France and Japan. Haver Analytics · 1w ago
- U.S. nonfarm business productivity surged 3.6% on a quarterly seasonally adjusted annualized rate in the third quarter of 2026, exceeding the 2.7% forecast and following an upwardly revised 2.1% gain in the second quarter. Output per hour increased significantly while compensation growth slowed to 2.9%, resulting in a 0.7% quarterly decline in unit labor costs. Manufacturing productivity growth decelerated to 0.3% in the same period, causing unit labor costs in that sector to jump 2.7%. Benchmark revisions extending back to 2021 showed modest but generally positive adjustments, raising the annual productivity growth rate from 1.50% to 1.62%. Haver Analytics · 1w ago
- GSGoldman Sachs President John Waldron describes the current economic environment as characterized by resilient nominal growth exceeding 6% in the US, despite higher inflation and interest rates. The firm anticipates a record year for mergers and acquisitions, driven by a strategic bias toward scale and significant capital raising for artificial intelligence infrastructure. Goldman Sachs is deploying a four-pronged AI strategy focused on employee literacy, software development efficiency, process automation, and client-facing tools. Additionally, the firm is expanding its asset management capabilities through targeted acquisitions of Industry Ventures, Innovator, NEO Investments, and LCN Capital Partners to fill specific market gaps. Goldman Sachs Insights · 1w ago
Interviews
More →- Jensen Huang Saga Tests AI Trade Ahead of Anthropic IPOFollowing allegations of three extramarital affairs and espionage involving a woman linked to China, NVIDIA's board removed CEO Jensen Huang and appointed CFO Colette Kress as interim leader while an independent chair addresses governance concerns. Jensen Huang faces a Senate Banking Committee hearing regarding security protocols, a development that may accelerate US export control legislation and prompt China to hasten its domestic chip manufacturing and AI partnerships. Despite the leadership upheaval, Asian markets rallied and NVIDIA shares recovered on strong supply chain demand, though analysts warn that interim conservative fiscal strategies could slow AI startup funding in the near term. Bloomberg Television · 44m ago
- Nvidia Fallout Looms Over Trump-Xi MeetingFollowing revelations of personal misconduct and a suspected link to Chinese espionage, NVIDIA CEO Jensen Wang stepped down, prompting CFO Colette Kress to assume interim leadership while the board initiates a search for a permanent replacement. The scandal triggered a $180 billion market value loss and spurred bipartisan congressional investigations into national security breaches and potential policy obfuscation involving Commerce Secretary Howard Lutnick. With a special prosecutor potentially under consideration, the fallout is intensifying diplomatic tensions ahead of President Trump's scheduled summit with Chinese President Xi Jinping while prompting calls for stricter semiconductor export controls in upcoming legislation. Bloomberg Television · 4h ago
- Allen Says US Needs Stronger Export-Control EnforcementInvestigations into semiconductor export violations involving Jensen Wong have prompted congressional calls for intensified scrutiny of the Department of Commerce, while former officials question why regulations were not accelerated despite senior leadership's awareness of Chinese smuggling tactics. To address these security failures, proposed remedies include expanding enforcement capabilities and potentially appointing a special prosecutor, even as the administration plans to avoid public accusations of espionage during upcoming diplomatic engagements to preserve stability in Asia and critical mineral access. Concurrently, the incoming Democratic Congress anticipates combative hearings with figures like Howard Lutnick regarding policy delays, while the White House shifts focus toward domestic corruption and maintains a patient strategy on Iran to avoid appearing desperate. Bloomberg Television · 5h ago
- Rep. Meeks Says Questions Remain Over Nvidia WarningRanking member inquiries will focus on Jensen Wong's closed-door testimony regarding delays in notifying him of his associate's espionage ties and potential negligence by Secretary Rubio or the President. Concurrently, the committee is examining Commerce Secretary Howard Lutnick's handling of NVIDIA's continued sales to Megaspeed while simultaneously targeting Defense Secretary Pete Hegseth for impeachment over military conduct failures. These investigations aim to shape stricter global export controls through the National Defense Authorization Act and may extend into the 120th Congress if immediate legislative action is not secured. Bloomberg Television · 5h ago
- Engineering the Next Era of Human Health | Future of Health Summit 2026The 2026 Future of Health Summit convened 200 leaders to confront the disparity between rapid medical advancements, such as cell therapy and AI-driven diagnostics, and persistent access barriers affecting millions of patients. Key executives from Flagship Pioneering, Bristol-Myers Squibb, and Microsoft detailed strategies to reduce clinical trial timelines by 30% while exposing systemic inefficiencies that drive a projected 9.2% rise in healthcare costs. In a major policy shift, the Milken Institute Women's Health Network launched the "Elevate Investment Initiative" to mobilize $1 billion in capital aimed at closing gender-specific health funding gaps and ensuring scalable implementation of precision medicine. Milken Institute · 6h ago
- Nvidia’s Huang Ousted by BoardNVIDIA's board ousted founder and CEO Jensen Huang amid investigations into two extramarital affairs, including one with a woman linked to espionage, forcing him to forfeit $108 million in equity and ending his 33-year tenure. Interim CEO Colette Kress and new chairman Harvey C. Jones assume control as the company faces a 14.4% intraday share drop, while the U.S. Justice Department probes Huang's former partner for potential smuggling of chips to China. This leadership crisis at the $4 trillion AI giant has triggered concerns over succession planning, sparked geopolitical tensions ahead of the APEC summit, and drawn scrutiny to U.S. officials regarding their awareness of potential national security risks. Bloomberg Television · 7h ago
- Huang Ousted By Nvidia Board As CEO | Closing BellWall Street closed lower amid NVIDIA's 4.4% intraday decline triggered by leadership uncertainty surrounding CEO Jensen Huang, prompting investor rotation into rivals AMD and Broadcom. While the broader AI trade showed resilience and Anthropic's IPO drew massive institutional interest, Cisco Systems and Applied Materials posted positive earnings guidance that drove their shares higher despite mixed after-hour reactions. Energy prices climbed above $96 a barrel, and regulatory scrutiny continues as the market evaluates NVIDIA's long-term stability independent of its current founder. Bloomberg Television · 7h ago
- Jensen Exits, AI Debt Under Review, Treasuries SlideFollowing allegations of extramarital affairs and a separate U.S. Department of Justice espionage probe involving alleged Chinese spy Alice Wong, NVIDIA board member Colette Kress has been appointed interim CEO while the board evaluates a permanent successor. The abrupt leadership change triggered a 14% initial drop in NVIDIA shares and sparked debate among investors regarding the company's governance, even as credit markets initially absorbed the news with limited systemic risk. Concurrently, analysts warn that Huang's departure removes a critical financial backstop for the AI ecosystem, potentially slowing capital expenditure growth and exacerbating market concerns over inventory gluts and rising interest rates. Bloomberg Television · 8h ago
- Trump Backs Lutnick Amid Chip UproarFollowing the resignation of CEO Jensen Wong amid espionage allegations involving a foreign national, NVIDIA has appointed CFO Colette Kress as interim leader and installed Harvey Jones as board chair while shares plummeted over 14%. The company now faces intense scrutiny from House committees and the Justice Department regarding export control failures, prompting bipartisan legislative efforts to tighten regulations on chip transshipment. Concurrently, President Trump has hinted at potential leadership changes and increased enforcement of diffusion rules, setting a contentious tone for upcoming congressional hearings on national security and AI infrastructure. Bloomberg Television · 9h ago
- Jensen Huang resigns as Nvidia CEO | The EconomistNVIDIA CEO Jensen Huang resigned amidst admissions of affairs with a suspected Chinese agent and a direct report, causing the company's market value to plummet by nearly half a trillion dollars. His departure removes a unique geopolitical figure who held critical access to both U.S. and Chinese leadership, sparking immediate concerns that the centralization of AI financing and chip design around his personal network will severely disrupt industry operations and freeze U.S.-China relations. Finance Chief now leads the company as an interim successor while investors grapple with the revelation that the CEO's personal influence was priced as an indispensable, yet now compromised, asset. The Economist · 9h ago
- Open Interest 11/12/2026Following an investigation into an alleged affair with a subordinate and potential national security risks, Jensen Huang resigned as CEO of NVIDIA, prompting the appointment of CFO Colette Kress as interim leader and the separation of the Chairman and CEO roles under new Chairman Harvey C. Jones. The abrupt leadership transition triggered a 12–13% plunge in NVIDIA's stock value while prompting legal scrutiny from the U.S. Justice Department and multiple congressional inquiries regarding export control violations. Although operations are confirmed to continue without interruption, the market now faces significant uncertainty regarding the company's long-term strategic direction and the preservation of its high-level government and supply chain relationships. Bloomberg Television · 10h ago
- Is Claude on the cusp of taking over its own development? What experts saw inside AnthropicMeter's exclusive analysis of Anthropic reveals that the company has reached a recursive self-improvement threshold where internal AI systems drove an approximate 1.97x acceleration in model development by October 2025. This shift has prompted leading AI safety experts to revise superintelligence timelines to within one to two years, while simultaneously sparking bipartisan legislative calls to ban fully automated research loops. Despite Anthropic's proposed safety monitoring and acknowledgment of crossing its internal speedup line, critics warn that voluntary audits lack the mandatory independent oversight needed to manage the risks of exponentially compounding progress. 80,000 Hours · 10h ago
- Bloomberg Surveillance 11/12/2026Following the immediate resignation of CEO Jensen Huang amid allegations involving extramarital affairs and national security concerns, NVIDIA's board has appointed CFO Colette Kress as interim leader while separating the chair role for the first time. This sudden governance overhaul triggered an 11% pre-market stock plunge that erased nearly $700 billion in market value and sparked investor rotation toward competitors like AMD and Alphabet. Simultaneously, the scandal has intensified geopolitical scrutiny, prompting U.S. lawmakers to demand stricter export controls that could disrupt the broader AI ecosystem and complicate upcoming diplomatic negotiations. Bloomberg Television · 11h ago
- The AI Chip Race with Apple’s Former Chief Chip Architect | Power On with Mark GurmanGerard Williams III founded NuvaCore in April 2024 to design high-performance, architecture-agnostic CPUs by leveraging AI tools to compress clean-sheet development timelines from years to approximately 18 months. Building on his tenure as Apple's Chief Architect for the A7 through M-series chips and his experience founding Nuvia, Williams aims to challenge the industry's GPU-centric focus by prioritizing power efficiency and orchestration capabilities for future AI workloads. The company targets full silicon production within a three-year window, envisioning a landscape where AI-augmented workflows become accessible through ordinary consumer devices like AR glasses and smartphones. Bloomberg Television · 12h ago
- Nvidia Shake-Up Is a Buying Opportunity, Says Analyst ChkaibanAmid a search for a permanent successor to CEO Jensen Huang, NVIDIA has secured $1 trillion in orders to maintain operational continuity despite analysts warning that the loss of Huang's central coordination role poses long-term risks to supplier networks and bargaining power. While the stock trades at a discounted valuation of 6.5 times 2028 earnings reflecting fears of market share erosion from competitors like AMD, the company's entrenched CUDA ecosystem and delivery capacity support a "buy" rating for the near term. Although no specific successor has been identified and shareholder litigation remains a potential threat, the current strategy aims to stabilize the fragmented customer base while navigating a complex transition period that could inadvertently strengthen the leverage of top hyperscalers. Bloomberg Television · 12h ago
- Delta Sees No Pushback on Higher Fares, CEO SaysDelta Air Lines CEO Ed Bastian characterizes the current AI adoption phase as an early investment period focused on efficiency rather than immediate revenue growth, noting that significant returns will likely require new business models. The airline maintains strong holiday travel demand despite fare increases, while simultaneously advancing its long-term in-flight Wi-Fi strategy through an Amazon Kuiper partnership and monitoring AI agent interactions on a case-by-case basis. Although Delta has offset current fuel costs, Bastian warns that geopolitical tensions could drive jet fuel prices higher within the next year, posing financial risks to smaller carriers. Bloomberg Television · 13h ago
- Jensen Huang Resigns as Nvidia CEOFollowing a recent crisis, NVIDIA's board has appointed CFO Colette Kress as interim CEO while engaging an external firm to recruit a permanent successor, a move that triggered an 11% market correction. Although Stanford-born architect Ian Buck is the leading internal candidate, experts warn that replacing Jensen Huang's unique combination of technical leadership and supplier relationship management presents a significant hurdle for maintaining the company's aggressive six-month product cadence. Bloomberg Television · 14h ago
- Stocks Fall on Nvidia Worries; Nvidia Board Considers Huang's FutureNVIDIA's board convened to evaluate CEO Jensen Huang's future following allegations of extramarital affairs and a suspected security breach, prompting a succession review and causing the company's market capitalization to lose nearly $300 billion amid fears of tightened U.S.-China chip restrictions. This governance crisis triggered a broader market correction where Asian tech indices fell and U.S. rivals like AMD and Broadcom gained share, while geopolitical tensions threatened to disrupt the upcoming Trump-Xi summit. Concurrently, global economic developments included a UK GDP surge, a historic Democratic Senate victory in Mississippi, and UN Secretary-General Antonio Guterres warning of an AI-driven "perfect storm" requiring multilateral safety oversight at the upcoming COP 31 conference. Bloomberg Television · 15h ago
- UN Secretary-General Warns of ‘Perfect Storm’ of Global RisksThe UN Secretary General warns of a global "perfect storm" characterized by geopolitical paralysis, the Russia-Ukraine and U.S.-Iran conflicts, accelerating climate change, and uncontrolled artificial intelligence expansion. He calls for urgent reform of the UN Security Council and Bretton Woods institutions to better represent emerging economies and advocates for taxing windfall oil profits to fund a "Loss and Damage" mechanism that currently pales in comparison to industry gains. Furthermore, he urges the establishment of multilateral AI oversight to mitigate existential risks while noting that market forces in the U.S. continue to drive renewable energy adoption despite federal policy shifts. Bloomberg Television · 17h ago
- Nvidia CEO Crisis Deepens as Board Weighs Jensen Huang FutureAmid a $671 billion market collapse and revelations of CEO Jensen Huang's affairs with a woman linked to Chinese intelligence, NVIDIA's board is actively seeking a successor while facing congressional investigations into national security breaches. The crisis has exposed critical governance gaps and intensified geopolitical tensions, prompting calls for stricter U.S. export controls and broader corporate reforms led by experts like McKinsey's Bob Sternfels. Concurrently, global leaders are addressing related regional instabilities, including EU defense spending increases in Ireland and diplomatic efforts to unify a European response to hybrid warfare and the ongoing conflict in Ukraine. Bloomberg Television · 17h ago
- How Ukraine blinded Russia’s drones: Operation Vivaldi explained | The EconomistUkraine has executed Operation Vivaldi by shifting front-line tactics toward intelligence-led interdiction of Russian drone networks while deploying Starlink-guided and "5.1" drones to conduct mid-to-long-range strikes against Russia's military-industrial complex and Crimean supply chains. These asymmetric operations have decimated Russian diesel export capacity to 140,000 barrels daily and forced insurance premiums in Novorossiysk to 20%, yet they face a retaliatory volume of five times more Russian deep strikes alongside a surge in jet-propelled Geran drone production. While successfully straining Russian logistics, this strategy has sparked geopolitical friction by inadvertently inflating global fuel prices and providing Moscow with a narrative to blame Ukraine for economic instability among neutral partners. The Economist · 18h ago
- Why The Fed Is A Bigger Risk For The AI Boom Than NvidiaNVIDIA's board is convening to potentially remove CEO Jensen Huang amid a governance crisis triggered by extramarital scandals and allegations that an involved subordinate acted as a spy for China. This leadership turmoil has sent shares tumbling while simultaneously accelerating geopolitical decoupling, prompting fears of stricter U.S. export controls and diplomatic friction ahead of the Trump-Xi meeting in Shenzhen. Concurrently, the broader market faces pressure from AI bubble risks and rising interest rates, creating a volatile environment where NVIDIA's instability could exacerbate global liquidity concerns and regional supply chain disruptions. Bloomberg Television · 18h ago
- Why Alexis Ohanian Bet on Women's Sports Before Everyone Else | The DealIn March 2019, Alexis Ohanian launched Angel City FC to capitalize on the undervaluation of elite women's athletes, projecting that the sector will eventually outpace the market capitalization of Reddit within a decade. His portfolio, which includes the Golden State Valkyries and various new leagues, leverages high-engagement player brands to secure rapid revenue growth and billion-dollar valuations despite a lack of traditional legacy media deals. Ohanian positions these ventures as a strategic counter to synthetic AI content, arguing that the human element of live sports will drive future profitability as technology-driven operational efficiencies replace obsolete industry infrastructure. Bloomberg Originals · 20h ago
- Nvidia Board Considers Replacing CEO Jensen HuangAmid allegations of multiple affairs and unreported chip shipments to China, Nvidia's board is actively seeking a replacement for CEO Jensen Huang, a move that has triggered a 30% stock decline and global market losses. The crisis has drawn scrutiny from U.S. regulators and President-elect Trump, while competitors like AMD and Broadcom gained value as investors reassessed supply chains in the AI sector. Simultaneously, geopolitical tensions are escalating as the scandal threatens to overshadow upcoming trade talks with China and complicates negotiations between Ukraine and Russia. Bloomberg Television · 20h ago
- Nvidia Board Weighs Huang’s Future as Congress Prepares SubpoenaNVIDIA's board is considering leadership changes amid CEO Jensen Huang's personal scandals, triggering a sharp sell-off that dragged down the broader tech sector and Asian markets while benefiting competitors like AMD and Broadcom. In the capital markets, AI firm Anthropic targets a $1.4 trillion valuation for an upcoming IPO, whereas the UAE government highlights economic resilience and is opening infrastructure sectors to private capital to diversify funding sources. Simultaneously, institutional investors are pivoting toward asset-based private credit and self-sufficiency themes to mitigate geopolitical risks and address global market concentration. Bloomberg Television · 20h ago
- Ruchir Sharma on AI Bubble Risks, Opportunities in IndiaThe speaker warns that an AI bubble collapse would trigger a global recession if rising interest rates pierce the U.S. market, which currently absorbs 70% of global equity flows and drives consumer spending through wealth effects. While retail investors sustain the bubble with reflexive buying and access to technology, the speaker identifies undervalued quality stocks in Europe, Japan, and the U.S. as superior long-term holdings alongside the Swiss Franc as a defensive currency. The analysis concludes that divergent regional performances, particularly China's structural failures and India's limited near-term tech adoption, underscore the necessity of hedging against a concentrated U.S. exposure. Bloomberg Television · 21h ago
- Top Neurologist: The Weekend Habit That Could Raise Your Dementia Risk!Dr. David Perlmutter redefines Alzheimer's disease as a preventable metabolic synaptopathy driven by lifestyle factors and neuroinflammation, shifting focus away from ineffective amyloid-targeting drugs toward modulating microglial function through diet, exercise, and social connection. Research highlights that physical activity can reduce APOE4-related risk by 67% while dietary changes, such as avoiding ultra-processed foods and managing glucose spikes, help restore supportive M2 microglia states. The presentation underscores that immediate intervention via lifestyle modification offers a viable strategy for stabilizing or reversing early cognitive decline, effectively countering the biological mismatch between modern environments and human genetics. The Diary Of A CEO · 21h ago
- Nvidia Board Meets As Jensen Huang Fallout WidensAmid allegations of an extramarital affair with a Chinese national linked to espionage, NVIDIA's board is actively considering the removal of CEO Jensen Huang and appointing CFO Colette Kress as an interim leader. These governance and national security concerns triggered an 8% stock decline and caused major firms like Bernstein and Baird to slash price targets, while U.S. lawmakers investigate potential export control violations. Consequently, analysts warn that the scandal could permanently sever NVIDIA's access to the Chinese market and disrupt its sovereign AI partnerships, prompting competitors to watch for succession opportunities. Bloomberg Television · 22h ago
- The Rise and Reckoning of Jensen Huang | The Circuit with Emily ChangFollowing an investigation into CEO Jensen Huang's extramarital affair with a foreign executive suspected of espionage, NVIDIA faces its most significant corporate crisis while board members confirm no immediate evidence of national security breaches. Amidst this internal turmoil and external scrutiny regarding AI safety and export controls, Huang reaffirms the company's commitment to a decade-long infrastructure expansion and voluntary industry regulation despite mounting investor skepticism about the AI sector's economic sustainability. The scandal also highlights critical succession risks, as the company's global dominance remains inextricably linked to Huang's personal judgment and leadership during a period of intensifying geopolitical tension over semiconductor sovereignty. Bloomberg Originals · 1d ago
- Nvidia Weighs Ousting Jensen Huang as Infidelity Scandal DeepensFollowing the revelation that CEO Jensen Huang engaged in an extramarital affair with a Megaspeed executive suspected of espionage and admitted to a second relationship with a subordinate, the Nvidia board has convened to consider ousting Huang and engaging a search firm for a replacement. This governance crisis has triggered a severe market correction with shares plummeting over 30 percent, prompting analysts to downgrade the stock while competitors like AMD and Broadcom capture shifting investor interest. Beyond the immediate leadership vacuum, the situation forces a reevaluation of Nvidia's aggressive capital allocation strategies and exposes the fragility of an AI ecosystem heavily reliant on the founder's personal network amid tightening geopolitical export restrictions. Bloomberg Television · 1d ago
Earnings Releases
By sector →- MXCNov 12, 5:28 PMMexco Energy Corporation reported a net income of $945,152, or $0.45 per diluted share, for the six months ended September 30, 2026, representing a 67% increase from the same period in the prior year. Operating revenues rose 21% to $4,102,157, driven primarily by a 43% increase in average oil prices despite a 23% decline in natural gas prices and a 7% drop in oil production. During this period, the company invested approximately $3.2 million in acquiring oil and gas royalty interests and plans to drill 55 horizontal wells and complete 20 others in the fiscal year ending March 31, 2027.Energy
- LGLNov 12, 5:27 PMThe LGL Group, Inc. reported total revenues of $1.464 million for the third quarter of 2026, representing a 32.1% increase from the same period in 2025. Net loss attributable to common stockholders was $45,000 for the quarter, a significant decline from the $772,000 net income recorded in 2025, primarily due to a reversal of a previously recorded uncertain tax position. The company's backlog in the Electronic Instruments segment grew substantially to $6.5 million as of September 30, 2026, up from $625,000 at the end of 2025. Cash and cash equivalents, along with marketable securities, increased to $87.0 million, driven largely by a rights offering that generated $41.5 million in net proceeds in July 2026.Technology
- BMTMNov 12, 5:27 PMBright Mountain Media, Inc. reported revenue of $11.6 million for the third quarter of 2026, a 17% decrease from the same period in 2025, while net loss narrowed to $3.0 million from $2.8 million. For the nine months ended September 30, 2026, revenue totaled $39.2 million, down 10% year-over-year, with the net loss improving by 26% to $7.5 million compared to $10.1 million in the prior period. Adjusted EBITDA increased to $1.5 million for the quarter and $3.6 million for the nine-month period, reflecting a 10% and 88% improvement respectively. The company's balance sheet showed total assets of $32.75 million and a stockholders' deficit of $84.09 million as of September 30, 2026.
- ROCNov 12, 5:21 PMRank One Computing Corporation reported record third-quarter 2026 revenue of $8.0 million, representing a 50% year-over-year increase and achieving its first quarterly net income of approximately $0.6 million. The company secured a historic $64.3 million federal contract with the Department of Justice for its ROC Evidence platform and a $5.1 million contract for ROC ABIS, while product revenue grew 24% to $5.7 million driven by strong performance in ROC SDK and ROC ABIS. Gross margin improved to 90% due to a favorable mix of high-margin software licensing, and the company completed the acquisition of Zuccaro Technical Consulting to expand its digital forensics capabilities.Technology
- AKTXNov 12, 5:21 PMAkari Therapeutics initiated GLP toxicology studies for its lead candidate AKTX-101, a TROP2-targeted antibody-drug conjugate utilizing the novel PH1 payload, to support a planned Phase 1 clinical trial in mid-2027. New preclinical data demonstrated that AKTX-101 exhibited significant tumor growth inhibition in urothelial cancer models resistant to existing therapies like Padcev and Trodelvy. The company reported third-quarter 2026 financial results showing $5.7 million in cash, a net loss of $4.8 million, and the full repayment of $0.7 million in convertible notes. Additionally, Akari strengthened its business development capabilities with the appointment of a new Chief Business Officer and expanded its intellectual property portfolio with a new patent application covering PH1's RNA splicing modulation mechanisms.Healthcare
- ITHUFNov 12, 5:21 PMiAnthus Capital Holdings reported fiscal third quarter 2026 revenue of $38.4 million, representing a sequential increase of $3.0 million from the previous quarter. The company achieved a gross profit of $16.7 million with a gross margin of 43.5%, while reporting a net loss of $13.2 million. Adjusted EBITDA for the quarter reached $5.2 million, an increase from $4.4 million in the second quarter and $2.5 million in the prior year's third quarter. Additionally, the company appointed Macias Gini & O'Connell LLP as its new independent registered public accounting firm effective November 12, 2026, following the resignation of PKF O'Connor Davies.
- ELTPNov 12, 5:20 PMElite Pharmaceuticals, Inc. reported consolidated revenues of $40.1 million for the second quarter of fiscal year 2027, representing a 10.4% increase from the prior year period. This growth was primarily driven by higher sales from the company's amphetamine and naltrexone product lines under the Elite label. The company recorded income from operations of $9.9 million and net income attributable to common shareholders of $17.3 million for the quarter. Management is scheduled to host a conference call on November 13, 2026, to discuss these financial results and recent business developments.Healthcare
- TBNNov 12, 5:18 PMTamboran Resources achieved first gas sales from its Shenandoah South Pilot Project in the Beetaloo Basin in September 2026, delivering 40 TJ/d to the Northern Territory Government under a fixed-price contract. Initial production tests on wells SS2-3H and SS2-5H confirmed average IP30 rates of 8.8 and 10.0 MMcf/d, while the SS2-2H ST1 well demonstrated a cleaned-up rate of 10.2 MMcf/d. The company reported US$1.8 million in gas sales revenue for the first quarter of fiscal year 2027, maintaining a pro forma cash balance of approximately US$180 million. Tamboran continues to advance its development strategy with ongoing drilling programs and strategic partnerships aimed at scaling production across its 2.8 million net prospective acres.Energy
- SLNDNov 12, 5:17 PMSouthland Holdings reported third-quarter 2026 revenue of $233.8 million, an increase from $213.3 million in the same period the prior year, driven by strong demand in its Civil and Transportation segments. The company achieved a gross profit of $20.6 million with an 8.8% margin, a significant improvement over the 0.9% margin recorded in the previous year, largely due to a $28.7 million settlement gain with Liberty Mutual. Net income attributable to stockholders reached $33.7 million, or $0.62 per diluted share, contrasting sharply with a net loss of $75.3 million in the prior year quarter. Additionally, Southland's backlog grew to $1.71 billion, reflecting continued execution of its strategic plan and operational improvements.Industrials
- LGVNNov 12, 5:11 PMLongeveron Inc. reported a net loss of $6.1 million for the third quarter ended September 30, 2026, driven by research and development expenses of $4.0 million and general and administrative costs of $3.3 million. The company's Phase 2b ELPIS II clinical trial for hypoplastic left heart syndrome did not meet its primary efficacy endpoint, prompting a request for a meeting with the FDA to determine future development steps. Concurrently, Longeveron is evaluating strategic alternatives, including potential partnerships, mergers, or sales, with Lucid Capital Markets retained as financial advisor to maximize stockholder value. The company implemented a 1-for-10 reverse stock split in August and currently holds $7.2 million in cash, which is expected to fund operations into the first quarter of 2027.Healthcare
- VGZNov 12, 5:10 PMVista Gold Corp. announced a consolidated net loss of $6.4 million, or $0.05 per share, for the quarter ended September 30, 2026, while maintaining cash reserves of $43.5 million with no debt. On September 20, 2026, the company entered into an arrangement agreement with Artemis Gold Inc. to be acquired via a court-approved plan of arrangement. Under the proposed terms, each Vista common share will be exchanged for 0.0966 of an Artemis common share, resulting in Vista shareholders collectively owning approximately 5% of the combined entity. The transaction aims to leverage Artemis's resources to advance the development of Vista's Mt Todd gold project while expanding the Blackwater operation.Basic Materials
- NNUPNov 12, 5:08 PMNocopi Technologies reported a 763% increase in third-quarter 2026 revenues to $3.329 million, driven by a renewed license agreement and sales from the acquired Polymeric business. The company achieved a net income of $1.397 million for the quarter, a significant turnaround from the net loss recorded in the same period of the previous year. Operating expenses rose to $0.982 million due to the inclusion of Polymeric's operations and elevated professional fees associated with the acquisition. As of September 30, 2026, the company maintained a strong balance sheet with $10.278 million in cash and investments and no outstanding debt.
- PALNov 12, 5:03 PMProficient Auto Logistics reported third-quarter 2026 total operating revenue of $149.0 million, a 30.3% increase from the prior year period, driven by the inclusion of Hansen & Adkins following its acquisition on August 13, 2026. The company delivered 839,036 units, representing a 38.6% year-over-year growth, though total operating income declined to a loss of $3.9 million compared to a $0.1 million loss in the previous year. Adjusted operating income for the quarter was $0.3 million, with the adjusted operating ratio rising to 99.8% due to elevated costs in insurance, wages, and fuel surcharge under-recovery. The integration of Hansen & Adkins is progressing on schedule, with the company now identifying a synergy opportunity range of $20 million to $30 million, significantly higher than the initial estimate.Industrials
- KIDZNov 12, 5:00 PMKIDZ AI Inc. reported a 40% sequential increase in third-quarter 2026 revenue, marking its first quarter-over-quarter growth in the year. The company achieved a gross margin of 65.9% and narrowed its net loss to $654,057, while strengthening its balance sheet with stockholders' equity rising 349% to $16.9 million. As of September 30, 2026, the firm maintained a net cash position of approximately $14.9 million, representing roughly 12 times its market capitalization. During the quarter, KIDZ AI repurchased 74,082 shares of Class B common stock at an average price of $3.36 per share.Consumer Defensive
- CWDNov 12, 5:00 PMCaliber reported a third quarter 2026 platform revenue of $3.8 million and a platform net loss of $4.3 million, resulting in a positive platform Adjusted EBITDA of $0.1 million for the second consecutive quarter. The company revised its full-year 2026 total platform revenue guidance down to a range of $15.0 million to $17.0 million due to tighter credit conditions, while reaffirming its profitability guidance. During the quarter, Caliber completed the tokenization of three additional real estate projects, bringing the total tokenized offerings to four with up to $110 million in combined offered equity. Additionally, the company held 229,203 LINK tokens valued at $3.3 million, which contributed a $1.6 million gain from changes in fair value.Financial Services
- MSGMNov 12, 5:00 PMMotorsport Games reported third-quarter 2026 revenues of $3.8 million, representing a 21.8% increase from the prior year period, driven by growth in Le Mans Ultimate downloadable content and RaceControl subscriptions. The company achieved its seventh consecutive quarter of profitability with net income of $0.7 million and expanded its gross profit margin to 88.0%. Le Mans Ultimate surpassed two million combined unit sales and set a new concurrent player record of 11,941 during a special event in October. Additionally, the company strengthened its balance sheet, ending the quarter with $5.4 million in cash and deferred revenue, while RaceControl subscription revenues grew by 186.2% over the nine-month period.Communication Services
- BGMSNov 12, 5:00 PMBio Green Med Solution, Inc. reported a net loss of $0.4 million for the third quarter ended September 30, 2026, narrowing from a $1.0 million loss in the prior-year period. The company's fire safety business generated $454,000 in product revenue, representing a significant increase from $81,000 in the same period last year, while general and administrative expenses decreased by 37% year over year. As of September 30, 2026, the company held $3.5 million in cash and cash equivalents, which management estimates will fund operations through the second quarter of 2027. Additionally, the company announced that its Form S-4 regarding a proposed business combination with Future NRG Sdn. Bhd. was declared effective in October, with a shareholder special meeting planned for November 2026.Industrials
- DIODNov 12, 5:00 PMDiodes, Inc. reported record third-quarter 2026 revenue of $532.6 million, representing a 36% year-over-year increase and a 20% sequential rise. The company achieved a gross margin of 36.1%, driven by strong demand in automotive, industrial, and AI-related computing sectors, alongside capacity expansion and product mix improvements. Management projects fourth-quarter revenue to reach approximately $550 million with a non-GAAP gross margin of 37%, aiming to exceed its three-year financial goals.Technology
- PRSONov 12, 4:58 PMPeraso Inc. reported third-quarter 2026 total net revenue of $0.3 million, a significant decline from $1.3 million in the prior quarter and $3.2 million in the same period last year, driven by reduced shipments to fixed wireless access customers. The company posted a GAAP net loss of $2.7 million, or $0.18 per share, while achieving a gross margin of 78.5% due to a favorable product mix and a one-time inventory accrual reversal. Management noted early signs of renewed demand in the fourth quarter, highlighted by a production order exceeding $2 million received in October, and announced a private placement with Nant Capital that raised approximately $10 million to support strategic initiatives in defense and drone communications.Technology
- SPRUNov 12, 4:52 PMSpruce Power reported a net income of $6.0 million for the third quarter of 2026, marking a significant turnaround from a net loss of $0.9 million in the same period the previous year. Operating EBITDA increased by 3% year-over-year to $27.0 million, driven by a 23% reduction in SG&A expenses resulting from streamlining efforts and labor savings initiatives. The company ended the quarter with $87.3 million in cash and cash equivalents, reduced its outstanding debt principal by $21.9 million, and finalized a non-binding term sheet to refinance key facilities extending their maturity to January 2027.Technology
- NSPRNov 12, 4:45 PMInspireMD, Inc. reported a net loss of $9.76 million for the third quarter of 2026, driven by a decline in total revenue to $2.24 million due to a voluntary U.S. recall of its CGuard Prime delivery system. The company received FDA approval for its CGuard Prime TransCarotid Stent System for TCAR procedures, which is expected to expand its addressable market by over 35,000 annual procedures and commence U.S. sales in the fourth quarter of 2026. International revenue grew by 9.1% to $2.21 million, offsetting the loss of U.S. sales, while the company continues to advance its SwitchGuard neuroprotection system and plans to submit a PMA supplement for an enhanced CAS delivery system in December 2026.Healthcare
- ALMUNov 12, 4:45 PMAeluma, Inc. reported a net loss of $3.8 million for the first quarter of fiscal 2027, with revenue declining to $0.6 million from $1.4 million in the prior year period. The company finalized a purchase agreement with Aixtron to acquire a new 200 mm capable MOCVD system, aiming to expand manufacturing capacity for non-indium-phosphide photonics. Aeluma continues to advance technology readiness for the AI datacom market through the development of high-speed photodetectors and quantum dot lasers while engaging with customers for potential high-volume demand. Additionally, the company is in negotiations with the U.S. Department of Commerce for up to $30 million in CHIPS R&D funding to support the commercialization of photonics for AI and advanced computing.Technology
- STRONov 12, 4:45 PMSutro Biopharma reported third-quarter 2026 financial results showing $9.1 million in revenue and a net loss of $31.5 million, while maintaining a cash balance of $142.2 million expected to fund operations through the first half of 2028. The company advanced its STRO-004 ADC program with encouraging early clinical data and initiated dosing for the STRO-006 ITGB6-targeting ADC, with both programs scheduled for further clinical updates in 2027. Additionally, the STRO-227 dual-payload ADC is set to enter clinical trials in early 2027, and a collaboration with Astellas triggered a $10 million milestone payment following the dosing of a second dual-payload program.Healthcare
- SPRONov 12, 4:43 PMSpero Therapeutics announced its third-quarter 2026 financial results, reporting a net loss of $44.3 million and research and development expenses of $38.2 million, which included a $35 million upfront payment for the in-licensing of SP001 from Innovent Biologics. The company secured $105 million in non-recourse financing in July 2026, bringing its cash and cash equivalents to $107.9 million as of September 30, 2026, sufficient to fund operations into the second half of 2029. SP001, a third-generation anti-CD40L antibody, is advancing toward a Phase 2 study in IgG4-related disease scheduled for the second quarter of 2027. Spero has also strengthened its leadership team with new appointments for Chief Medical Officer, Chief Regulatory and Quality Officer, and a new Board member to support its clinical development strategy.Healthcare
- LSFNov 12, 4:42 PMLaird Superfood reported third-quarter 2026 net sales of $42.0 million, representing a 225% increase from the prior year period, driven by the integration of Navitas Organics and Terrasoul Superfoods. The company achieved a net income of $1.7 million and an Adjusted EBITDA of $2.1 million, while e-commerce sales grew 268% to account for 54% of total revenue. For the full fiscal year 2026, the company maintains a revenue guidance range of $135 million to $140 million and an Adjusted EBITDA range of $5 million to $6 million. As of September 30, 2026, Laird Superfood held $17.3 million in cash with no outstanding debt.Consumer Defensive
- BATLNov 12, 4:41 PMBattalion Oil Corporation reported third quarter 2026 sales volumes of 11,359 barrels of oil equivalent per day, with average daily production of 4,915 net barrels of oil. The company generated $45.6 million in operating revenue, driven by a $5.13 per Boe increase in average realized prices, while reporting a net loss of $41.1 million largely due to $44.8 million in net losses on derivative contracts. Financial highlights include $92.1 million in cash and cash equivalents, a reduction in net debt to $70.4 million, and the commencement of drilling operations under a joint exploration agreement ahead of schedule. Additionally, the company executed a midstream transaction to transition crude transportation from trucking to pipeline and appointed John Juneau to its board of directors.Energy
- DMACNov 12, 4:40 PMDiaMedica Therapeutics reported a net loss of $11.3 million for the third quarter of 2026, with total cash, cash equivalents, and short-term investments standing at $34.9 million as of September 30, 2026. The company completed enrollment in the first two cohorts of its Phase 2 trial for early-onset fetal growth restriction and surpassed the 200-participant threshold for its ReMEDy2 acute ischemic stroke trial. Regulatory progress includes conditional authorization from the European Medicines Agency and Health Canada for early-onset preeclampsia studies, while the company continues to address FDA feedback regarding nonclinical reproductive toxicity data for a U.S. Investigational New Drug application. Management anticipates the ReMEDy2 interim analysis to be completed in the first quarter of 2027 and expects current cash reserves to fund operations through the fourth quarter of 2027.Healthcare
- DDSNov 12, 4:39 PMDillard's, Inc. reported net income of $130.9 million for the third quarter ended October 31, 2026, representing a 1% increase in total retail sales compared to the prior year period. For the 39 weeks ended October 31, 2026, the company achieved net income of $479.1 million, driven by a 2% increase in total retail sales and significant non-operating gains from tariff refunds and a litigation settlement. The retailer maintained a retail gross margin of 45.3% for the quarter and 44.0% for the year-to-date period, while operating expenses rose due to higher payroll costs. Additionally, Dillard's announced the closure of its Boynton Beach Mall Clearance Center in January 2027 and operates 272 stores across 30 states.Consumer Cyclical
- GEMINov 12, 4:35 PMGemini Space Station, Inc. reported third-quarter 2026 total revenue of $40.9 million, a 19% decrease from the prior year, driven by a 73% decline in platform spot trading volume. Total operating expenses fell 30% year-over-year to $119.9 million, resulting in a net loss of $58.6 million, which represents a 63% improvement over the same period in 2025. Services revenue and interest income accounted for 59% of net revenue, while exchange revenue dropped 47% to $13.4 million due to reduced retail trading activity. The company maintained disciplined cost management with lower compensation and marketing spend, despite a 38% increase in transaction losses primarily attributed to credit card charge-offs.Financial Services
- WHKNov 12, 4:34 PMWhiteHawk Minerals Corp. reported third-quarter 2026 net production of 71.3 million cubic feet equivalent per day, representing a 10% year-over-year increase. The company announced the signing of 13 acquisitions totaling $45.5 million in core Appalachian and Haynesville mineral interests, which are expected to generate approximately $5.6 million in incremental cash flow in 2027. For the quarter, WhiteHawk declared a quarterly dividend of $0.50 per share, achieved net income of $6.9 million, and reported adjusted EBITDA of $21.1 million.Energy
- CVNov 12, 4:34 PMCapsoVision reported third-quarter 2026 revenue of $3.6 million, a slight increase from $3.5 million in the same period of 2025, while net loss narrowed to $7.3 million from $7.9 million. The company received FDA clearance for its AI Highlights tool in September 2026 and launched it commercially in November, alongside completing enrollment for its CapsoCam Colon study with an expected FDA submission by year-end. Financial results reflected a gross margin decline to 49% due to higher material costs and inventory charges, though operating expenses decreased to $9.1 million. To support its operations and development pipeline, CapsoVision raised approximately $19.5 million in net proceeds through a registered direct offering and an at-the-market program during the quarter.Healthcare
- UPXINov 12, 4:31 PMUpexi, Inc. reported fiscal first quarter 2027 net income of $89.1 million, or $0.68 per diluted share, driven primarily by $102.0 million in unrealized gains on digital assets. Total revenue for the quarter reached $3.5 million, with digital asset revenue accounting for $3.1 million and product revenue declining to $0.4 million as the company shifted away from legacy consumer product lines. The company strengthened its balance sheet by increasing its Solana treasury to approximately 2.35 million SOL and raising cash on hand to $6.4 million, while also reducing the interest rate on its BitGo borrowings from 11.5% to 7.5%. Stockholders' equity improved significantly to $49.2 million as of September 30, 2026, reversing a deficit of $53.8 million recorded at the end of the previous quarter.Communication Services
- SPCENov 12, 4:31 PMVirgin Galactic reported a net loss of $59 million for the third quarter of 2026, driven by $59 million in operating expenses and revenue of $0.4 million. The company holds $184 million in cash and marketable securities as of September 30, 2026, while its first commercial spaceflight is expected in early 2027. Operational updates include the completion of a rocket motor production facility in Arizona and the opening of limited bookings for spaceflight expeditions at $850,000 per seat. Additionally, Virgin Galactic projects a high-cadence launch hangar opening in late 2028 to increase annual spaceflight capacity to 150.Industrials
- PROPNov 12, 4:30 PMPrairie Operating Co. reported third-quarter 2026 sales volumes of 2.4 million barrels of oil equivalent, representing a 21% increase from the prior quarter and driving revenue to $129.5 million. The company generated $65.3 million in Adjusted EBITDA, a 92% quarter-over-quarter increase, while reducing lease operating expenses per barrel of oil equivalent by 17%. Year-to-date through September 30, 2026, total revenue reached $311.8 million, an increase of approximately 97% compared to the same period in 2025. Production reached approximately 32,287 barrels of oil equivalent per day by early October, following the online status of the Burnett and Castor development pads.Energy
- AEMDNov 12, 4:30 PMAethlon Medical, Inc. reported a net loss of $2.62 million for the second quarter ended September 30, 2026, with operating expenses rising 77.2% to $2.7 million primarily due to professional fees associated with a proposed merger. On September 17, 2026, the company entered into a merger agreement with North Immunology, Inc., under which the combined entity will operate as North Immunology and shareholders will receive contingent value rights tied to the legacy Hemopurifier business. During the quarter, the company treated its second patient in the final dosing cohort of its Phase 1 oncology study in Australia and implemented workforce reductions to align with the merger timeline. As of September 30, 2026, the company held approximately $6.5 million in cash and cash equivalents.Healthcare
- LGCYNov 12, 4:30 PMLegacy Education Inc. reported a record student population of 3,684 for the first quarter of fiscal 2027, representing a 5.4% increase from the prior year. The company achieved $20.0 million in revenue and $0.9 million in net income, while expanding its footprint with a new campus lease in Houston, Texas. Strategic investments in faculty, facilities, and new programs drove educational services expenses up by 13.0%, resulting in a lower net income margin compared to the previous year. Additionally, the company recorded an estimated $0.7 million legal settlement expense and maintained a strong balance sheet with $21.7 million in cash and minimal debt.Consumer Defensive
- PLNHNov 12, 4:28 PMPlanet 13 Holdings Inc. reported a net loss of $6.4 million and revenue of $23.1 million for the third quarter of 2026. The company achieved a gross profit margin of 56.2%, a significant increase from the prior year, driven by the exit from California wholesale operations and a reduction in inventory reserves. Adjusted EBITDA improved to a loss of $0.2 million, reflecting better cost control and higher gross margins despite lower tourist traffic in Nevada. Additionally, the company announced that its Form S-4 merger registration with Vireo Growth Inc. was declared effective, with a shareholder vote scheduled for December 10, 2026.
- VRCANov 12, 4:27 PMVerrica Pharmaceuticals reported third-quarter 2026 total revenue of $6.9 million, driven by a record $5.7 million in net product revenue from YCANTH, which represents an 11.9% increase over the previous quarter. The company completed enrollment in its first pivotal Phase 3 trial for common warts and achieved milestones to unlock an additional $15.0 million in non-dilutive growth capital, extending its cash runway into the fourth quarter of 2027. Additionally, Verrica announced it is exploring the development of its oncolytic peptide, VP-315, for the treatment of Gorlin syndrome, a rare genetic disease characterized by frequent basal cell carcinomas.Healthcare
- NKTRNov 12, 4:25 PMNektar Therapeutics reported a net loss of $55.7 million for the third quarter of 2026, driven by increased research and development expenses totaling $44.1 million as the company advances its lead candidate rezpegaldesleukin into Phase 3 trials for atopic dermatitis and alopecia areata. Revenue for the quarter declined to $9.4 million from $11.8 million in the same period the previous year, while cash and investments rose significantly to $952.9 million. The company has initiated all three global registrational trials for the ZENITH AD program and expects topline data in mid-2028, with a target Biologics License Application submission in 2029.Healthcare
- ARMPNov 12, 4:24 PMArmata Pharmaceuticals reported a net income of $54.9 million for the third quarter of 2026, driven primarily by a $69.6 million gain from changes in the fair value of its convertible loan. The company advanced preparations for its pivotal Phase 3 superiority study of AP-SA02, receiving FDA Breakthrough Therapy designation and securing an additional $3.7 million in non-dilutive funding from the U.S. Department of War. Operating expenses for the quarter totaled $10.5 million, while the company held $18.3 million in unrestricted cash and cash equivalents as of September 30, 2026.Healthcare
- FGINov 12, 4:24 PMFGI Industries reported third-quarter 2026 total revenue of $31.7 million, an 11.6% decrease from the prior year, driven by softness in housing and remodeling activity. The company posted a gross profit of $8.7 million with an expanded gross margin of 27.6%, while operating and net losses were recorded at $0.5 million and $0.9 million, respectively. Revenue declined across core categories including sanitaryware and shower systems, though the custom kitchen cabinetry segment grew by 32.8%. Consequently, FGI revised its full-year 2026 net revenue guidance downward to a range of $120-127 million and adjusted its operating and net income forecasts to reflect continued market challenges.Consumer Cyclical
- XOSNov 12, 4:23 PMXos, Inc. reported a third consecutive quarter of positive GAAP gross profit for the period ended September 30, 2026, with the nine-month GAAP gross margin expanding to 26.9% from 13.3% in the prior year. Revenue for the quarter increased 17.0% sequentially to $5.5 million on 33 units delivered, while operating expenses were reduced by 10.0% year-over-year to $25.8 million for the nine-month period. The company delivered its first Xos Hub units internationally to support Waymo's autonomous vehicle operations in London and now has over 1,000 units in the field. Xos revised its full-year 2026 outlook to project revenue between $25 million and $35 million and unit deliveries between 185 and 250 units.Consumer Cyclical
- ENSCNov 12, 4:22 PMEnsysce Biosciences reported a net loss of $82.3 million for the third quarter of 2026, primarily driven by a $79.9 million non-cash charge for acquired in-process research and development related to the Cy Biopharma acquisition. The company completed the acquisition of Cy Biopharma in August, adding the CY200 pipeline asset for Complex Regional Pain Syndrome, and submitted a Phase 2a protocol for this candidate to the UK's MHRA in September. Additionally, Ensysce finished enrollment in the final stage of its PF614-MPAR-102 study for its abuse-deterrent opioid and ended the quarter with $29.7 million in cash and cash equivalents.Healthcare
- INVNov 12, 4:21 PMInnventure, Inc. reported a net loss of $333.8 million for the third quarter of 2026, driven primarily by a $323.5 million goodwill impairment charge. The company is executing a strategic repositioning that includes reducing parent-level headcount from 40 to 15 and transitioning its AeroFlexx and Refinity businesses away from reliance on Innventure capital. During the nine-month period ended September 30, 2026, Innventure generated $3.9 million in revenue while utilizing $74.5 million in operating cash flows. Management aims to preserve and maximize the value of its interest in Accelsius through disciplined capital allocation and cost reductions.Financial Services
- CRDFNov 12, 4:21 PMCardiff Oncology reported a net loss of $30.4 million for the nine months ended September 30, 2026, driven by $32.0 million in operating expenses. The company's Phase 2 trial for onvansertib in first-line RAS-mutated metastatic colorectal cancer remains ongoing, with median progression-free survival not yet reached in the 30 mg onvansertib plus FOLFIRI/bev arm compared to approximately 11 months in standard-of-care arms. As of late September 2026, all patients in the 30 mg onvansertib arm have exceeded 21 months on treatment, with the longest duration surpassing 29 months. Cardiff holds approximately $33.8 million in cash and cash equivalents as of September 30, 2026, and plans to initiate a registrational Phase 3 trial in the first quarter of 2027.Healthcare
- VATENov 12, 4:21 PMINNOVATE Corp. reported third-quarter 2026 consolidated revenue of $495.5 million, a 42.8% increase from the prior year, driven primarily by its Infrastructure segment. The company completed the sale of DBM Global to IES Holdings for approximately $413 million in cash and stock, and sold a controlling interest in HC2 Broadcasting to CONX Corp., retaining a 25% stake. Net income attributable to common stockholders rose to $15.8 million in the quarter, compared to a net loss of $9.4 million in the same period last year, largely due to a $32.9 million gain on the sale of the broadcasting interest. Total Adjusted EBITDA for the quarter reached $40.5 million, more than doubling the $19.8 million reported in the previous year.Industrials
- LVLUNov 12, 4:21 PMLulus reported a 20% year-over-year decline in third-quarter 2026 net revenue to $58.6 million, driven by a 20% drop in total orders placed and higher return rates. The company posted a net loss of $4.3 million and an adjusted EBITDA loss of $1.8 million, while successfully reducing inventory by 17% and improving gross margin by 230 basis points to 44.9%. Management revised its full-year 2026 outlook downward due to the continued impact of historical assortment decisions, though it anticipates revenue decline rates to moderate in fiscal 2027. Additionally, the company expects capital expenditures for 2026 to range between $1.5 million and $2.0 million.Consumer Cyclical
- CDXSNov 12, 4:20 PMCodexis, Inc. reported third-quarter 2026 total revenues of $19.3 million, a significant increase from $8.6 million in the same period of 2025, driven by higher product revenue from newly approved customer products. The company achieved a product gross margin of 74.5% for the quarter and reduced its net loss to $8.1 million, or $0.08 per share, compared to a $19.6 million loss in the prior year period. Financial stability was strengthened through a $25 million equity raise completed in July and a $60 million senior secured loan facility with Trinity Capital, which included a $42.5 million drawdown used to refinance existing debt. Codexis reiterated its full-year 2026 revenue guidance of $72 million to $76 million and expects its cash and investments to fund operations through the end of 2028.Healthcare
- YSSNov 12, 4:20 PMYork Space Systems reported third-quarter 2026 revenue of $84.2 million, a 7% decrease from the prior year, while recording a net loss of $807.4 million largely driven by a $749.7 million non-cash goodwill impairment charge. The company's backlog stood at $581.0 million as of September 30, 2026, supported by new contract wins and modifications, and its identified pipeline expanded by over 30% to $14.9 billion. York announced the permanent appointment of Brian Frantz as Chief Financial Officer and outlined strategic initiatives including the proposed acquisition of Outlook Industries to enter the unmanned systems market. Full-year 2026 revenue guidance was narrowed to a range of $380 million to $400 million, with the company maintaining total liquidity of $459 million.Industrials
- SCTXNov 12, 4:20 PMScribe Therapeutics reported third-quarter 2026 financial results, recording a net loss of $9.9 million and holding $174.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026. The company completed an upsized initial public offering in July 2026, raising approximately $155.5 million in aggregate gross proceeds, which extends its funding runway into the first half of 2029. Clinical progress includes ongoing enrollment in the first-in-human Phase 1 trial for STX-1150, an epigenetic silencing therapy targeting LDL-C lowering, with initial data expected in the first half of 2027. Additionally, Scribe expanded its strategic collaboration with Sanofi to include access to its ELXR epigenetic silencing technology alongside its existing gene-editing platform.Healthcare
- CRWSNov 12, 4:19 PMCrown Crafts, Inc. reported second-quarter fiscal 2027 net sales of $19.0 million, a decrease from $23.7 million in the prior-year period. The company achieved a gross profit margin of 32.0%, an increase from 27.7% in the previous year, driven by $0.4 million in tariff refunds and offset by $0.2 million in severance expenses. Net income for the quarter rose to $1.3 million, or $0.12 per diluted share, compared to $1.2 million, or $0.11 per share, in the prior year. Additionally, the Board of Directors declared a quarterly cash dividend of $0.03 per share on the Series A common stock.Consumer Cyclical
- RMRNov 12, 4:19 PMThe RMR Group Inc. announced its financial results for the fiscal quarter ended September 30, 2026. The company, a leading U.S. alternative asset management firm focused on commercial real estate, manages approximately $37 billion in assets through over 800 professionals across more than 30 offices. A conference call to discuss these results was scheduled for November 13, 2026, at 11:00 a.m. Eastern Time, with a live webcast and replay options available.Real Estate
- GROWNov 12, 4:18 PMU.S. Global Investors reported a 18% increase in operating revenues to $2.7 million for the first quarter of fiscal 2027, ending the period with an operating income of $55,000 compared to a loss in the prior year. Average assets under management grew 14% to $1.6 billion, driven by a 45% surge in gold and precious metals strategies. The company also highlighted growth in its defense-focused WAR ETF and shipping-focused SEA ETF, while maintaining a shareholder yield of 8.33% and a strong liquidity position with $35.4 million in net working capital.Financial Services
- PMNNov 12, 4:17 PMProMIS Neurosciences reported a net loss of $8.2 million for the third quarter of 2026, with cash reserves totaling $44.1 million as of September 30, 2026. The company's lead Alzheimer's candidate, PMN310, remains on track to deliver unblinded 12-month topline data from the PRECISE-AD Phase 1b trial in the first quarter of 2027. Recent interim data showed no amyloid-related imaging abnormalities with edema and a 4.4% rate of hemorrhage, all of which were mild and asymptomatic. Ivana Rubino, Ph.D., a former senior executive at Biogen and Roche, was appointed Chief Commercial Officer effective October 5, 2026, to guide the company's late-stage development and commercial strategy.Healthcare
- PARKNov 12, 4:17 PMPark Dental Partners reported third-quarter 2026 revenue of $64.9 million, representing a 6.0% increase from the prior year, driven by same-practice growth and acquisitions. The company achieved net income of $1.7 million and adjusted EBITDA of $5.0 million for the quarter, while supporting 225 affiliated doctors across 88 practices. Full-year 2026 revenue is now projected to range between $262.0 million and $265.0 million, incorporating the expected contribution from the recently acquired Village Family DSO. Additionally, the company completed the acquisition of Village Family DSO in November 2026, with integration activities commencing immediately.Healthcare
- PROKNov 12, 4:17 PMProKidney Corp. reported third-quarter 2026 financial results, ending the period with $141.9 million in cash and cash equivalents to support operations through mid-2027. The company's pivotal Phase 3 PROACT 1 trial is on track to deliver eGFR slope topline results in the second quarter of 2027, with full enrollment expected to exceed 500 patients by the first quarter of 2027. During the quarter, research and development expenses rose to $40.8 million, driven primarily by increased clinical study and manufacturing costs associated with the ongoing trial. Additionally, the company presented eight new data abstracts at the ASN Kidney Week 2026 to further support the mechanistic and clinical evidence for its lead candidate, rilparencel.Healthcare
- ETRANov 12, 4:17 PMElectra Therapeutics reported a net loss of $23.9 million for the third quarter of 2026, supported by a cash position of $402.5 million following a $350 million IPO. The company is advancing its lead candidate, ipsoprubart, through a global registrational program for secondary hemophagocytic lymphohistiocytosis with enrollment completion expected in the second half of 2027. Additionally, ipsoprubart is being evaluated in a Phase 1 trial for T/NK cell malignancies, while the second candidate, ELA822, has initiated a Phase 1 trial in healthy volunteers with data expected in early 2027.Healthcare
- CTSONov 12, 4:16 PMCytoSorbents Corporation reported third-quarter 2026 revenue of $9.7 million, representing a 3% increase from the prior year, while achieving positive operating cash flow of approximately $43,000 excluding restructuring payments. The company improved its gross margin to 75% and reduced total operating expenses by 11% to $8.5 million, resulting in a net loss of $1.8 million compared to $3.2 million in the same period last year. Management highlighted progress on four strategic value drivers, including sustaining cash flow breakeven, revitalizing the core CytoSorb franchise in Germany, advancing the DrugSorb-ATR submission to the FDA for the U.S. market, and exploring commercial opportunities for the HemoDefend-BGA technology.Healthcare
- DFLINov 12, 4:16 PMDragonfly Energy reported third-quarter 2026 net sales of $12.2 million, a 23.8% decrease year-over-year, driven by softness in the recreational vehicle market despite heavy-duty trucking revenue more than doubling sequentially to $1.3 million. The company recorded a net loss attributable to common stockholders of $6.7 million and an adjusted EBITDA loss of $2.3 million, while completing the acquisition of the Dakota Lithium brand to expand its product portfolio. Management projects fourth-quarter 2026 net sales of approximately $12.5 million with adjusted EBITDA expected to reach breakeven, supported by continued fleet adoption and cost-reduction initiatives.Industrials
- ANABNov 12, 4:16 PMAnaptysBio reported fiscal first quarter 2027 results showing Jemperli global net sales of $1.0 billion for the nine months ended September 30, 2026, representing 29% year-over-year growth. The company received $30.3 million in collaboration revenue for the quarter, driven by Jemperli royalties, while net income from continuing operations was $3.9 million. Regulatory updates include FDA approval for Jemperli in locally advanced rectal cancer and an expected PDUFA decision for Quimilza in December 2026. Additionally, a post-trial hearing in the litigation with GSK and Tesaro was held on October 20, 2026, with a judgment anticipated in late 2026 or early 2027.Healthcare
- MSAINov 12, 4:16 PMMultiSensor AI Holdings, Inc. reported third-quarter 2026 net revenue of $1.5 million, a decrease from $1.6 million in the same period of 2025, driven by lower hardware sales and the discontinuation of inspection services. Software subscriptions now constitute the majority of revenue, accounting for 58% of the total, while the company posted a net loss of $1.9 million for the quarter. The company ended the period with $20.4 million in cash and cash equivalents, having reduced its cash burn rate through disciplined spending and strong collections. Strategic progress included the launch of a 14-site rollout in North America for a major global distributor and the expansion of deployments with Manchester Airports Group and a new pilot in the Asia-Pacific region.Technology
- WATTNov 12, 4:16 PMEnergous Wireless Power Solutions reported third-quarter 2026 revenue of approximately $3.4 million, representing a 167% increase compared to the same period in 2025. Year-to-date revenue for the nine months ended September 30, 2026, reached $9.6 million, a 270% rise over the prior year that exceeded the company's full-year 2025 revenue of $5.6 million. The company achieved a gross margin of 14% in the third quarter, improving from 3% in the second quarter, while shipping over 69,500 transmitters since 2024. Energous maintained a net loss of approximately $2.5 million for the quarter, or $0.45 per share, and held $28.8 million in cash and cash equivalents as of September 30, 2026.Technology
- RNANov 12, 4:16 PMAtrium Therapeutics reported third-quarter 2026 financial results, recording $15.3 million in collaboration revenue primarily from a milestone payment with Bristol Myers Squibb. The company dosed the first patient in its Corventis Phase 1/2 clinical trial for ATR 1072, a treatment targeting the root cause of PRKAG2 syndrome, following nonclinical data showing the drug reversed cardiac glycogen accumulation. A $50 million private placement closed in October, bringing the pro-forma cash balance to $293.6 million and extending the company's operational runway through 2028. For the quarter, the company reported research and development expenses of $13.8 million and general and administrative expenses of $8.2 million.Healthcare
- AMPGNov 12, 4:16 PMAmpliTech Group reported third-quarter 2026 revenue of $6.58 million, an 8.0% increase year-over-year, with gross margin expanding sequentially to 34.2%. The company achieved a nine-month gross profit growth of 41.1% to $7.07 million while narrowing its net loss to $1.89 million for the quarter. Following quarter-end, AmpliTech announced record bookings near $25 million in October, pushing its total backlog to over $52 million. Management revised its full-year 2026 revenue outlook to at least $28 million, citing supply-chain constraints and deployment delays that prevented the achievement of a previously withdrawn $50 million target.Technology
- TNONNov 12, 4:15 PMTenon Medical, Inc. reported third-quarter 2026 revenue of $1.4 million, representing a 22% increase compared to the same period in 2025. The company achieved a gross profit of $1.0 million with a gross margin of 66.3% and ended the quarter with $8.3 million in cash and cash equivalents. During the quarter, Tenon raised approximately $15.6 million in gross proceeds, fully repaid its senior convertible notes, and launched the 3D-printed lateral screw for its SImmetry+ SI Joint Fusion System. Additionally, the company added eight new U.S. patents to its portfolio, bringing the total to 38 issued patents.Healthcare
- VNRXNov 12, 4:15 PMVolitionRx Limited reported third-quarter 2026 revenue of approximately $1.6 million, a 157% increase from the prior year, driven by deferred revenue recognition. The company narrowed its operating loss to $3.3 million and reduced its net loss to $3.8 million while strengthening its balance sheet with $2.4 million in cash and the full repayment of a $7.5 million convertible note. Strategic progress includes the launch of the DETECSEPS program for sepsis detection, active licensing discussions for its Capture-Seq technology targeting a combined market over $36 billion, and a pending reimbursement submission for its lung cancer test in France. Additionally, the CEO and board voluntarily reduced their compensation by 50% to align with the company's cost-reduction efforts and commitment to securing licensing agreements.Healthcare
- RCKTNov 12, 4:15 PMRocket Pharmaceuticals reported a net loss of $49.2 million for the third quarter of 2026, with cash, cash equivalents, and investments totaling $279.4 million as of September 30, 2026. The company received FDA alignment to complete its pivotal Phase 2 trial of RP-A501 for Danon disease, with dosing expected to finish by mid-2027. Additionally, dosing has begun in the Phase 1 trial for RP-A701 targeting BAG3-associated dilated cardiomyopathy, and the commercial product KRESLADI achieved readiness with activated treatment centers on October 1, 2026.Healthcare
- QXONov 12, 4:15 PMQXO, Inc. reported a net loss of $123 million for the third quarter of 2026, with net sales reaching $4.90 billion. Despite the GAAP loss, the company achieved an Adjusted Net Income of $229 million and Adjusted EBITDA of $557 million, driven by a 2.2% year-over-year pricing increase and strong demand in mechanical insulation and data centers. The company serves 194,000 customers across its integrated legacy businesses and has authorized a $500 million share repurchase program. Management projects reaching $4 billion in adjusted EBITDA and $50 billion in annual revenue by 2030 through organic growth and acquisitions.Industrials
- GCTSNov 12, 4:15 PMGCT Semiconductor Holding, Inc. reported third-quarter 2026 net revenues of $1.1 million, representing a 148.6% increase from the prior year period, driven by shipments of over 3,200 5G chipsets. The company achieved a net loss of $7.4 million, a 46.7% decrease year-over-year, which included $6.2 million in gains from changes in the fair value of warrant liabilities. Cash and cash equivalents stood at $17.2 million as of September 30, 2026, while the company extended the maturities of $26.5 million in loans during the quarter. Management expects 5G shipment volumes to ramp significantly into the first half of 2027 as customer integration schedules progress.Technology
- NEOVNov 12, 4:15 PMNeoVolta Inc. reported revenue of $2.8 million for the quarter ended September 30, 2026, a significant increase from the previous quarter driven by initial sales through its third-party ownership residential platform. The company achieved a gross profit of $1.0 million, reversing a prior gross loss, while reporting a GAAP net loss of $7.7 million and adjusted EBITDA of negative $5.5 million. Financial results were supported by a $20 million senior secured term loan, bringing total cash and restricted cash to $28.8 million. Strategic progress included the ramp-up of the Pendergrass, Georgia manufacturing facility, a $116 million master purchase agreement for utility-scale products, and a supply collaboration with SK On for 9 GWh of battery cells.Industrials
- CBIONov 12, 4:15 PMCrescent Biopharma completed dose escalation in its Phase 1/2 ASCEND trial for CR-001, having dosed over 125 patients across the United States, Europe, and South Korea, with initial monotherapy data expected in the first quarter of 2027. The company has also dosed the first patient in the global APOLLO trial for CR-002, a PD-L1-targeted ADC, while multiple Phase 2 studies of CR-001 combinations with sacituzumab tirumotecan are ongoing in China. Financially, Crescent reported a net loss of $37.7 million for the third quarter of 2026, with cash and cash equivalents totaling $289.4 million as of September 30, 2026.Healthcare
- FLONov 12, 4:15 PMFlowers Foods, Inc. reported third-quarter 2026 net sales of $1.169 billion, a 4.7% decrease from the prior year, driven by a 7.0% decline in volume that outweighed a 2.3% favorable price and mix. Net income fell 63.6% to $14.4 million, while adjusted net income decreased 56.0% to $21.4 million, resulting in diluted earnings per share of $0.07. The company cited challenging market conditions, including pressure on household budgets and higher logistics costs, as key factors impacting performance. Consequently, Flowers Foods revised its full-year 2026 guidance downward, projecting net sales between $5.016 billion and $5.063 billion and adjusted diluted EPS between $0.63 and $0.68.Consumer Defensive
- BLSMNov 12, 4:15 PMBlossomHill Therapeutics reported a net loss of $24.0 million for the third quarter of 2026, driven by increased research and development expenses related to its lead candidate BH-30643. The company aligned with the FDA on a recommended Phase 2 dose of 50 mg twice daily for BH-30643 and announced the upcoming SOLARA-2 pivotal trial, which is expected to dose its first patient in the first quarter of 2027. Additionally, BlossomHill plans to submit an Investigational New Drug application for its pan-KRAS inhibitor, BH-501284, in the first quarter of 2027. As of September 30, 2026, the company held $224.9 million in cash and cash equivalents, which is projected to fund operations through the second quarter of 2028.Healthcare
- AZTRNov 12, 4:15 PMAzitra, Inc. reported a net loss of $3.0 million for the quarter ended September 30, 2026, with total operating expenses reaching $2.9 million. The company announced positive ex vivo results for its ATR-COSF program, demonstrating a 50% reduction in fine lines and improved skin elasticity, and plans to initiate a first-in-human cosmetic study with results expected by year-end. Additionally, Azitra completed Cohort 1 of its ATR-04 Phase 1/2 trial and received approval to proceed to Cohort 2, which will expand eligibility to include patients with KRAS and MEK inhibitor-associated rashes. As of September 30, 2026, the company held $3.8 million in cash and cash equivalents.Healthcare
- IMMXNov 12, 4:15 PMImmix Biopharma reported a 89% complete response rate across all 45 patients in its NEXICART-2 clinical trial for NXC-201, with potential for up to 98% complete response. The company appointed David He as Senior Vice President of Technical Operations and Karin McIntosh as Senior Vice President of Regulatory Affairs to advance commercial launch preparations. Immix plans to submit a Biologics License Application in mid-2027 and initiate the NEXICART-3 front-line trial in the first half of 2027. For the third quarter ended September 30, 2026, the company reported $340.9 million in cash and marketable securities, providing an operating runway into mid-2028, alongside $15.9 million in operating expenses.Healthcare
- HKHCNov 12, 4:15 PMHorizon Kinetics Holding Corporation reported a net loss of $18.4 million for the third quarter of 2026, driven by unrealized declines in the fair value of key investment holdings. Management and advisory fees remained flat at $17.8 million for the quarter, while assets under management decreased 7.3% to $10.0 billion. The company declared a $0.13 per share cash dividend and authorized a $25 million share repurchase program. Year-to-date results showed a net income of $35.8 million, reflecting unrealized gains that offset the quarterly losses.
- KLCNov 12, 4:15 PMKinderCare Learning Companies reported a net loss of $85.0 million for the third quarter of 2026, driven by $83.4 million in impairment losses and a 5.9% decline in enrollment at its early childhood education centers. Total revenue for the period decreased 1.7% to $665.3 million, while adjusted EBITDA fell to $42.5 million compared to the prior year quarter. The company closed 20 centers as part of an optimization initiative and updated its full-year 2026 revenue guidance to a range of $2.64 billion to $2.66 billion.Consumer Defensive
- MRLNNov 12, 4:14 PMMerlin, Inc. reported a third quarter 2026 GAAP net income of $73.8 million, a significant turnaround from the $58.4 million loss in the second quarter of 2026. Total revenue for the quarter reached $3.5 million, while the company ended the period with $161.6 million in cash, cash equivalents, and short-term investments and no outstanding debt. The company secured an $8.9 million task order from USSOCOM for its C-130J autonomy program and a $500,000 contract from USAFRICOM for an autonomous casualty evacuation demonstration. Looking ahead, Merlin plans to reduce 2027 operating expenses by focusing investment on funded programs with clear revenue paths to preserve its balance sheet.Industrials
- NTLANov 12, 4:14 PMIntellia Therapeutics has submitted a Biologics License Application for lonvo-z, an investigational one-time in vivo CRISPR gene editing therapy for hereditary angioedema (HAE), with a PDUFA goal date of March 10, 2027. Phase 3 HAELO trial data demonstrated a 62% reduction in mean attack rates and an 87% reduction in attack-free weeks compared to placebo, with benefits sustained for up to four years in long-term follow-up. The treatment permanently inactivates the KLKB1 gene to stop excess kallikrein production, offering a potential cure that eliminates the need for chronic long-term prophylaxis and significantly reduces the disease burden for patients.Healthcare
- TACTNov 12, 4:13 PMTransAct Technologies reported preliminary third-quarter 2026 net sales of $14.4 million, representing a 10% increase year-over-year driven by a 33% rise in Food Service Technology revenue. The company recorded a net loss of $440 thousand for the quarter, with adjusted EBITDA reaching $289 thousand, while revising its full-year 2026 revenue guidance to between $55 million and $56 million. Management highlighted strong growth in FST software revenue and online unit installations, though the Casino and Gaming segment experienced a decline due to cyclicality. Additionally, the Board has initiated a strategic review of the Casino and Gaming business, potentially including a sale of the FST division, to maximize stockholder value.Technology
- SERNov 12, 4:13 PMSerina Therapeutics reported a net loss of $7.9 million for the third quarter of 2026, driven by increased research and development expenses related to clinical activities. The company advanced its investigational Parkinson's disease treatment, SER-252, to Cohort 2 of its registrational study following a positive safety review by an independent committee. Cash and cash equivalents increased to $19.4 million as of September 30, 2026, supported by financing activities. Topline data from the single-ascending-dose portion of the SER-252 trial is expected in the first half of 2027.Healthcare
- SSTINov 12, 4:12 PMSoundThinking, Inc. reported third-quarter 2026 revenues of $25.0 million, a slight decrease from the prior year, while GAAP net loss widened to $8.5 million compared to $2.0 million in the same period of 2025. The company announced a definitive merger agreement with Transom Capital Group to be acquired for $8.00 per share in cash plus contingent value rights, with an expected closing in the fourth quarter of 2026. Due to the pending transaction, SoundThinking will not provide forward-looking guidance or host an earnings conference call for this quarter or future quarters. Adjusted EBITDA for the quarter totaled $2.2 million, down from $3.5 million in the previous year, driven by increased acquisition-related costs and higher operating expenses.Technology
- OFRMNov 12, 4:12 PMOnce Upon a Farm reported third-quarter 2026 net sales of $89.1 million, representing a 34.9% increase from the prior year period. The company posted a net loss of $3.8 million and an adjusted EBITDA loss of $1.0 million, driven by trade investments and cooler placement costs that reduced gross margin to 36.1%. As of September 30, 2026, the company held $106.4 million in cash and cash equivalents with no outstanding debt. Consequently, the company updated its full-year 2026 outlook, lowering net sales guidance to $290–$300 million and adjusting the adjusted EBITDA loss forecast to $4.5–$7 million due to the impact of a voluntary product recall.Consumer Defensive
- SRTSNov 12, 4:12 PMSensus Healthcare reported third-quarter 2026 revenues of $6.0 million, a 13% decrease from the prior year, driven by a shift toward lower-priced SRT-100 systems and the absence of sales to a historically large customer. Despite lower revenue, gross profit increased to $3.3 million as the gross margin improved to 55% due to a favorable product mix and lower cost of sales. The company shipped 26 systems during the quarter, including eight carried over from the previous quarter, and announced the sale of its 1,000th SRT system subsequent to the quarter end. Net loss for the period was $1.5 million, or $0.09 per share, while adjusted EBITDA improved to a negative $1.5 million from negative $2.4 million in the prior year.Healthcare
- BOLTNov 12, 4:11 PMBolt Biotherapeutics completed the acquisition of Prana Therapies in a stock-for-stock reverse merger and secured $120 million in concurrent private placement financing. The company has designated the INSPIRE-built pipeline, led by the Phase 2 bispecific antibody PRA-216, as its primary development focus for treating asthma, atopic dermatitis, and chronic obstructive pulmonary disease. PRA-216 Phase 1 data demonstrated the potential for at-home maintenance dosing every 8 to 12 weeks, with initial Phase 2 proof-of-concept data expected in the second quarter of 2027. For the third quarter of 2026, the company reported a net loss of $4.4 million and operating expenses of $4.7 million, while its cash runway is projected to extend into 2028.Healthcare
- BCDANov 12, 4:11 PMBioCardia, Inc. reported a net loss of $1.8 million for the third quarter of 2026, with total operating expenses reaching $1.8 million. The company successfully completed regulatory interactions with Japan's PMDA regarding its CardiAMP autologous cell therapy and expects to submit for approval in Japan during late 2026 or early 2027. Additionally, the FDA accepted the company's pre-submission minutes for the Helix transendocardial delivery system, with a full De Novo submission targeted for the first quarter of 2027. BioCardia ended the quarter with $2.2 million in cash and cash equivalents, providing an anticipated runway into 2027.Healthcare
- MGNXNov 12, 4:11 PMMacroGenics reported a net loss of $20.1 million for the third quarter of 2026, with total revenue declining to $18.7 million from $53.0 million in the same period last year. The company's cash position increased to $287.7 million as of September 30, 2026, supported by milestone payments from partners and the sale of its GMP manufacturing operations. Clinical progress included the completion of Phase 1 dose escalation for MGC028, the reporting of interim results for MGC026 and lorigerlimab at ESMO 2026, and the dosing of the first patient in the Phase 1 study for MGC030. Additionally, the Board of Directors was strengthened by the appointment of two new independent directors with oncology expertise, and Gilead Sciences exercised an option to license a preclinical bispecific program, triggering a $10 million payment.Healthcare
- FDMTNov 12, 4:11 PM4D Molecular Therapeutics completed enrollment and randomization for the 4FRONT-2 Phase 3 clinical trial of its lead candidate 4D-150 in wet age-related macular degeneration, with topline data expected in the second half of 2027. The company also initiated the global 4SIGHT Phase 3 trial for 4D-150 in diabetic macular edema and presented two-year data from PRISM and SPECTRA trials demonstrating durable clinical activity and a favorable safety profile. Financially, the company reported a net loss of $78.1 million for the third quarter of 2026, driven by increased research and development expenses, while maintaining a cash position of $375 million expected to fund operations through the second half of 2028.Healthcare
- PLRXNov 12, 4:11 PMPliant Therapeutics reported a net loss of $24.4 million for the third quarter of 2026, with research and development expenses remaining flat at $17.9 million despite the termination of its bexotegrast program. The company's lead candidate, PLN-101095, continues to enroll ahead of schedule in the FORTIFY Phase 1b trial for immune checkpoint inhibitor-refractory solid tumors, with interim data expected in 2027. Pliant also announced the appointment of David Raben as Chief Medical Officer and Craig Blanchette as Senior Vice President of Research to lead its RNAi initiatives. The company's proprietary integrin-mediated delivery platform has demonstrated over 75% target gene knockdown in non-human primate studies while avoiding liver exposure, supporting plans to target neuromuscular and cardiac diseases. As of September 30, 2026, Pliant held $142.6 million in cash and short-term investments, which is projected to fund operations through mid-2028.Healthcare
- ALMSNov 12, 4:11 PMAlumis Inc. reported a net loss of $94.9 million for the third quarter of 2026, driven by $80.8 million in research and development expenses and $20.2 million in general and administrative costs. The company highlighted new Phase 3 data for its lead candidate envudeucitinib in plaque psoriasis, which demonstrated rapid and durable improvements in skin clearance and itch resolution, supporting a planned New Drug Application submission in the fourth quarter of 2026. Conversely, the Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus did not meet its primary endpoints in the overall population, though robust responses were observed in a subgroup with high interferon gene signatures. As of September 30, 2026, Alumis held $431.3 million in cash and marketable securities, which is expected to fund operations through the fourth quarter of 2027.Healthcare
- CBUSNov 12, 4:11 PMCibus reported a net loss of $21.9 million for the third quarter of 2026, with cash used in operating activities decreasing by approximately 19% year-over-year to $9.3 million. The company advanced its Rice herbicide-tolerance traits into customer field trials in Ecuador and initiated manufacturing for two biofragrance products, which represent a potential $100 million peak annual revenue opportunity. Regulatory progress included U.S. FDA clearance for an altered-lignin Alfalfa trait and European Union legislation treating precise genomic edits as conventional breeding. Cibus anticipates exiting 2026 with an annualized net cash usage run rate of approximately $35 million, supported by a cash balance of $10.7 million as of September 30, 2026.Healthcare
- INVENov 12, 4:11 PMINVE Technologies reported third-quarter 2026 revenue of $3.1 million, a decrease from $5.0 million in the prior year, driven by lower RFID unit sales and the divestiture of its IoT business to Trackonomy. The company achieved a GAAP net income of $0.6 million, or $0.02 per share, compared to a net loss of $3.5 million in the same period last year, primarily due to gains recognized on the asset sale and the dissolution of a foreign subsidiary. Following the September 15, 2026, sale of its IoT business, INVE Technologies currently has no commercial revenue and has suspended financial guidance. Non-GAAP operating expenses decreased to $4.0 million from $4.5 million in the prior year, reflecting disciplined cost control despite higher strategic transaction-related costs.Technology
- AAWHNov 12, 4:10 PMAscend Wellness Holdings reported third-quarter 2026 net revenue of $130.0 million, representing a 4.2% year-over-year increase and a 3.1% sequential rise. The company generated $31.1 million in Adjusted EBITDA, achieving a margin of 23.9%, while net cash provided by operating activities reached $5.4 million despite a $19.1 million semi-annual interest payment. Retail operations expanded to 61 stores, exceeding the year-end target of 60, and the company maintained its position as the number two brand house across Illinois, New Jersey, and Massachusetts. Additionally, Ascend secured $11 million in non-dilutive mortgage loans and entered a brand licensing agreement to introduce its products to the Canadian market in early 2027.
- LFMDNov 12, 4:10 PMLifeMD reported third-quarter 2026 revenue of $44.6 million, representing a 7% decline from the prior year, while adjusting its full-year revenue guidance downward to a range of $188 million to $191 million. The company achieved an adjusted EBITDA loss of approximately $0.4 million, a significant sequential improvement driven by a 34% reduction in selling and marketing expenses. Total active subscribers grew 13% year-over-year to 350,000, and the pharmacy division saw shipment volume increase by 58.3%. Strategic developments included new dispensing agreements for branded GLP-1 medications with Novo Nordisk and Eli Lilly, as well as an exclusive partnership with AT&T to serve its customer base.Healthcare
- RLMDNov 12, 4:10 PMRelmada Therapeutics reported a net loss of $13.9 million for the third quarter of 2026, with research and development expenses rising to $9.2 million. The company holds approximately $202.1 million in cash and short-term investments as of September 30, 2026, which is projected to fund operations through 2029. Clinical updates indicate that 86% of patients in the NDV-01 Phase 2 study who achieved a complete response at 12 months remained in complete response at 18 months. Relmada remains on track to submit Investigational New Drug applications for both NDV-01 and sepranolone by the end of 2026, with the registrational Phase 3 SPECTRUM program for NDV-01 expected to commence upon clearance.Healthcare
- OPHCNov 12, 4:10 PMOptimumBank Holdings, Inc. reported net income of $7.2 million, or $0.30 per share, for the third quarter of 2026, marking an increase from the previous quarter and the same period last year. The company's gross loan portfolio grew by $150.2 million to $1.37 billion, while total deposits rose by $128.8 million to $1.34 billion during the quarter. Net interest income increased to $16.8 million, driven by higher yields on loans and securities, resulting in a net interest margin of 4.63%. Additionally, the company strengthened its capital position through a $35.0 million subordinated debt offering and maintained strong asset quality with net charge-offs of only $11,000.Financial Services
- UAMYNov 12, 4:10 PMUnited States Antimony Corporation reported third-quarter 2026 revenues of $10.1 million, a 16% increase from the prior year, driven by a 68% rise in antimony pounds sold. The company achieved a gross profit margin of 42%, up from 23% in the previous year, resulting in $4.3 million in gross profit despite a net loss of $9.5 million due to non-cash stock-based compensation and an unrealized loss on an equity investment. Antimony sales included approximately 162,000 pounds of metal ingots accepted by the Defense Logistics Agency, contributing $5.1 million in revenue, while industrial sales volumes increased 10% year-over-year. The company provided full-year 2026 guidance for antimony sales volumes between 1.68 million and 1.81 million pounds, representing a 24% increase over 2025, and maintained significant liquidity with $51.0 million in cash and U.S. Treasury securities.Basic Materials
- PEWNov 12, 4:10 PMGrabAGun Digital Holdings reported third-quarter 2026 net revenues of $21.2 million, a 4.7% decrease from the prior year, driven by lower firearms and non-firearms sales. Despite the revenue decline, the company achieved a 44% increase in gross profit and expanded its gross margin by 480 basis points to 14.4%, supported by improved average selling prices and sourcing. The company posted a net loss of $3.0 million for the quarter and $6.7 million for the first nine months, while maintaining $96.0 million in cash and minimal debt. Subsequent to the quarter, GrabAGun completed the acquisition of Camfour, a New England-based wholesale distributor, to broaden its distribution capabilities.Industrials
- FLNTNov 12, 4:10 PMFluent, Inc. reported third-quarter 2026 revenue of $53.6 million, a 14% increase year-over-year, driven by Commerce Media Solutions revenue doubling to $37.5 million. The company's Commerce Media Solutions segment now accounts for 70% of total revenue with an annual run rate exceeding $145 million and a gross margin of 30%. Net loss for the quarter narrowed to $3.1 million from $7.6 million in the prior year period, while adjusted EBITDA reached near-breakeven at $0.0 million. Fluent expects full-year 2026 to deliver double-digit revenue growth on aggregate continuing businesses and improved adjusted EBITDA.Communication Services
- SMTINov 12, 4:10 PMSanara MedTech Inc. reported third-quarter 2026 net revenue of $28.4 million, an 8% increase from the prior year, driven by growth in soft tissue repair products. The company posted a net loss from continuing operations of $1.3 million, or $0.15 per diluted share, compared to a net income of $0.8 million in the same period last year. Adjusted EBITDA for the quarter rose to $5.6 million, while the company updated its full-year 2026 revenue guidance to a range of $110 million to $115 million. Additionally, Sanara continues to advance its pending merger with MiMedx Group, Inc., which received shareholder approval in September.Healthcare
- SNALNov 12, 4:10 PMSnail, Inc. reported third-quarter 2026 net revenues of $33.1 million, representing a 139.2% increase from the prior year period, driven primarily by strong sales of ARK: Survival Ascended and its downloadable content. The company achieved a net income of $6.7 million for the quarter, a significant turnaround from a net loss of $7.9 million in the same period last year, while total units sold rose 73.3% to 2.0 million. Key operational highlights included the launch of new ARK content updates, the release of titles such as Bellwright and Honeycomb: The World Beyond, and the unveiling of upcoming AAA projects like 9 Yin Sutra and For The Stars. Looking ahead, Snail expects continued momentum from its established ARK content pipeline extending through 2027 and the anticipated release of ARK: Dragontopia in December 2026.Communication Services
- EQNov 12, 4:10 PMEquillium, Inc. initiated a Phase 1 clinical trial for its investigational drug EQ504 in October 2026, with proof-of-mechanism data expected in the second quarter of 2027. The company reported cash and cash equivalents of $53.3 million as of September 30, 2026, and secured an additional $20 million in financing later that month, extending its cash runway into 2029. For the third quarter of 2026, Equillium recorded a net loss of $4.6 million, driven by research and development expenses of $2.5 million and general and administrative expenses of $2.6 million. EQ504 is a selective aryl hydrocarbon receptor modulator designed to treat ulcerative colitis and other inflammatory disorders through a non-immunosuppressive mechanism.Healthcare
- LCTXNov 12, 4:10 PMLineage Cell Therapeutics reported a net income of $4.2 million for the third quarter of 2026, driven primarily by a non-cash gain from the fair value remeasurement of warrant liabilities. The company acquired NeuroAirmid Therapeutics, adding the HUNT1 clinical-stage cell therapy candidate for Huntington's Disease to its pipeline, and secured a U.S. patent for its AlloSCOPE 5D manufacturing technology. Financial results showed total revenues of $1.4 million and operating expenses of $8.8 million, with cash and marketable securities totaling $45.2 million expected to fund operations through the second quarter of 2028. Key program updates include the advancement of the ReSonance hearing loss therapy into the second year of its collaboration with William Demant Invest and the initiation of preclinical testing for the COR1 corneal endothelial disease program.Healthcare
- ELDNNov 12, 4:10 PMEledon Pharmaceuticals reported a net loss of $3.9 million for the third quarter of 2026, driven by $17.8 million in research and development expenses, while maintaining $69.7 million in cash and short-term investments sufficient to fund operations into the second quarter of 2027. The company received FDA Fast Track designation for tegoprubart in kidney transplantation and cleared an IND application for a registrational study in islet cell transplantation for type 1 diabetes. Clinical updates included new patient-reported outcome data showing improved quality of life and symptom burden for tegoprubart compared to tacrolimus in kidney transplant recipients, alongside long-term data demonstrating sustained eGFR advantages. Upcoming milestones include the initiation of the global Phase 3 LEGACY trial for kidney transplantation in the fourth quarter of 2026 and the start of a registrational path study for islet cell transplantation.Healthcare
- RKDANov 12, 4:09 PMArcadia Biosciences reported third-quarter 2026 total revenues of $1.619 million, representing a 24% year-over-year increase driven by strong summer program volumes. The company achieved net income of $1.755 million for the quarter, a significant improvement from the $856,000 net income recorded in the same period of 2025, largely due to a $2.6 million gain from changes in the fair value of warrant and option liabilities. Zola brand revenues reached their highest quarterly sales ever, with a new 1-liter espresso formulation beginning shipments and slim can variants scheduled for launch in early 2027. Operating expenses for the nine-month period decreased by 23% compared to the prior year, offset by a $2.7 million reduction in other operating income related to the absence of prior-year patent transfer gains.Consumer Defensive
- ACCVNov 12, 4:08 PMAccelevation Holdings Corp. reported third-quarter 2026 revenue of $202.2 million, representing a 65.9% year-over-year increase, while bookings surged 364% to $768.9 million. The company achieved a backlog of $1.7 billion and an adjusted EBITDA of $37.7 million, with operating cash flow turning positive to $62.5 million. Following its initial public offering in October 2026, the company entered into a new $650 million senior secured credit agreement to reduce leverage. Management has issued full-year 2026 guidance projecting revenue between $905 million and $915 million and adjusted EBITDA between $155 million and $165 million.Industrials
- REKRNov 12, 4:08 PMRekor Systems reported a net loss of $2.9 million for the third quarter of 2026, narrowing from $4.1 million in the prior year period, while recurring revenue grew 16% to $7.5 million. The company reduced its nine-month operating cash use by 49% to $10.6 million following a major rightsizing initiative that eliminated approximately $9.7 million in lease liabilities. Recent business developments include a potential $1.4 million five-year contract with the Oregon Department of Transportation and a 94% increase in the contract ceiling with the Florida Department of Transportation. Additionally, Rekor expanded its Born Authentic product line to include audio authentication and is actively pursuing refinancing for its $15 million Series A Prime Revenue Sharing Notes due in December 2026.Technology
- ERASNov 12, 4:08 PMErasca, Inc. reported a net loss of $51.3 million for the third quarter ended September 30, 2026, while maintaining a cash position of $947.8 million. The company's lead candidate, ERAS-0015, received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma in August 2026. Erasca is advancing toward three potentially registration-enabling trials in pancreatic and lung cancers, with preliminary data for ERAS-4001 expected in the second half of 2026. Additionally, the firm completed an upsized public offering in July 2026 that raised approximately $632.5 million to fund its development pipeline.Healthcare
- OBXNov 12, 4:07 PMObsidian Therapeutics reported third-quarter 2026 financial results showing a net loss of $50.7 million and cash reserves of $324.4 million as of September 30, 2026. The company presented updated efficacy data for its lead candidate amsoki-cel in advanced melanoma, demonstrating a 67% objective response rate and a median progression-free survival of 8.3 months in the registration-enabling cohort of the Agni-01 study. Enrollment in this cohort is expected to conclude by the end of the first quarter of 2027, with topline data anticipated by the end of 2027. Corporate updates include the completion of a $350 million financing round, the closing of a transaction with Galera Therapeutics, and the appointment of Mark Reisenauer to the Board of Directors.Healthcare
- SHIMNov 12, 4:07 PMShimmick Corporation reported a net income of $1 million for the third quarter ended October 2, 2026, marking its first positive net income since the third quarter of 2023. Revenue for the quarter reached $136 million, driven entirely by Shimmick Projects which saw a 28% increase quarter-over-quarter, while Adjusted EBITDA rose 106% to $9 million. The company's liquidity increased by $20 million to $53 million, and its backlog stands at approximately $907 million with Shimmick Projects representing 98% of the total. Management reaffirmed full-year 2026 Adjusted EBITDA guidance between $20 million and $25 million and raised revenue expectations to a range of $500 million to $525 million.Industrials
- IDNNov 12, 4:07 PMIntellicheck reported a net income of $0.5 million for the third quarter of 2026, marking its fifth consecutive quarter of profitability. Revenue for the period totaled $5.7 million, while Adjusted EBITDA increased to $0.9 million, representing the sixth consecutive quarter of positive performance. The company ended the quarter with $13.2 million in cash and no debt, its highest cash balance since the end of 2021. Banking and lending remained the fastest-growing vertical, with momentum also observed in emerging sectors such as cargo, freight, and automotive credit.Technology
- TMCNov 12, 4:07 PMThe Metals Company reported a net loss of $28.4 million for the third quarter of 2026, with liquidity of approximately $123 million available as of September 30. The company's subsidiary, TMC USA, received an updated timeline from NOAA expecting a final certification determination by mid-December 2026 for its USA-A commercial recovery permit application. TMC is advancing a capital-light production strategy with Allseas to initiate operations upon permit grant, while simultaneously pursuing U.S. government funding for a processing facility in Brownsville, Texas. Additionally, the company appointed Liam Mallon, former President of ExxonMobil Upstream, to its Board of Directors to leverage his extensive energy and offshore experience.Basic Materials
- NPCENov 12, 4:07 PMNeuroPace reported third-quarter 2026 total revenue of $23.1 million, with RNS System revenue reaching $22.9 million, representing a 1.4% year-over-year growth. The company revised its full-year 2026 revenue guidance downward to a range of $91 million to $92 million, citing the need to improve commercial execution following isolated account-level issues. Despite a net loss of $3.3 million for the quarter, the company achieved a positive adjusted EBITDA of $0.4 million and increased its non-GAAP gross margin to 84.8%. Strategic advancements include an FDA submission for the NeuroPace Remote Care system and the initiation of the AURORA study to support indication expansion for adolescents.Healthcare
- SLSNov 12, 4:07 PMSELLAS Life Sciences reported a net loss of $10.1 million for the third quarter of 2026, with research and development expenses rising to $7.0 million due to costs associated with the Phase 3 REGAL trial and potential Biologics License Application for GPS. The company holds $134.7 million in cash and cash equivalents as of September 30, 2026, providing capital to advance its clinical programs. Topline primary endpoint results for the Phase 3 REGAL trial of Galinpepimut-S in acute myeloid leukemia are expected to be announced following the 80th event milestone. Additionally, 40 patients have been enrolled in the Phase 2 trial of tambiciclib (SLS009) for newly diagnosed AML, with preliminary data anticipated in the fourth quarter.Healthcare
- LFTONov 12, 4:07 PMLiftoff Mobile reported third-quarter 2026 revenue of $238 million, representing an 8% increase from the previous quarter and a 32% year-over-year growth. The company achieved a net income of $87 million and an adjusted EBITDA of $145 million, with margins of 37% and 61% respectively. Trailing twelve-month free cash flow rose 158% to $249 million, driven by strong performance across key app categories. Management provided fourth-quarter revenue guidance between $244 million and $249 million and full-year revenue guidance between $907 million and $912 million.Communication Services
- KSCPNov 12, 4:06 PMKnightscope reported third-quarter 2026 revenue of $8.7 million, representing a 177% increase year over year and marking the third consecutive quarter of triple-digit growth. The company achieved a positive gross margin of $0.4 million, driven by a 349% surge in service revenue to $8.6 million, while operating expenses rose to $12.0 million. Knightscope unveiled its Autonomous Security Force at GSX 2026 and secured approximately $27 million in renewals and bookings since May 2026, though the company reported a net loss of $11.8 million for the quarter.Industrials
- AZRNov 12, 4:06 PMAzora Therapeutics, Inc. reported a net loss of $64.6 million for the third quarter ended September 30, 2026, driven primarily by a $57.1 million non-cash charge related to the change in fair value of milestone warrant rights liability. The company's cash and cash equivalents stood at $22.0 million as of the quarter's end, which is expected to fund operations through the initiation of a Phase 1a clinical trial. Azora advanced its lead candidate, AT177, an oral AhR agonist for ulcerative colitis, through IND-enabling studies with a planned IND submission and Phase 1a trial initiation in the first half of 2027. Corporate updates include a name change from Adial Pharmaceuticals, a new Nasdaq ticker symbol (AZR), and the appointment of a new executive team and Board of Directors effective late October 2026.Healthcare
- STEXNov 12, 4:06 PMStreamex Corp. reported a net loss of $17.5 million for the third quarter of 2026, driven primarily by $9.3 million in non-cash stock-based compensation. The company's gold-backed token, GLDY, grew by 240 net ounces to reach 3,351 ounces, while external ownership of the token doubled to 17.7% of the outstanding supply. Streamex ended the quarter debt-free with a total liquidity position of $36.5 million, including $13.2 million in cash and investments, and announced that GLDY will soon launch on Equity Trust's IRA platform.Healthcare
- CSCONov 12, 4:06 PMCisco reported record first-quarter revenue of $18.5 billion, representing a 24% year-over-year increase, alongside record non-GAAP earnings per share of $1.40. The company raised its full-year fiscal 2027 revenue guidance to a range of $74.8 billion to $75.8 billion and increased its AI infrastructure revenue expectation from hyperscalers to $9 billion for the year. Operating performance was driven by broad-based demand, with product revenue growing 32% and double-digit growth observed across all geographic regions and customer markets.Technology
- EVMNNov 12, 4:06 PMEvommune, Inc. reported a net loss of $30.9 million for the third quarter of 2026, with cash and investments totaling $262.3 million as of September 30, 2026. The company in-licensed EVO570, an oral VAV-1 molecular glue degrader, for $30 million and concurrently raised $30 million through a private placement of common stock. Clinical updates include positive Phase 2a data for EVO301 in atopic dermatitis, which supports a Phase 2b trial expected to initiate in mid-2027, alongside plans to begin Phase 1 trials for EVO570 and EVO646 in early 2027.Healthcare
- HQINov 12, 4:06 PMHireQuest reported third-quarter 2026 net income of $1.7 million, or $0.12 per diluted share, a decrease from $2.3 million in the same period of 2025. Total revenue for the quarter reached $8.8 million, representing a 4.0% increase year-over-year, while adjusted EBITDA remained consistent at $4.5 million. The decline in net income was primarily driven by a $1.3 million write-down of notes receivable related to a franchised location repossession and higher workers' compensation expenses. System-wide sales for the quarter totaled $131.2 million, with pro forma growth of 11.4% after accounting for the MRINetwork Assets Divestiture.Industrials
- SLSNNov 12, 4:06 PMSolésence, Inc. reported record third-quarter 2026 financial results with revenue increasing 38% year-over-year to $20.2 million. The company achieved its highest-ever net income of $3.7 million, a significant turnaround from a $1.0 million net loss in the same period of 2025. Gross margin expanded substantially to 39.3% from 23.8% in the prior year, driven by operational improvements and capacity enhancements. These results position the company for sustained growth as it continues to scale its manufacturing and innovation capabilities.Consumer Defensive
- OPNWNov 12, 4:05 PMOpenWorld, Inc. reported third-quarter 2026 revenue of $7.4 million, driven by a $6.4 million contribution from its new real-world asset (RWA) platform which achieved an 80% gross margin. The company recorded a GAAP net loss of $10.2 million for the quarter, primarily due to $6.4 million in non-recurring stock-based compensation and $6.0 million in merger-related professional fees. Subsequent to the quarter, OpenWorld secured $1.1 billion in non-binding letters of intent for tokenized financing programs involving AI infrastructure and intellectual property. The company also completed a $3.5 million registered direct offering and the acquisition of Blocksight Holdings to enhance its platform capabilities.Technology
- DERMNov 12, 4:05 PMJourney Medical Corporation reported total revenues of $19.0 million for the third quarter of 2026, representing an 8% increase from the prior year period. The company's flagship product, Emrosi, generated $9.0 million in revenue, marking an 84% year-over-year growth driven by increased prescription demand and improved reimbursement mixes. Gross margin improved to 69% for the quarter, while the GAAP net loss narrowed to $1.3 million compared to $2.3 million in the same period of 2025. The company ended the quarter with $22.3 million in cash and cash equivalents and achieved positive non-GAAP EBITDA of $3.5 million.Healthcare
- JCAPNov 12, 4:05 PMJefferson Capital reported record third-quarter 2026 results with collections growing 35% to $319.2 million and deployments surging 111% to $318.0 million. The company achieved a record Estimated Remaining Collections (ERC) of $3.6 billion, representing a 23% increase from the prior year period. Financial performance included pre-tax income of $58.9 million and net income of $46.9 million, resulting in earnings per share of $0.76. Additionally, the Board of Directors declared a quarterly cash dividend of $0.24 per share, payable in December 2026.Financial Services
- ADRXNov 12, 4:05 PMADARx Pharmaceuticals completed its initial public offering and a concurrent private placement, generating approximately $602.5 million in aggregate gross proceeds. The company advanced three Phase 2 clinical trials for its lead candidate agazisiran to treat complement-mediated diseases and received Fast Track designation from the FDA for onvuzosiran in hereditary angioedema. For the third quarter ended September 30, 2026, the company reported collaboration revenue of $2.2 million, research and development expenses of $26.7 million, and a net loss of $28.1 million. As of the end of the quarter, ADARx held $901.0 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into 2030.Healthcare
- NMAXNov 12, 4:05 PMNewsmax Inc. reported record third-quarter 2026 revenues of $69.0 million, representing a 52.5% year-over-year increase, driven by a $14.0 million non-recurring service revenue termination fee. Excluding this one-time item, the company achieved a record $55.0 million in revenue, a 21.6% increase, alongside a net income of $15.2 million and adjusted EBITDA of $19.0 million. The broadcaster expanded its audience reach to 22.5 million total viewers and grew social media followers by 13% to 26.8 million while launching international services including Newsmax Ukraine. Newsmax maintained its full-year 2026 revenue guidance of $212 million to $216 million, excluding the one-time payment, which reflects 13% year-over-year growth at the midpoint.Communication Services
- DMRCNov 12, 4:05 PMDigimarc Corporation reported third-quarter 2026 total revenue of $6.4 million, a decrease from $7.6 million in the same period of 2025, driven by the expiration and step-down of major commercial contracts. The company's ending Annual Recurring Revenue (ARR) declined to $10.8 million from $15.8 million the prior year, though service revenue increased to $3.3 million. Net loss attributable to Digimarc Corporation for the quarter was $8.1 million, or $0.36 per diluted share, while non-GAAP net loss was $2.9 million. At the end of the quarter, the company held $22.1 million in cash, cash equivalents, and marketable securities, with free cash flow usage totaling $4.3 million.Technology
- PRMENov 12, 4:05 PMPrime Medicine dosed the first patient in its global Phase 1/2 clinical trial for PM577a, an in vivo Prime Editing therapy for Wilson disease, with initial data expected in 2027. The company received FDA clearance for its Investigational New Drug application for PM647 to treat Alpha-1 Antitrypsin Deficiency, also anticipating initial clinical data in 2027. Prime Medicine plans to submit a Biologics License Application for PM359 in Chronic Granulomatous Disease during the first half of 2027. In November 2026, the company raised $143.7 million in gross proceeds from a public offering, bringing its pro-forma cash position to approximately $209.5 million to fund operations through 2027.Healthcare
- SSTNov 12, 4:05 PMSystem1, Inc. reported third-quarter 2026 revenue of $26.0 million, a significant decline from the $61.6 million recorded in the same period of 2025. The company posted a GAAP net loss of $61.5 million and an adjusted EBITDA of negative $0.7 million, driven by substantial impairment charges and reduced monetization from Google's AI overviews. Key operational highlights included the MapQuest app reaching number one on major app stores and Startpage integrating into Mozilla's Firefox browser. In response to these financial pressures and strategic shifts, System1 announced its intention to voluntarily delist from the New York Stock Exchange and move to the OTC Venture Market.Industrials
- INTZNov 12, 4:05 PMIntrusion Inc. reported third-quarter 2026 revenue of $2.7 million, marking an 84% sequential increase and a 36% year-over-year rise driven by the first full quarter of contributions from the VigilAigent acquisition and a contract with the State of Texas. The company recorded a net loss of $2.9 million for the quarter, with operating expenses rising to $4.3 million due to integration costs, while gross profit margin decreased to 55% from 66% in the prior quarter. On October 29, 2026, Intrusion completed a $4.0 million debt-for-equity exchange, which increased stockholders' equity to over $5.0 million and secured an additional 180-day extension from Nasdaq to regain compliance with minimum bid price requirements.Technology
- TLPHNov 12, 4:05 PMTalphera reported a net loss of $4.0 million for the third quarter of 2026, with cash and investments totaling $14.2 million as of September 30, 2026. The company submitted a briefing document to the FDA seeking approval to close enrollment in its NEPHRO CRRT study by December 31, 2026, citing that the current enrollment of over 75% of the target provides more than 80% statistical power for the primary endpoint. Updated market research has raised the estimated peak sales for nafamostat in the CRRT market to over $200 million. Talphera plans to file a Form S-3 Shelf Registration Statement to replace its existing registration that expires in November 2026.Healthcare
- HOURNov 12, 4:05 PMHour Loop, Inc. reported net revenues of $32.1 million for the third quarter of 2026, a 4% decrease from the prior year, while nine-month revenues rose 11% to $95.9 million. Net income for the third quarter was $0.4 million, down from $0.5 million in the same period last year, and totaled $2.3 million for the first nine months of 2026. The company narrowed its full-year 2026 revenue guidance to a range of $147.0 million to $152.0 million, anticipating 3% to 6% year-over-year growth. Cash and cash equivalents decreased to $1.1 million as of September 30, 2026, primarily due to increased inventory investments ahead of the holiday season.Consumer Cyclical
- CADLNov 12, 4:05 PMCandel Therapeutics reported a net loss of $21.9 million for the third quarter of 2026, driven by increased research and development expenses related to clinical trials and manufacturing. The company holds $203.1 million in cash and cash equivalents as of September 30, 2026, which is projected to fund operations through the second quarter of 2028. Clinical updates include the acceptance of three poster presentations at the SITC 2026 Annual Meeting and the announcement of a planned Biologics License Application submission for aglatimagene in prostate cancer in mid-2027. Recent corporate developments include the appointment of Martine Zimmermann to the Board of Directors and Maria Ostrovsky as General Counsel to support regulatory and commercial readiness.Healthcare
- GUTSNov 12, 4:05 PMFractyl Health reported positive six-month results from its REMAIN-1 Pivotal Cohort, demonstrating that the Revita procedure maintained approximately 80% of GLP-1-induced weight loss compared to 67% for the sham group with high statistical significance (p=0.0023). The company announced a strategic shift to focus exclusively on Revita, resulting in a 45% workforce reduction and the discontinuation of its Rejuva gene therapy program. Financially, Fractyl reported a net loss of $14.2 million for the third quarter of 2026 and expects its cash runway to extend into the second quarter of 2027. The company plans to submit a De Novo marketing application to the FDA in late 2026 and anticipates topline 12-month data in the first quarter of 2027.Healthcare
- ASMBNov 12, 4:05 PMAssembly Biosciences initiated a Phase 2 clinical study for its drug ABI-6250 in patients with chronic hepatitis delta virus infection and received FDA approval to proceed with a Phase 2 study for cholestatic liver diseases. The company exercised its option to share 40% of U.S. development costs and profits for the HSV helicase primase inhibitor program under its collaboration with Gilead Sciences. Assembly Biosciences received a $75 million collaboration extension fee from Gilead, bringing its total cash, cash equivalents, and marketable securities to $314.3 million as of September 30, 2026, which is projected to fund operations into 2029. For the third quarter of 2026, the company reported revenue of $3.0 million from collaborative research and a net loss of $20.3 million.Healthcare
- BLNENov 12, 4:05 PMBeeline Holdings reported a 30% year-over-year increase in Q3 2026 net revenues to $3.0 million, while its net loss decreased to $3.8 million. The company originated 268 loans during the quarter, achieving an overall margin of 3.56% and narrowing its adjusted EBITDA loss by 33% sequentially to $1.8 million. Management is advancing a proposed acquisition of TYTL, which is expected to finalize definitive agreements soon, and has initiated a $3 million annualized cost reduction plan. Additionally, the CEO will cancel 3 million merger shares upon closing to reduce dilution for existing shareholders.Financial Services
- BSEMNov 12, 4:05 PMBioStem Technologies reported third-quarter 2026 net revenue of $7.6 million, with hospital revenue rising sequentially to $6.8 million. The company raised its full-year 2026 revenue guidance to a range of $28 million to $29 million, up from the previous outlook. In-house production of Neox and Clarix products is scheduled to commence in the first half of 2027, marking progress toward vertical integration. The company also closed a private placement generating approximately $3 million in gross proceeds and established a $40 million committed equity facility.Healthcare
- LINKNov 12, 4:04 PMInterlink Electronics reported third-quarter 2026 revenue of $3.06 million, a 3.4% increase from the prior year, driven by higher shipments of force-sensing and gas-sensor products. The company posted a net loss of $316,000 for the quarter and $406,000 for the first nine months, while Adjusted EBITDA improved to a positive $79,000 for the nine-month period. Strategic expansions included opening a new 4,000-square-foot R&D center in Rotherham, UK, and adding a 10,000-square-foot facility in Irvine, Scotland, to support smart textiles and medical applications. Management anticipates closing a transformative acquisition before year-end, which is projected to generate combined pro forma revenue of $50 million and over $4 million in Adjusted EBITDA for 2026.Technology
- HAWKNov 12, 4:04 PMHawkEye 360 reported third-quarter 2026 revenue of $59.3 million, representing an 84% increase from the prior-year period, driven by a record international revenue of $23.3 million. The company raised its full-year 2026 revenue guidance to a range of $225 million to $227 million and non-GAAP Adjusted EBITDA guidance to $38 million to $40 million. As of September 30, 2026, the company's backlog stood at $300.3 million, supported by new multi-year contracts with allied partners and the recent launch of Clusters 15 and 16.Industrials
- IZEANov 12, 4:03 PMIZEA Worldwide, Inc. reported third-quarter 2026 revenue of $6.2 million, representing a 23% decrease from the prior-year period, driven by the strategic shift away from non-core small and mid-sized business accounts. Despite the revenue decline, Managed Services bookings surged 94% to $7.0 million, reflecting strong demand from enterprise clients including Disney-ABC, HBO Max, and Hulu. The company recorded a net loss of $0.4 million for the quarter while maintaining a cash position of $46.4 million with no long-term debt. Management projects fourth-quarter revenue to range between $7.5 million and $8.1 million, anticipating a 24% to 34% year-over-year growth.Communication Services
- CBRSNov 12, 4:03 PMCerebras Systems reported record third-quarter 2026 GAAP revenue of $210.8 million, representing a 55% year-over-year increase, while core non-GAAP revenue reached $230.9 million, up 70%. The company secured 700 megawatts of data center capacity under contract and announced new commercial wins with two hyperscalers, including an integration with Oracle Cloud Infrastructure. Looking ahead, Cerebras raised its full-year 2026 core revenue outlook to a range of $940 to $960 million and projects tripling revenue in 2027.Technology
- ENHANov 12, 4:03 PMEnhanced Group Inc. reported a third-quarter 2026 net loss of $13.5 million and revenue of $3.3 million, driven by telehealth sales and sponsorship recognition. The company signed a definitive agreement to acquire a 77% controlling interest in DEAG Deutsche Entertainment AG through an all-stock transaction valued at 5.3 times DEAG's FY2027E Adjusted EBITDA. Concurrently, Enhanced secured a $15 million private investment in public equity (PIPE) to support the acquisition and future growth. Following the expected closing in the first quarter of 2027, the combined entity projects approximately $670 million in revenue and $26 million in Adjusted EBITDA for the full year 2027.Consumer Defensive
- MTEXNov 12, 4:03 PMMannatech reported net sales of $24.9 million for the third quarter of 2026, representing a 14.6% decrease compared to the same period in 2025. The company recorded a net income of $8.9 million, or $4.61 per diluted share, driven primarily by a $10.9 million non-cash income tax benefit related to the remeasurement of deferred tax liabilities on unremitted foreign earnings. Operating performance showed a decline, with income from operations dropping to $0.3 million from $2.0 million in the prior year, while the number of independent associates and preferred customers fell to approximately 111,000. Additionally, the company's cash and cash equivalents decreased by 12.4% to $5.4 million as of September 30, 2026.Consumer Defensive
- CVSINov 12, 4:03 PMCV Sciences, Inc. reported third-quarter 2026 revenue of $3.0 million, a 7.0% decrease from the same period in 2025, driven by lower sales volume and average prices due to restrictive federal and state regulations. The company achieved a gross margin of 50.0% and recorded a positive adjusted EBITDA of $32,000, marking a significant improvement over the adjusted EBITDA losses in the prior year and the second quarter of 2026. Operating expenses were reduced by 11.6% year-over-year to $1.6 million, excluding the benefit from a $500,000 gain on a legal settlement. At the end of the quarter, the company held a cash balance of $0.3 million and strengthened its working capital position to $0.7 million.
- LWAYNov 12, 4:03 PMLifeway Foods reported record third-quarter 2026 net sales of $67.8 million, representing an 18.6% year-over-year increase driven by higher volumes of branded drinkable kefir. Despite this top-line growth, net income for the quarter declined to $0.3 million due to elevated input costs for milk, packaging, and transportation, which reduced gross profit margins to 18.0%. Year-to-date 2026 net sales reached $197.7 million, a 25.8% increase, while the company anticipates margin expansion in 2027 following planned price increases and the completion of its Waukesha facility.Consumer Defensive
- NUWENov 12, 4:03 PMNuwellis reported a 24% year-over-year improvement in its third-quarter 2026 operating loss to $2.1 million, driven by a 430 basis point expansion in gross margin to 69.5% and a 13% reduction in operating expenses. Net sales for the quarter remained flat at $2.2 million due to a prior-year backorder comparison, though sales grew 12% sequentially and 13% for the first nine months to $6.6 million. The company sold 32 Aquadex consoles in the first nine months of 2026, an 88% increase from the prior period, while strengthening its balance sheet to $8.3 million in cash and cash equivalents. Strategic initiatives included an FDA 510(k) submission to expand Aquadex indications for pediatric patients and new distribution agreements for the AtriAmp and Zorro-Flow products.Healthcare
- AMATNov 12, 4:02 PMApplied Materials reported record fourth-quarter revenue of $10.41 billion, representing a 53% year-over-year increase, driven by strong demand for semiconductor equipment. The company achieved a non-GAAP gross margin of 50.6% and non-GAAP earnings per share of $4.16, marking a 92% increase from the prior year. For the full fiscal year 2026, revenue reached a record $34.45 billion with non-GAAP EPS of $12.89, while generating $8.87 billion in operating cash flow. Additionally, the company unveiled the EPIC Center in Silicon Valley to accelerate collaborative R&D and announced new partnerships with Intel, KIOXIA, Besi, and UCLA.Technology
- HTFLNov 12, 4:02 PMHeartflow, Inc. reported third-quarter 2026 total revenue of $72.9 million, representing a 57% year-over-year increase driven by growth in U.S. FFR(CT) and Plaque revenue case volumes. The company raised its full-year 2026 revenue guidance to a range of $262 million to $264 million, reflecting an anticipated 49% to 50% growth rate, while maintaining a non-GAAP gross margin target of approximately 82.5%. For the quarter, Heartflow recorded a non-GAAP net operating loss of $5.0 million and a non-GAAP net loss of $2.7 million, with cash, cash equivalents, and investments totaling $253.0 million as of September 30, 2026.Healthcare
- VTSINov 12, 4:02 PMVirTra, Inc. reported third-quarter 2026 total revenue of $7.6 million, representing a 42% increase from the prior year period, driven by growth in government and international sales. The company achieved net income of $2.2 million for the quarter, or $0.19 per diluted share, while bookings surged 87% to $10.3 million, bringing the total backlog to $27.6 million. Over the first nine months of 2026, total revenue declined 13% to $16.9 million due to delivery delays for customers booked in late 2025, resulting in net income of $0.6 million. Recent operational highlights include the award of a five-year sole-source contract with U.S. Customs and Border Protection valued at up to $14 million and a $1.5 million contract with the U.S. Army.Technology
- ANDGNov 12, 4:02 PMAndersen Group Inc. reported third-quarter revenue of $337.3 million for the period ended September 30, 2026, representing an 18.7% increase from the prior year. Consolidated GAAP net income for the quarter was $68.0 million, while Adjusted EBITDA rose 18.8% to $154.5 million with a margin of 45.8%. The company completed eight acquisitions through September 30, 2026, contributing to broad-based growth across all service lines and geographic regions. Andersen introduced full-year 2027 revenue guidance of $1.275 billion to $1.325 billion, reflecting an expected 30% growth at the midpoint over its 2026 guidance.Consumer Cyclical
- SMSINov 12, 4:02 PMSmith Micro Software reported third-quarter 2026 revenue of $5.0 million, representing a 16% sequential increase and an 81.6% gross margin, which is a five-year high. For the nine months ended September 30, 2026, the company generated $13.6 million in revenue with a GAAP net loss of $8.3 million, a significant improvement from the $25.4 million loss recorded in the same period of 2025. Non-GAAP net loss for the quarter narrowed to $0.3 million, or $0.05 per share, compared to a $2.6 million loss in the prior year quarter. The company's cash and cash equivalents totaled $2.4 million as of September 30, 2026, following a period of sequential revenue growth and expanded customer contracts.Technology
- ARWRNov 12, 4:01 PMArrowhead Pharmaceuticals reported a net loss of $724.2 million for the fiscal year ended September 30, 2026, driven by a $215 million acquisition of a Priority Review Voucher and increased research and development expenses. The company's commercial product, REDEMPLO (plozasiran), expanded its market presence with new prescriptions growing 63% quarter-over-quarter and achieved marketing authorization in Germany and the United Kingdom for familial chylomicronemia syndrome. In clinical development, plozasiran demonstrated significant triglyceride reductions in Phase 3 trials for severe hypertriglyceridemia, while investigational candidates ARO-DIMER-PA and ARO-MAPT showed promising early results in targeting multiple genes and crossing the blood-brain barrier, respectively. Additionally, Arrowhead refinanced its credit facility to lower borrowing costs and announced a change in its fiscal year-end to December 31, effective January 1, 2027.Healthcare
- KODNov 12, 4:00 PMKodiak Sciences reported that its Phase 3 DAYBREAK study for Zenkuda met the primary endpoint in wet age-related macular degeneration, demonstrating vision gains and sustained retinal drying with a 6-month dosing interval for 54% of patients. The company also announced that the Phase 3 DAYBREAK study for Tabirafusp-ted met its primary vision endpoint and is actively enrolling in the Phase 3 ALTO study for diabetic macular edema. Financial results for the third quarter of 2026 showed a net loss of $66.2 million, with the company holding $88.7 million in cash and raising an additional $69 million in net proceeds from an equity offering subsequent to the quarter. Kodiak plans to submit a multi-indication Biologics License Application for Zenkuda by the end of 2026 and expects to announce the first Phase 3 results for KSI-101 in December 2026.Healthcare
- ARTNANov 12, 2:21 PMArtesian Resources Corporation reported diluted net income per share of $0.65 for the third quarter of 2026, a decrease from $0.68 in the same period of 2025, while total revenues rose 4.8% to $31.9 million. For the nine months ended September 30, 2026, diluted net income per share increased 3.3% to $1.87, with year-to-date revenues reaching $90.4 million, up 6.4% from the prior year. The company invested $40.8 million in water and wastewater infrastructure projects during the first nine months of 2026 to ensure service reliability and regulatory compliance, including PFAS treatment upgrades and system renewals.Utilities
- TCINov 12, 12:47 PMTranscontinental Realty Investors, Inc. reported a net loss of $0.1 million, or $0.02 per share, for the three months ended September 30, 2026, compared to a net income of $0.7 million in the same period of 2025. Total revenue increased to $13.9 million from $12.8 million, driven by a $1.5 million rise in multifamily property revenues due to lease-up activities, which was partially offset by a decrease in commercial property revenue. The company's net operating loss widened to $2.4 million from $1.4 million, primarily due to a $1.4 million increase in operating expenses associated with development properties. Additionally, the company acquired four multifamily properties totaling 782 units in exchange for settling notes receivable and a $12.0 million cash payment, while also selling 21 lots for a $0.8 million gain.Real Estate
- ARLNov 12, 12:42 PMAmerican Realty Investors, Inc. reported a net loss of $0.7 million, or $0.04 per share, for the three months ended September 30, 2026, compared to a net income of $0.1 million per share in the same period of 2025. Total revenue increased to $13.9 million from $12.8 million, driven by a $1.5 million rise in multifamily property revenues due to lease-up activities, which was partially offset by a decrease in commercial property revenue. The company's net operating loss widened to $2.6 million from $1.6 million, primarily attributed to a $1.4 million increase in operating expenses associated with development properties. Additionally, the company acquired four multifamily properties totaling 782 units in exchange for settling notes receivable and a $12.0 million cash payment, while also selling 21 lots for a $0.8 million gain.Real Estate
- IORNov 12, 12:42 PMIncome Opportunity Realty Investors, Inc. reported net income of $0.9 million, or $0.22 per diluted share, for the quarter ended September 30, 2026. This represents a decrease from the $1.0 million, or $0.25 per share, reported in the same period of 2025, primarily due to lower interest income. For the nine months ended September 30, 2026, the company recorded net income of $2.6 million, or $0.64 per share, compared to $3.0 million, or $0.74 per share, in the prior year. The company, based in Dallas, holds a portfolio of notes receivable and invests in real estate through direct equity ownership and partnerships.Financial Services
- TRTNov 12, 12:28 PMTrio-Tech International reported a 29% year-over-year revenue increase to $19.9 million for the first quarter of fiscal 2027, driven by a 39% surge in its Semiconductor Back-End Solutions segment. The company achieved a consolidated gross margin of 20.6%, up from 16.7% in the prior year, resulting in net income of $846,000 and diluted earnings per share of $0.07. Management highlighted strong demand for AI-related testing services and EV applications, supported by a new facility expansion in Malaysia that began operations in September 2026. Despite elevated working capital requirements due to increased inventory and receivables, the company maintains a strong balance sheet with $25.6 million in cash and recently approved an additional $1.0 million for share repurchases.Technology
- PRHINov 12, 11:43 AMPresurance Holdings reported a net income of $3.5 million for the nine months ended September 30, 2026, a significant turnaround from the $1.4 million loss in the prior-year period. The company's overall underwriting combined ratio improved to 97.1% for the first nine months of 2026, down from 133.7% in 2025, driven by profitable results in its Personal Lines business. Gross written premiums decreased by 40.8% to $30.7 million year-to-date as the company focused on underwriting discipline and managed its legacy Commercial Lines portfolio in runoff. Book value per share stood at $6.45 as of September 30, 2026, reflecting the company's strategic shift toward a dedicated Texas homeowners portfolio.Financial Services
- EXPDNov 12, 11:42 AMExpeditors International of Washington, Inc. will host an Investor Day event on Wednesday, November 18, 2026, in New York City. The webcast will run from 8:30 a.m. to 12:00 p.m. EST and feature presentations by President and CEO Dan Wall, Senior Vice President and CFO Dave Hackett, and other leadership team members. The session will cover company operations, strategies, and the financial outlook, including a question and answer period that replaces the standard 8-K filing following the third quarter earnings release. A replay of the event will be available on the company's investor relations website for at least 90 days after the broadcast.Industrials
- AMSNov 12, 11:27 AMAmerican Shared Hospital Services reported third-quarter 2026 revenue of $7.6 million, a 6% increase from the prior year, driven by a 14% rise in Direct Patient Services revenue. For the first nine months of 2026, total revenue grew 14% to $23.1 million, while the company generated $5.8 million in cash from operating activities. The company reported a net loss of $620,000 for the quarter and $1.7 million for the nine-month period, with adjusted EBITDA declining to $1.4 million and $3.8 million respectively. Cash, cash equivalents, and restricted cash increased to approximately $9.5 million as of September 30, 2026, supported by a recent subordinated financing arrangement.Healthcare
- INKTNov 12, 9:49 AMMiNK Therapeutics reported its first pre-commercial product revenue in the third quarter of 2026 from agenT-797 supplied via an international named-patient access program. The company's randomized Phase 2 trial for acute respiratory distress syndrome (ARDS) is advancing with U.S. dosing expected before year-end, targeting a population with approximately 40% 28-day mortality. Additionally, agenT-797 was selected for the ARPA-H BoSS program to develop room-temperature deployable cell therapies, while preclinical data presented at SITC 2026 demonstrated the therapy's ability to clear senescent cells and enhance tumor killing in colorectal cancer models. Financially, the company achieved a 23% year-over-year improvement in net loss per share and reduced general and administrative expenses by 44%.Healthcare
- IPWRNov 12, 9:25 AMIdeal Power Inc. reported a net loss of $3.6 million for the third quarter of 2026, an increase from $2.9 million in the same period the previous year, while operating expenses rose to $3.9 million due to higher personnel costs and patent impairment charges. The company's cash and cash equivalents grew significantly to $38.3 million as of September 30, 2026, following a substantial financing activity that generated over $40 million in proceeds. During the quarter, the company advanced its B-TRAN® commercial strategy by demonstrating a solid-state circuit breaker prototype with Power Integrations, initiating shipments of new reference design kits, and expanding its sales funnel to approximately $450 million. Additionally, Ideal Power continued to develop its electric vehicle contactor opportunity with Stellantis and progressed toward JEDEC qualification for its semiconductor foundry production.Technology
- DGIINov 12, 9:23 AMDigi International reported record fourth-quarter fiscal 2026 revenue of $143 million, representing a 25% increase year-over-year, while full-year revenue reached $535 million, a 24% rise. The company achieved an annualized recurring revenue (ARR) of $197 million at the end of the quarter, up 30% from the prior year, driven by organic growth and acquisitions of Particle and Jolt Software. Net income for the quarter was $15 million, and adjusted net income reached $30 million, with adjusted EBITDA increasing to $42 million. Looking ahead to fiscal 2027, Digi projects revenue growth of 10-15% and anticipates ARR growth of at least 15%, targeting $200 million in both ARR and Adjusted EBITDA.Technology
- BRUNNov 12, 9:20 AMBoost Run Inc. reported third-quarter 2026 revenue of $39.9 million, representing a 496% year-over-year increase. The company currently holds $2.7 billion in total contracted value, with all funds either live, in deployment, or scheduled for 2027. Operating cash flow for the quarter reached $65.6 million, supported by approximately $600 million in non-dilutive project-based financing secured year-to-date. CEO Andrew Karos expects 26% of the contracted value to be live by the end of November, with full deployment targeted for 2027.Technology
- NEONNov 12, 9:18 AMNeonode reported a loss of $1.1 million, or $0.07 per share, from continuing operations for the three months ended September 30, 2026, compared to a net income of $13.9 million in the same period of the prior year. Total revenues for the quarter reached $0.5 million, representing a 24.4% increase year-over-year, driven by a 279.2% rise in non-recurring engineering revenue and a 9.4% increase in license fees. Operating expenses decreased by 13.2% to $1.8 million, primarily due to lower payroll and professional fees, while cash used by operations totaled $1.6 million. For the nine-month period, the company recorded a loss of $5.1 million with revenues of $1.6 million, as the prior year's results included a $15.5 million one-time gain from a patent assignment that was not repeated in 2026.Technology
- SGANov 12, 9:05 AMSaga Communications, Inc. reported a net loss of $7.1 million for the third quarter of 2026, driven primarily by a $9.2 million non-cash impairment charge on FCC license values. Net revenue for the quarter decreased 5.4% to $26.7 million, while station operating expense fell 1.7% to $24.2 million. The company declared a quarterly cash dividend of $0.25 per share, payable on December 11, 2026, to shareholders of record on November 23, 2026. For the nine-month period ended September 30, 2026, the company recorded a net loss of $8.5 million and net revenue of $75.9 million.Communication Services
- TGENNov 12, 8:59 AMTecogen Inc. reported third-quarter 2026 revenues of $7.87 million, representing a 9.6% increase from the same period in 2025, while the net loss narrowed to $1.59 million from $2.13 million. For the nine months ended September 30, 2026, total revenues declined 8.3% to $19.96 million, resulting in a net loss of $5.86 million compared to $4.25 million in the prior year period. The company's gross profit margin improved to 37.4% in the third quarter, driven by higher revenue and lower costs in the Services segment, and the backlog exceeded $8 million. At the end of the quarter, Tecogen held $5.33 million in cash and cash equivalents, with the CEO noting an expected increase to $5.7 million due to recent customer deposits.Industrials
- MPTINov 12, 8:55 AMM-tron Industries, Inc. reported third-quarter 2026 revenues of $15.7 million, representing an 11.1% increase from the same period in 2025. Net income for the quarter rose 66.4% to $3.0 million, or $0.70 per diluted share, driven by strong demand in aerospace and defense markets and an expansion of gross margin to 44.5%. For the nine months ended September 30, 2026, the company achieved revenues of $45.5 million and net income of $7.3 million, while its backlog grew to $84.9 million as of the end of the quarter.Technology
- STRRNov 12, 8:52 AMStar Equity Holdings reported a net loss of $2.2 million, or $0.60 per diluted share, for the third quarter of 2026, with total revenue increasing 12.4% to $53.9 million. The company generated $1.5 million in adjusted EBITDA and ended the quarter with $7.8 million in total cash, while repurchasing approximately $0.3 million of its common stock. Recent strategic actions include the acquisition of a machine shop in Vernal, Utah, and the purchase of Cornerstone RPO to expand its Business Services division. Additionally, the company has initiated a process to monetize two real estate assets through sale-leaseback transactions expected to yield over $9.0 million in gross proceeds.Industrials
- PODCNov 12, 8:50 AMPodcastOne reported record financial results for the first half of fiscal 2027, achieving revenue of $31.5 million and adjusted EBITDA of $2.9 million. For the second quarter of fiscal 2027, revenue increased to $15.4 million year-over-year, while adjusted EBITDA rose 27% to $1.4 million. The company delivered over 15 million downloads and streams in September, reaching 5.8 million unique listeners and securing a #6 ranking on Podtrac. Despite these operational gains, the company reported a net loss of $2.0 million for the six-month period ended September 30, 2026.Communication Services
- CURINov 12, 8:49 AMCuriosityStream reported third-quarter 2026 revenue of $20.7 million, representing a 13% increase from the prior year, while adjusted EBITDA rose 67% to $5.0 million. The company achieved net income of $4.8 million, a significant improvement from the $3.7 million net loss recorded in the same period last year, driven by a $0.9 million non-cash gain on a venture remeasurement. Management raised its full-year 2026 guidance to a revenue range of $79–$82 million and an adjusted EBITDA range of $20–$22 million. Additionally, the Board declared a fourth-quarter cash dividend of $0.085 per share, and the company acquired the remaining 68% interest in its German documentary channel business, Spiegel Venture.Communication Services
- LVONov 12, 8:45 AMLiveOne reported H1 Fiscal 2027 revenue of $37.3 million and an Adjusted EBITDA of $3.6 million, with its Audio Division contributing $36.3 million in revenue. The company revised its full Fiscal 2027 guidance to $70–$75 million in revenue and over $10 million in Adjusted EBITDA, while issuing first-time Fiscal 2028 guidance of $100 million or more. LiveOne has reduced its senior debt balance to $9 million after extinguishing $25 million in debt and liabilities since February 2026. Additionally, the company announced a five-year partnership with Groove Technology Solutions for Slacker Radio and highlighted accelerating AI initiatives across its subsidiaries.Communication Services
- DFDVNov 12, 8:41 AMDeFi Development Corp. reported strong third-quarter 2026 results, with net asset value per share increasing over 300% and SOL per share growing more than 20% between August 12 and September 30, 2026. The company's total SOL and SOL equivalents rose to 2,549,137 by the end of the quarter, while SOL-denominated borrowings declined by approximately 13%. Additionally, the firm launched CHAD, a perpetual capital vehicle that reached its $10 par value within 48 days of trading, and increased its annual dividend rate to 14% effective November 2.Financial Services
- HSDTNov 12, 8:41 AMSolana Company reported third-quarter 2026 revenue of $3.4 million, driven primarily by $3.3 million in staking revenue, marking a significant increase from the prior-year period. The company achieved a net income of $105.2 million, or $1.17 per diluted share, contrasting with a net loss of $352.8 million in the same quarter of the previous year. During the quarter, Solana Company expanded its treasury holdings to approximately 2.4 million SOL with a fair value of $288.2 million and executed a $15 million registered direct offering to purchase an additional 125,000 SOL. Operational highlights included the launch of the Pacific Backbone infrastructure, which now holds 1.3 million SOL in delegated stake, and the company's participation in Solana's first on-chain governance vote.Financial Services
- CTA-PANov 12, 8:34 AMCorteva reported third-quarter 2026 net sales of $1.59 billion, a 9% decline from the prior year, driven by pricing pressures in North America and Latin America. The company updated its full-year 2026 guidance, projecting Adjusted Pro Forma Operating EBITDA between $1.1 billion and $1.125 billion and Adjusted Pro Forma Operating EPS between $0.76 and $0.80. Latin America experienced a significant 31% organic sales decline due to farmer liquidity constraints and elevated channel inventory, while North America and EMEA posted organic growth of 7% and 14% respectively. Pro Forma GAAP income from continuing operations for the quarter was a loss of $54 million, whereas Adjusted Pro Forma Operating EBITDA for the nine-month period totaled $943 million.Basic Materials
- AENTNov 12, 8:32 AMAlliance Entertainment Holding Corporation reported first-quarter fiscal 2027 net revenues of $278.8 million, representing a 10% increase from the prior-year period. GAAP net income rose 56% to $7.6 million, driven by a 13% increase in gross profit and a 49% reduction in interest expense following a refinancing. Revenue growth was led by a 20% surge in physical movie sales, a 14% rise in vinyl revenue, and an 87% jump in collectibles revenue. The company also saw operating cash flow increase to $4.3 million and maintained compliance with its credit facility covenants while holding $48.9 million in available liquidity.Communication Services
- TULPNov 12, 8:30 AMBloomia Holdings, Inc. reported a net loss of $2.4 million for the first fiscal quarter ended September 30, 2026, representing a 17% improvement over the same period in the prior year. Revenue for the quarter totaled $5.0 million, a decrease from $5.2 million in the previous year, primarily driven by lower stem sales due to excess waste. Adjusted EBITDA improved to a loss of $1.9 million from a loss of $2.4 million in the prior year quarter, aided by higher prices and reduced general and administrative costs. The company's cash balance decreased to $0.7 million as of September 30, 2026, while revolver borrowings increased to $8.6 million.Consumer Defensive
- NSYSNov 12, 8:30 AMNortech Systems reported third-quarter 2026 net sales of $33.0 million, an 8.4% increase from the same period in 2025, resulting in net income of $637 thousand. The company achieved an adjusted EBITDA of $2.0 million for the quarter, up from $1.3 million in the prior year, while total backlog grew 20% to $92.8 million. Year-to-date through September 30, 2026, net sales reached $96.9 million with a net income of $919 thousand. Management highlighted strong performance in the Aerospace & Defense and Industrial markets, noting that China operations saw net sales growth exceeding 56%.Healthcare
- VANINov 12, 8:29 AMVivani Medical reported a net loss of $7.3 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its Biopharm Division. The company anticipates announcing top-line results from its SLIM-1 Phase 1 trial for the NPM-139 semaglutide implant later in November 2026. Additionally, the merger between Cortigent and ClearOne remains pending final regulatory approvals required to establish Cortigent as a standalone Nasdaq-traded entity. Vivani's cash and cash equivalents totaled $15.5 million as of the end of the quarter, down from $20.8 million in the previous quarter.Healthcare
- SGPNov 12, 8:25 AMSpyGlass Pharma acquired Advanced Vision Science, Inc. for approximately $13 million to secure scalable manufacturing capacity for its lead product, the Bimatoprost Drug Pad-IOL System. The company announced four-year follow-up data from its first-in-human trial showing a 37% reduction in intraocular pressure and 86% of patients remaining off topical drops, while Phase 3 enrollment remains on track for completion in 2027. Additionally, the first implantations were completed for the Bimatoprost-Drug Ring System, a non-IOL-based delivery platform designed to provide up to seven years of treatment. For the third quarter ended September 30, 2026, the company reported a net loss of $24.3 million and held $215.8 million in cash and short-term investments.Healthcare
- ONDSNov 12, 8:24 AMOndas Inc. reported record third-quarter 2026 revenue of $167.5 million, representing a 100% sequential increase and more than a 16-fold year-over-year growth. The company secured $214 million in new orders, bringing its backlog to $835 million, and raised its full-year 2026 revenue outlook to at least $550 million. Ondas initiated a 2027 revenue target of at least $1.1 billion and expects to achieve company-wide Adjusted EBITDA profitability by the third quarter of 2027. Strategic expansions included the establishment of Ondas Sentinel and Regna AI, alongside six acquisitions that enhanced capabilities in defense, sovereign AI, and autonomous systems.Technology
- MOVENov 12, 8:21 AMCorvex, Inc. reported third-quarter 2026 financial results showing total revenue of $5.0 million, a 31% increase from the previous quarter, driven by its AI platform and services following the transfer of legacy healthcare assets. The company secured approximately 8 MW of critical IT capacity, with 1.5 MW currently live supporting $22 million in contracted annual recurring revenue, while expanding operations at Mid-Atlantic 1 and Midwest-1 facilities. Despite the revenue growth, the company recorded a net loss of $17.5 million for the quarter, or $0.60 per share, largely due to $11.3 million in stock-based compensation expenses. Corvex also raised approximately $33 million through a private placement and launched its Corvex Token Factory platform to enable serverless inference for open-weight models.Technology
- LEATNov 12, 8:20 AMLeatt Corporation reported third-quarter 2026 revenues of $20.46 million, representing a 43% increase from the same period in 2025 and marking the company's highest quarterly revenue in four years. Net income for the quarter surged 309% to $2.20 million, or $0.35 per basic share, driven by a 48% rise in gross profit and strong sales growth across body armor, helmets, and other product categories. For the nine months ended September 30, 2026, total revenues reached $56.36 million with net income increasing 74% to $4.88 million, while operating cash flows more than tripled to $4.59 million compared to the prior year.
- RUMNov 12, 8:17 AMRUM Group Inc. reported record third-quarter 2026 revenue of $96.6 million, representing a 290% year-over-year increase driven primarily by the Quake AI business which contributed $68.2 million. The company achieved its first profitable quarter on an Adjusted EBITDA basis, with utilization of its 22,000 GPU fleet reaching approximately 85%. Total liquidity stood at $142.3 million as of September 30, 2026, while the company advanced its acquisition of Northern Data AG to approximately 98% ownership. Management has set a fourth-quarter 2026 revenue outlook between $88 million and $94 million.Technology
- SESNov 12, 8:15 AMSES AI Corporation reported third-quarter revenue of $6.6 million, a 31% increase from the previous quarter, driven primarily by its energy storage business. The company achieved a GAAP net loss of $13.4 million, narrowing from $17.9 million in the second quarter, while completing the ramp-up of its Chungju, Korea facility to produce 1 million NDAA-compliant drone cells annually. Management reiterated its full-year 2026 revenue outlook of $30 million to $35 million and announced a reverse stock split to broaden institutional ownership eligibility. The firm maintains approximately $137 million in liquidity with no debt as it focuses on scaling drone manufacturing and advancing its Molecular Universe battery materials platform.Consumer Cyclical
- SPHNov 12, 8:14 AMSuburban Propane Partners, L.P. reported net income of $109.0 million for fiscal year 2026, representing a slight increase from the prior year, while Adjusted EBITDA rose 2.2% to $284.0 million. The company achieved this performance through strong propane demand in the eastern United States, the completion of capital projects for its renewable natural gas business, and the recognition of $12.4 million in production tax credits. During the fiscal year, the partnership acquired two propane businesses in California and refinanced $350.0 million of senior notes to extend maturities by nearly nine years. Consequently, the company increased its annualized distribution rate to $1.40 per Common Unit, reflecting a 7.7% increase over the previous rate.Utilities
- DXYNNov 12, 8:12 AMThe Dixie Group reported net income of $577,000 for the third quarter of 2026, marking its third consecutive profitable quarter. Net sales increased 4.6% to $65.2 million, while gross profit margin improved to 26.6% from 24.8% in the prior year period. For the nine months ended September 26, 2026, the company generated net income of $2.8 million with operating income rising to $8.7 million compared to $1.2 million in the same period of 2025. The company attributed these results to cost reductions, improved operating efficiencies, and new product introductions in both soft and hard surface flooring segments.Consumer Cyclical
- FRMMNov 12, 8:12 AMForum Markets reported third-quarter 2026 revenue of $2.0 million, driven entirely by commercial aircraft engine leases, and posted a net income of $7.9 million. The company formed a joint venture, Forum Edge AI, to deploy high-performance GPU compute capacity while simultaneously expanding its aircraft engine portfolio with two new acquisitions. Due to rising equipment and financing costs following the midterm elections, Forum revised its full-year 2026 revenue guidance down to $8 million–$9 million, though it maintains its 2027 revenue outlook of $125 million–$175 million. Additionally, the company repurchased approximately 330,000 shares for $1.9 million during the quarter and holds $19.8 million remaining in its share repurchase authorization.Healthcare
- TOVXNov 12, 8:10 AMTheriva Biologics reported third-quarter 2026 financial results showing cash and cash equivalents of $8.5 million with a projected runway into the first quarter of 2027. The company completed the sale of its SYN-004 antibiotic-degrading enzyme portfolio to Biossil Labs Inc. for a $350,000 upfront payment and up to $91 million in potential milestones and royalties. Clinical progress includes ongoing enrollment in the VIRAGE2 Phase 2a trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma, with enrollment expected to conclude in the fourth quarter of 2026. Additionally, detailed analyses of the VIRAGE Phase 2b trial data were published in Nature Medicine, demonstrating improved survival outcomes for patients treated with VCN-01 combined with chemotherapy.Healthcare
- SLNNov 12, 8:10 AMSilence Therapeutics plc reported a net loss of $12.4 million for the third quarter ended September 30, 2026, driven by $9.3 million in research and development expenses and $4.9 million in general and administrative costs. The company's cash position increased to $247.7 million, which includes $201.3 million in proceeds from a public offering announced in August 2026. Recent business milestones include positive Phase 2 results for the investigational siRNA therapy divesiran in polycythemia vera and the announcement of a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The acquisition transaction is expected to close in the first quarter of 2027, subject to customary closing conditions.Healthcare
- EUNov 12, 8:09 AMenCore Energy reported third-quarter 2026 revenue of $16.7 million, an 88% increase year-over-year, driven by the delivery of 200,000 pounds of U3O8 at an average realized price of $83.46 per pound. The company recorded a net loss of $33.9 million for the quarter, primarily due to higher costs associated with purchased uranium included in sales, resulting in a gross loss of $0.8 million. As of September 30, 2026, the company held $5.1 million in unrestricted cash and $33.6 million in marketable securities while maintaining an inventory of 116,631 pounds of U3O8. Operational progress includes the completion of the first phase of the Upper Spring Creek facility and the Alta Mesa wellfield 3 Extension, with extraction expected to commence before the end of 2026.Energy
- AVLNNov 12, 8:08 AMAvalyn Pharma Inc. reported a net loss of $29.7 million for the third quarter of 2026, driven by increased research and development expenses of $25.5 million and general and administrative costs of $7.6 million. The company ended the quarter with $386.6 million in cash and marketable securities, projecting a runway into 2029. Recent pipeline progress includes the initiation of a Phase 1 study for the fixed-dose combination AP03 in healthy volunteers, the presentation of new AP01 data at the ERS Congress, and the publication of AP02 Phase 1 results in Respiratory Research. Additionally, Robert J. Meyer, MD, was appointed to the company's Board of Directors in September.Healthcare
- MGTXNov 12, 8:08 AMMeiraGTx reported a net loss of $51.3 million for the third quarter of 2026, driven by increased research and development expenses and a loss on its equity method investee, while cash and cash equivalents rose to $184.7 million. The company plans to submit a Marketing Authorisation Application for its lead candidate, botaretigene sparoparvovec, to the European Medicines Agency in December 2026, followed by a Biologics License Application to the FDA in early 2027. Operational milestones include the completion of enrollment for the pivotal Phase 2 AQUAx2 study for radiation-induced xerostomia, with data expected in mid-2027, and the initiation of a Phase 3 study for AAV-GAD in Parkinson's disease in the first quarter of 2027. Additionally, MeiraGTx strengthened its leadership team with new appointments to the executive and board levels and highlighted upcoming presentations on its AAV-BDNF program for genetic obesity.Healthcare
- LUCDNov 12, 8:05 AMLucid Diagnostics reported that Medicare now fully reimburses its EsoGuard esophageal DNA test nationwide, enabling the company to accelerate commercialization efforts. In the third quarter of 2026, the company recognized $1.2 million in revenue from 2,871 tests, with October setting a record volume of over 1,800 tests. The company announced a $15 million private placement to strengthen its balance sheet and reported a GAAP net loss of $6.7 million for the quarter. Additionally, Lucid highlighted the publication of a large-scale real-world study and the inclusion of its test in draft American Gastroenterological Association guidelines as alternatives to endoscopy.Healthcare
- AKTSNov 12, 8:05 AMAktis Oncology reported a net loss of $29.9 million for the third quarter ended September 30, 2026, while increasing its cash position to $492.9 million. The company initiated its third Phase 1b clinical trial, BActinium-2, to evaluate AKY-2519 in non-small cell lung cancer and other B7-H3 expressing tumors. Additionally, backfill cohorts were started in the ongoing NECTINIUM-2 and BActinium-1 trials to further assess safety and antitumor activity for AKY-1189 and AKY-2519. Aktis expects to present preliminary data for AKY-1189 in the first quarter of 2027 and for AKY-2519 later in 2027.Healthcare
- COHNNov 12, 8:03 AMCohen & Company Inc. reported third-quarter 2026 financial results with total revenues of $32.4 million and net income attributable to the company of $6.7 million, or $0.12 per fully diluted share. The company's investment banking and new issue revenue declined to $12.7 million due to $17.6 million in mark-to-market losses, while its gestation repo book reached an all-time high of $4.5 billion. The Board of Directors declared a quarterly dividend of $0.25 per share, payable on December 14, 2026, to stockholders of record as of November 30, 2026. Daniel G. Cohen was appointed Chief Executive Officer, succeeding his role as Executive Chairman.Financial Services
- KYTXNov 12, 8:01 AMKyverna Therapeutics has completed the submission of a rolling Biologics License Application to the FDA for miv-cel in stiff person syndrome, requesting priority review under its Regenerative Medicine Advanced Therapy designation. The company reports that miv-cel demonstrated durable efficacy and a well-tolerated safety profile in registrational trials, with no high-grade cytokine release syndrome or neurotoxicity observed. Financial results for the third quarter of 2026 show a net loss of $41.9 million, while the company maintains $170.6 million in cash and marketable securities to support operations into 2028. Additionally, enrollment for the Phase 3 gMG trial is on track for completion in mid-2027, and the KYV-102 program has been deprioritized to focus resources on late-stage neurologic indications.Healthcare
- GRCENov 12, 8:01 AMGrace Therapeutics reported a net loss of $2.1 million for the three months ended September 30, 2026, driven by increased research and development expenses related to its dual-source manufacturing strategy for GTx-104. The company completed a $10 million private placement in August 2026, extending its cash runway through the end of 2028 to support regulatory resubmission efforts for its New Drug Application. Following a Complete Response Letter from the FDA in April 2026, Grace Therapeutics is addressing chemistry, manufacturing, and controls issues while initiating technology transfer to a second U.S.-based contract manufacturer. As of September 30, 2026, the company held $21.3 million in cash and cash equivalents to fund operations and resolve FDA-identified items.Healthcare
- MNPRNov 12, 8:01 AMMonopar Therapeutics reported a net loss of $6.2 million for the third quarter of 2026, with cash and investments totaling $129.4 million sufficient to fund operations through March 31, 2028. The company initiated a rolling New Drug Application submission to the FDA for ALXN1840, a first-in-class treatment for Wilson disease, and appointed Jeffrey D. Kent as Executive Vice President of Medical Affairs. Financial results showed increased research and development expenses driven by contractor and personnel costs, while interest income rose due to higher cash balances from a prior capital raise.Healthcare
- BTCSNov 12, 8:01 AMBTCS Inc. reported a record third quarter 2026 gross profit of $3.5 million with an 86% gross margin, surpassing its full-year target of $6 million within the first nine months of the year. Total revenues for the quarter increased 67% to $4.1 million, driven primarily by a 133% quarter-over-quarter growth in DeFi revenues from its Imperium business line. The company expanded its Imperium liquidity pool positions from approximately $8 million to $41 million and integrated operations on the Base network. Net income for the quarter was $54.5 million, largely attributed to $58.3 million in non-cash unrealized gains on digital assets due to Ethereum price appreciation.Financial Services
- IMNNNov 12, 8:00 AMIMUNON, Inc. reported a net loss of $3.8 million for the third quarter of 2026, with operating expenses totaling $3.4 million. The company advanced its lead candidate IMNN-001 in a Phase 3 trial for advanced ovarian cancer, supported by a new Cooperative Research and Development Agreement with the National Cancer Institute. Recent corporate developments include a debt-for-equity exchange reducing debt by approximately 43% and an agreement to sell rights to ThermoDox to VoxelDox Therapeutics. As of September 30, 2026, the company held $4.0 million in cash and cash equivalents alongside $5.0 million in restricted cash.Healthcare
- ARXNov 12, 8:00 AMAccelerant Holdings reported third-quarter 2026 results showing a 27% year-over-year increase in Exchange Written Premium to $1.33 billion, with third-party direct written premium accounting for 49% of the volume. The company recorded a GAAP net loss of $9.2 million, or $0.06 per diluted share, while reporting adjusted net income of $38.2 million and adjusted EBITDA of $71.3 million. Accelerant added 26 Managing General Agents during the quarter, bringing the total member count to 340, and announced a definitive merger agreement with Thoma Bravo expected to close in the first half of 2027. Due to the pending transaction, the company will not host an earnings conference call or provide guidance for the remainder of 2026.Financial Services
- ICUNov 12, 8:00 AMSeaStar Medical Holding Corporation reported net revenue of $635,000 for the third quarter of 2026, representing a 247% increase compared to the same period in 2025, driven by the adoption of its QUELIMMUNE therapy for pediatric acute kidney injury. The company achieved nearly 75% enrollment in its NEUTRALIZE-AKI pivotal clinical trial for adult patients and received Breakthrough Device Designation from the FDA for treating hyperinflammation in adults with sepsis. During the quarter, the company reported a net loss of $4.5 million, or $1.03 per share, while maintaining cash reserves of $4.0 million as of September 30, 2026.Healthcare
- CRMDNov 12, 8:00 AMCorMedix Therapeutics reported third-quarter 2026 consolidated revenue of $54.5 million and a net loss of $14.7 million, resulting in adjusted EBITDA of $3.1 million. The company announced a definitive agreement to acquire substantially all assets of Heron Therapeutics, a transaction expected to close in the first quarter of 2027 and contribute between $125 million and $150 million in revenue for the full year 2027. DefenCath sales declined to $17.2 million due to post-TDAPA pricing pressures, while the remainder of the portfolio generated $37.3 million in revenue. CorMedix maintained its full-year 2026 revenue guidance of $325 million to $345 million but narrowed its adjusted EBITDA guidance to $130 million to $140 million, while suspending 2027 DefenCath revenue guidance pending further clarity on CMS reimbursement frameworks.Healthcare
- LTCHNov 12, 7:51 AMLatch, Inc., operating as DOOR, reported third-quarter 2026 total revenue of $14.1 million, an 18.9% decrease year-over-year driven by lower hardware shipments and professional services activity. Software revenue grew 18.1% to $6.3 million, contributing to an expanded gross margin of 55.2% despite a net loss of $20.5 million that included a $13.6 million non-cash goodwill impairment charge. The company launched its OpenDOOR developer platform and executed a restructuring plan expected to reduce annualized operating costs by $10 million to $12 million. Additionally, DOOR settled a Securities and Exchange Commission investigation with a $1.0 million civil penalty and aims to achieve positive cash flow by the second half of 2027.Technology
- SGMTNov 12, 7:48 AMSagimet Biosciences initiated its registrational U.S. AURORA Phase 3 clinical trial for denifanstat in moderate to severe acne, with topline data expected in the second half of 2027. The company completed an underwritten offering of Series A common stock and pre-funded warrants in October 2026, generating $115 million in gross proceeds. As of September 30, 2026, Sagimet reported a pro forma cash balance of approximately $356 million, which is projected to fund operations through mid-2029. Additionally, the company presented positive 52-week efficacy data from its license partner Ascletis' Phase 3 trial in China and announced plans to initiate a Phase 2 trial for its FASN inhibitor TVB-3567 before the end of 2026.Healthcare
- EROCNov 12, 7:48 AMERock, Inc. reported a third quarter 2026 net income of $8.9 million and Adjusted EBITDA of $12.6 million, marking a nearly fourfold increase in revenue quarter-over-quarter to $152.8 million. The company began construction on a 366-megawatt generation facility for Meta in El Paso and expanded its manufacturing capacity with a new Atlas facility in Houston. ERock ended the quarter with $549 million in unrestricted cash, no outstanding debt, and a backlog reaching a new record level. The company reaffirmed its full-year 2026 guidance, projecting revenue between $435 million and $465 million and Adjusted EBITDA between $3 million and $9 million.Industrials
- ENVXNov 12, 7:44 AMEnovix Corporation reported Q3 2026 revenue of $11.0 million, representing a 38% year-over-year increase driven by strong demand in the drone and defense sectors. The company achieved a record non-GAAP gross margin of 34.5% and announced a new fiscal year 2027 revenue guidance range of $65 million to $85 million. Strategic initiatives included retiring $128 million of 2030 Notes at a 36% discount, executing a restructuring to reduce annual costs by $8.5 million, and expanding battery production capacity in South Korea. Additionally, Enovix declared a warrant dividend to retire its 2028 Notes and shifted its silicon-anode development focus toward smart eyewear applications following qualification challenges in the smartphone market.Industrials
- TSHANov 12, 7:38 AMTaysha Gene Therapies reported a net loss of $39.1 million for the third quarter of 2026, driven by increased research and development expenses related to its TSHA-102 clinical trials. The company successfully completed a BLA-enabling Process Performance Qualification manufacturing campaign for TSHA-102, which met all predefined product specifications and comparability criteria. As of November 2026, TSHA-102 has been generally well tolerated across 33 patients in the REVEAL and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed. Taysha expects to report topline data from the six-month interim analysis of the REVEAL pivotal trial and receive FDA feedback on its BLA submission pathway in the first half of 2027.Healthcare
- FBYDNov 12, 7:35 AMFalcon's Beyond Global, Inc. reported consolidated revenue of $7.3 million for the third quarter of 2026, representing an 80% increase compared to the prior year period. The company recorded a consolidated net loss of $7.7 million and an Adjusted EBITDA loss of $7.4 million for the quarter, though both metrics showed improvement over the previous year. Key unconsolidated entities contributed significantly to the results, with Falcon's Creative Group generating $5.2 million in revenue and the joint venture Producciones de Parques generating $11.8 million. The company's contracted pipeline for attractions and creative services totaled $28.0 million as of the end of the quarter.Industrials
- CAPSNov 12, 7:35 AMCapstone Holding Corp. reported third-quarter 2026 revenue of $20.0 million, representing a 46% year-over-year increase, with income from operations reaching $0.4 million. The company's Stone Business Adjusted EBITDA for the quarter was $1.5 million, and full-year revenue guidance was revised downward to approximately $70 million due to higher interest rates impacting housing activity. Despite these macroeconomic headwinds, organic revenue grew 7.5% in the third quarter, and all three operating businesses outperformed their respective markets.Basic Materials
- SBDSNov 12, 7:35 AMSolo Brands, Inc. reported fiscal 2026 third-quarter net sales of $43.7 million, a 17.6% decrease from the prior year period, driven by lower unit volumes and retail channel softness. Despite the revenue decline, the company achieved positive operating cash flow of over $6 million and improved segment adjusted EBITDA across its Solo Stove, Chubbies, and Watersports divisions. Consolidated net loss for the quarter was $20.8 million, while adjusted net loss narrowed to $11.6 million, reflecting disciplined cost management and reduced promotional activity. For the full year 2026, the company updated its guidance to project net sales between $270 million and $290 million and adjusted EBITDA between $21 million and $25 million.Consumer Cyclical
- ALTNov 12, 7:33 AMAltimmune, Inc. reported a net loss of $31.6 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its PERFORMA Phase 3 trial in MASH and RESTORE Phase 2 trial in ALD. The company holds $480 million in cash, cash equivalents, and investments as of the end of the quarter. Clinical progress includes the ongoing global PERFORMA Phase 3 trial in MASH with topline data anticipated in 2029, positive RECLAIM Phase 2 data in AUD presented at AASLD, and a scheduled End-of-Phase 2 meeting with the FDA for the AUD program in December 2026. Additionally, enrollment is complete for the RESTORE Phase 2 trial in ALD, with topline data expected in the second half of 2027.Healthcare
- LUNRNov 12, 7:32 AMIntuitive Machines reported record third-quarter 2026 revenue of $269 million, driven by satellite production, lunar delivery, and ground communication services. The company achieved a gross margin of $69 million (26%) and generated positive free cash flow of $33 million during the quarter. Backlog reached a record $1.9 billion, an increase of $1.7 billion from the end of 2025, fueled by new awards including NASA's CLPS 2 contract and the Accelerated Missile Defense Tranche 3 constellation. Full-year 2026 revenue is projected to fall between $920 million and $950 million, with the company expecting positive Adjusted EBITDA for the year.Industrials
- YSWYNov 12, 7:30 AMYesway, Inc. reported third-quarter 2026 net income of $24.8 million and Adjusted EBITDA of $59.6 million, reflecting growth in both fuel and inside merchandise categories. The company achieved a 1.9% year-over-year increase in same-store inside merchandise sales and a 1.1% increase in same-store fuel gallons sold, while total fuel gallons rose 4.8% to 164.7 million. Yesway opened two new stores during the quarter, including its first location in Arizona, bringing its total store count to 423 as of September 30, 2026. The company reaffirmed its full-year 2026 outlook, projecting Adjusted EBITDA between $235 million and $245 million and capital expenditures between $85 million and $95 million.Consumer Defensive
- LGNNov 12, 7:23 AMLegence Corp. reported record third-quarter 2026 revenues of $1.31 billion, representing an 85% increase from the prior year, driven by strong demand in the Installation & Maintenance segment. The company achieved a non-GAAP Adjusted EBITDA of $177.0 million, a 99% year-over-year increase, while total backlog and awarded contracts reached a record $5.90 billion. Following the acquisition of The Bowers Group, Inc., Legence raised its full-year 2026 revenue guidance to $4.87–$4.91 billion and established 2027 guidance of $5.3–$5.6 billion. Additionally, the Board authorized a $150 million stock repurchase program to reflect the company's strong financial position and capital allocation strategy.Industrials
- TWSTNov 12, 7:19 AMTwist Bioscience reported record full-year fiscal 2026 revenue of $459.4 million, representing a 22% increase over the prior year, with fourth-quarter revenue reaching $126.6 million. The company achieved a gross margin of 52.4% for the full year and posted positive adjusted EBITDA of $2.2 million in the fourth quarter. Fiscal 2027 revenue guidance is set between $550 million and $560 million, reflecting an expected 21% year-over-year growth at the midpoint. As of September 30, 2026, the company maintained a cash position of approximately $582 million while expanding its customer base to roughly 4,100 clients.Healthcare
- FLYXNov 12, 7:17 AMflyExclusive, Inc. reported consolidated revenue of $111 million for the third quarter of 2026, representing a 21% year-over-year increase. The company achieved a positive Adjusted EBITDA of $5.1 million, driven by a 95% year-over-year rise in gross profit and a 38% increase in MRO revenue. Operational efficiencies were highlighted by a 7% growth in flight hours despite a 19% reduction in the aircraft fleet, alongside a 930 basis point improvement in dispatch availability. Additionally, the company reduced long-term notes payable by $106 million since 2024 while maintaining a $92 million at-the-market facility availability.Industrials
- IPSCNov 12, 7:16 AMCentury Therapeutics reported a net loss of $23.5 million for the third quarter ended September 30, 2026, with research and development expenses decreasing to $18.1 million due to portfolio prioritization. The company maintains a cash position of $174.1 million, providing a runway into the first quarter of 2029. Nonclinical data for its CNTY-813 therapy demonstrated sustained normoglycemia in diabetic mice, supporting an anticipated IND submission in the fourth quarter of 2026. Additionally, the CD19-targeted CAR-iT cell therapy CNTY-308 remains on track to enter clinical trials in 2026 following alignment with health authorities.Healthcare
- GENBNov 12, 7:16 AMGenerate Biomedicines reported third-quarter 2026 financial results showing a net loss of $87.7 million and revenue of $4.2 million, with cash and marketable securities totaling $404.2 million as of September 30, 2026. The company advanced its lead candidate GB-0895, an AI-engineered anti-TSLP antibody, into two Phase 3 asthma studies and demonstrated sustained six-month pharmacological activity in COPD patients. Strategic partnerships were established with Zealand Pharma for a $30 million upfront payment to develop obesity therapeutics and with Anthropic to apply agentic AI to CAR T-cell research. Clinical progress included enrollment in the second cohort for GB-4362 in urothelial cancer and the first patient dosing for GB-5267 in ovarian cancer.Healthcare
- DPCNov 12, 7:15 AMDPC Holdings reported record third-quarter 2026 revenue of $308 million, representing a 39% year-over-year increase driven by strong performance in its Aerospace and Industrial Gas Turbine segments. The company achieved a net income of $32 million, a significant turnaround from a $42 million loss in the same period last year, while adjusted EBITDA rose 56% to $58 million. Strategic milestones included the acquisition of a 50% stake in Montana Precision Products, the signing of a fifth major customer partnership expected to generate over $100 million in annual incremental revenue by 2032, and the refinancing of debt facilities with a new $325 million credit line. Consequently, DPC Holdings raised its full-year 2026 revenue guidance to a range of $1.115 billion to $1.13 billion and introduced full-year 2027 guidance projecting revenue between $1.23 billion and $1.33 billion.Industrials
- ADIGNov 12, 7:15 AMADI Global Distribution reported a net loss of $655 million for the third quarter of 2026, driven primarily by a $659 million non-cash goodwill impairment charge triggered by residential market weakness. Net revenue for the quarter reached $1,306 million, representing a 9% year-over-year increase, while gross margin declined to 20.9% due to unfavorable product mix and inventory charges. The company lowered its full-year 2026 financial guidance, projecting net revenue between $4.91 billion and $4.93 billion and Adjusted Standalone EBITDA between $230 million and $240 million. Management cited continued challenges in the residential sector and weaker demand for Exclusive Brands products as key factors necessitating the revised outlook.Technology
- MWHNov 12, 7:14 AMSOLV Energy reported third-quarter 2026 revenue of $1.242 billion, representing a 65% year-over-year increase, with full-year revenue reaching $2.87 billion. The company achieved net income of $123 million for the quarter and $162 million year-to-date, driven by higher operating income and reduced interest expenses following the repayment of term debt. SOLV Energy raised its full-year 2026 financial guidance, projecting revenue between $4.03 billion and $4.12 billion and adjusted EBITDA between $525 million and $540 million. Additionally, the company completed the acquisition of ASB Energy Services in October 2026 and reported a total backlog of approximately $9.2 billion as of September 30, 2026.Utilities
- ABSINov 12, 7:11 AMAbsci Corporation reported third-quarter 2026 financial results showing $0.3 million in revenue and a net loss of $33.3 million. The company advanced its ABS-201 program for pattern hair loss, with 13-week interim proof-of-concept data anticipated in December 2026, and announced plans for a Phase 2 trial in endometriosis to begin in mid-2027. Absci appointed Gerry Muhle as Chief Commercial Officer to support the commercialization of its pipeline. As of September 30, 2026, the company held $173.7 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the second half of 2028.Healthcare
- DAIONov 12, 7:10 AMData I/O Corporation reported third-quarter 2026 net sales of $4.9 million and bookings of $5.0 million, reflecting a recovery in platform equipment demand despite softness in adapter sales. The company achieved a gross margin of 58.0% and recorded an adjusted EBITDA of negative $71,000, excluding equity compensation and one-time expenses. A transformational acquisition of V-TEK, Inc. and A&J Programming, Inc. was completed in October 2026 for $23 million, expanding the business into high-growth markets such as AI, data centers, and robotics. Financial results for the quarter included a net loss of $2.7 million driven by $1.5 million in one-time expenses related to debt, financing, and IT transitions. The company ended the quarter with $9.4 million in cash and subsequently secured $13.25 million in direct investment and a $7.5 million bank line of credit.Technology
- PTHSNov 12, 7:10 AMPelthos Therapeutics reported third-quarter 2026 net product revenue of $15.2 million for Zelsuvmi, representing an 114% increase from the same period in 2025. The company dispensed 12,384 units of Zelsuvmi to 4,942 unique prescribers while expanding formulary coverage to 127 million commercially covered lives. On October 30, 2026, Pelthos announced a definitive merger agreement with Castle Creek Biosciences to create a diversified biotechnology company focused on serious skin diseases, with the transaction expected to close by the end of the first quarter of 2027. For the quarter, the company recorded a net loss of $7.9 million and held a cash balance of $17.7 million as of September 30, 2026.Healthcare
- CWBHFNov 12, 7:09 AMCharlotte's Web Holdings reported a third-quarter 2026 operating loss of $3.7 million, narrowing from $5.3 million in the prior year despite revenue declining 18.3% to $9.4 million due to California hemp restrictions and reduced promotional discounting. The company successfully improved its gross margin to 46.9% by simplifying its product range and insourcing production, while total liabilities decreased significantly to $19.4 million following the conversion of convertible debentures into equity. Federal policy changes scheduled for December 11, 2026, may restrict full-spectrum products containing more than 0.4 milligrams of total THC, prompting the company to advocate for legislative protections and reintroduce broad-spectrum options in California. Additionally, the company is preparing for potential healthcare channel opportunities, including Medicare Advantage programs, while maintaining a cash position of $11.4 million.
- AADXNov 12, 7:07 AMApplied Aerospace & Defense reported record third-quarter 2026 revenue of $182.1 million, representing a 48.6% increase year over year, driven by strong demand across space, defense aviation, and advanced sensing markets. The company generated net income of $30.6 million and delivered Adjusted EBITDA of $39.7 million, while expanding its contract backlog to nearly $1.3 billion. Excluding the impact of 2026 acquisitions, organic revenue growth was 20.3%, with double-digit growth achieved in all three core end markets. For the full year 2026, the company updated its outlook to project total revenue between $660 million and $670 million and non-GAAP Adjusted EBITDA between $137 million and $142 million.Industrials
- YARWNov 12, 7:07 AMYarrow Bioscience reported a net loss of $9.7 million for the third quarter of 2026, with research and development expenses totaling $5.3 million and general and administrative expenses at $5.5 million. The company holds $268.9 million in cash and cash equivalents as of September 30, 2026, following a $172.5 million public offering completed in September, which extends its operational runway into 2030. Enrollment is ongoing for the Phase 2a portion of the DIRECTION-GD trial evaluating the anti-TSHR antibody YB-101 in patients with Graves' disease, with topline results expected in the second half of 2027. Additionally, data from a partner's Phase 1 trial in thyroid eye disease is anticipated in the same timeframe to inform global development plans.Healthcare
- PBLSNov 12, 7:07 AMParabilis Medicines reported third-quarter 2026 financial results showing $1.1 billion in cash and cash equivalents, sufficient to fund operations into 2030. The company presented updated Phase 1/2 data for zolucatetide in desmoid tumors at the ESMO Congress 2026, demonstrating a 72.2% objective response rate and a favorable safety profile. Parabilis reached alignment with the U.S. FDA on the design for the upcoming PEDESTAL Phase 3 registrational trial, which is scheduled to begin in the first half of 2027. Additionally, the company initiated a dose-ranging study for zolucatetide in familial adenomatous polyposis and entered a clinical collaboration with Revolution Medicines to evaluate the drug in combination therapies for metastatic colorectal cancer.Healthcare
- OCTVNov 12, 7:07 AMOctave Intelligence reported third-quarter 2026 total revenue of $415 million, representing a 6% year-over-year increase, while annualized recurring revenue (ARR) grew 7% to $1.17 billion. The company generated $95 million in operating cash flow and $65 million in free cash flow, with an adjusted operating margin of 28%. Recent strategic initiatives include the acquisition of Cerebre, the launch of Attune Facilities, and the release of a new version of its Alto geospatial solution. Additionally, the Board of Directors approved a $200 million share repurchase program to offset dilution and support capital allocation, while providing full-year 2026 revenue guidance between $1.64 billion and $1.66 billion.Technology
- EYPTNov 12, 7:05 AMEyePoint, Inc. reported a net loss of $95.6 million for the third quarter ended September 30, 2026, driven by $97.6 million in operating expenses primarily related to ongoing Phase 3 clinical trials. The company announced a strategic shift to prioritize its DURAVYU program for diabetic macular edema (DME), following Phase 3 trials for wet AMD that did not meet primary non-inferiority endpoints but showed significant reductions in treatment burden. To extend its financial runway, EyePoint implemented a workforce reduction of approximately 53%, expecting to generate $30 million in annualized savings. As of September 30, 2026, the company held $118 million in cash, cash equivalents, and short-term investments, with operations funded through the late third quarter of 2027.Healthcare
- CYNNov 12, 7:05 AMCyngn reported a net loss of $6.0 million for the third quarter of 2026, with revenue increasing to $156.5 thousand from $70 thousand in the prior year period. The company secured a follow-on order from a Fortune 100 heavy equipment manufacturer and achieved ISO 27001 certification alongside a zero-exception SOC 2 Type II examination. As of September 30, 2026, Cyngn held $34.9 million in unrestricted cash and short-term investments with no outstanding debt. The company also launched the DriveMod EasyLaunch program to facilitate lower-barrier adoption of its autonomous tugger technology.Technology
- MBGLNov 12, 7:03 AMMobility Global reported third-quarter 2026 revenue of $478 million, representing a 7.4% year-over-year increase driven by growth in both its CARFAX and B2B segments. The company achieved adjusted EBITDA of $195 million and net income of $42 million, marking its first full quarter as a standalone public entity. Management announced an $800 million share repurchase program and declared a quarterly dividend of $0.06 per share. Additionally, the company raised its full-year 2026 adjusted EBITDA guidance midpoint while maintaining its revenue outlook.Technology
- BKTINov 12, 7:03 AMBK Technologies reported third-quarter fiscal 2026 revenue of $25.3 million, representing a 3.6% increase year-over-year, driven by strong federal demand including a major order from the U.S. Forest Service. The company achieved a gross margin of 50.7% and net income of $3.7 million, while ending the quarter with $29.2 million in cash and no debt. Although a partial roof collapse at its West Melbourne headquarters in October temporarily disrupted BKR 9000 radio production, the company updated its full-year revenue outlook to approximately $85 million and reaffirmed its gross margin target of at least 50%. Additionally, the Board of Directors doubled its share repurchase authorization to $10 million and made a $3.0 million strategic investment in Tango Tango to expand its mission-critical software capabilities.Technology
- KARDNov 12, 7:02 AMKardigan, Inc. reported completing enrollment in Cohort 2 of the Phase 2b KINSHIP-DCM trial for its drug danicamtiv, with topline data expected in the second quarter of 2027. The company also finished enrollment in the Phase 2b KATALYST-AV trial for ataciguat, targeting aortic stenosis, and expects topline data for that study in the second half of 2027. Kardigan holds a cash position of $591.4 million as of September 30, 2026, which supports continued clinical advancement across its three programs, including the ongoing Phase 2 KARDINAL-ASH trial for tonlamarsen.Healthcare
- KPRXNov 12, 7:02 AMKiora Pharmaceuticals reported a net loss of $1.7 million for the third quarter of 2026, ending the period with approximately $16.3 million in cash and short-term investments. The company in-licensed exclusive development rights outside Asia for KIO-401, a late-stage oral calpain inhibitor, and has submitted a Type B pre-IND meeting request and an orphan drug designation request to the FDA for its use in treating Central Retinal Artery Occlusion. KIO-301 remains in Phase 2 development with the ABACUS-2 trial actively enrolling patients, while the company also expanded its commercial network by out-licensing rights in South Korea to Chong Kun Dang Pharmaceutical Corporation. Additionally, Kiora discontinued further research and development investment in KIO-104 and appointed Keith Lane as Executive Vice President of Clinical Development and Regulatory Affairs.Healthcare
- NIQNov 12, 7:01 AMNIQ Global Intelligence reported third-quarter 2026 revenue of $1,119.1 million, reflecting a 6.3% year-over-year increase and 5.8% organic constant currency growth. The company achieved its first positive GAAP net income since its IPO, recording $35.8 million in net income and $0.12 per share, while Adjusted EBITDA rose 17.8% to $263.6 million. NIQ reached a net leverage ratio of 2.9x, one quarter ahead of its target, and authorized a $150 million share repurchase program. Full-year 2026 guidance was raised to include 5.5% to 5.7% organic constant currency revenue growth and an Adjusted EBITDA margin of 23.6% to 23.8%.Communication Services
- LIENNov 12, 7:00 AMChicago Atlantic BDC, Inc. reported third-quarter 2026 net investment income of $8.3 million, or $0.36 per share, with total investment income reaching $15.4 million. The company's portfolio grew to a record fair value of $399.6 million across 39 portfolio companies, supported by $72.0 million in new funding to two borrowers during the quarter. Net assets increased by $8.0 million for the period, while the company maintained a 100% senior secured debt portfolio with a weighted average yield of 15.5%. Additionally, the Board declared a fourth-quarter dividend of $0.34 per share, and the company continues to pursue a merger with affiliated entity Chicago Atlantic Real Estate Finance, Inc.
- BWENNov 12, 7:00 AMBroadwind reported third-quarter 2026 total revenue of $22.3 million, representing a 48% year-over-year increase driven by strong demand in its Gearing and Industrial Solutions segments. The company recorded a GAAP loss from continuing operations of $1.0 million, or $0.04 per diluted share, while achieving a non-GAAP Adjusted EBITDA of $0.5 million. Total orders for the quarter reached $33.7 million, a 13% increase year-over-year, with power generation-related orders accounting for over 70% of the order book. At the end of the quarter, the company maintained liquidity of $39.7 million, including $5.9 million in total debt and financing leases.Industrials
- HYPDNov 12, 7:00 AMHyperion DeFi reported a record third-quarter 2026 net income of $39.6 million and adjusted EBITDA of $48.7 million, marking the third consecutive quarterly record. The company achieved breakeven core operating earnings of $0.56 million and positive adjusted net operating cash flow of $62,695, surpassing its year-end targets by one quarter. Hyperion DeFi retired all legacy debt totaling approximately $8.6 million and initiated a $20 million share repurchase program while growing its adjusted gross profit by 143% quarter-over-quarter to $2.8 million.Healthcare
- FRMINov 12, 7:00 AMFermi Inc. announced a new agreement with an investment-grade hyperscaler to advance 600 megawatts of power capacity at Project Matador, involving a $200 million prepayment and a $15 million early construction commitment. The company reported a net loss of $141.6 million for the third quarter of 2026, driven primarily by $142.2 million in general and administrative expenses, while maintaining $315.5 million in total cash and restricted cash. Additionally, Fermi terminated its data center lease with TensorWave and confirmed an ongoing partnership with the Texas Tech University System to support Project Matador development.Real Estate
- STDNNov 12, 7:00 AMStandard Nuclear reported third-quarter 2026 revenue of $6.0 million, a significant increase from $0.9 million in the prior-year period, driven by commercial TRISO fuel deliveries and development services. The company's total contract backlog more than doubled to $577.2 million, with funded backlog nearly doubling to $119.6 million, while the combined backlog and qualified pipeline reached approximately $1.4 billion. Key operational milestones included the completion and delivery of the first commercial reactor core for Radiant Industry, the substantial completion of construction at its Tennessee and Idaho production facilities, and the delivery of ultra-high-temperature fuel kernels for NASA's Nuclear Thermal Propulsion program. Despite these advancements, the company reported a net loss of $13.1 million for the quarter, primarily due to increased share-based compensation and costs associated with scaling production and public company infrastructure.Basic Materials
- AEBINov 12, 7:00 AMAebi Schmidt Group reported a 4.6% increase in third-quarter 2026 net sales to $493 million, driven by strong performance in North American Walk-In Van and Municipal sectors. Adjusted EBITDA rose 4.9% to $44.2 million, while net income significantly improved to $10.8 million despite an 80 basis point decline in gross margin due to inflationary pressures. The company updated its full-year 2026 guidance, projecting net sales between $1.95 billion and $2.00 billion and adjusted EBITDA between $170 million and $180 million. Additionally, the group announced a planned acquisition of O.J. Watson Company Inc to expand its presence in the Rocky Mountains and reported a reduction in net debt leverage to 2.66x.Industrials
- LACNov 12, 7:00 AMLithium Americas reported a net income of $96.4 million for the nine months ended September 30, 2026, driven by significant gains on financial instruments and increased interest income. The company updated its definitive capital cost estimate for the Thacker Pass Phase 1 project to $3.83 billion, reflecting increases due to labor inflation, tariff exposure, and additional contingency. Construction progress remains on track with mechanical completion targeted for late 2027, supported by a workforce of approximately 1,900 personnel and over 80% of third-party contract values committed. Financially, the company holds $1.3 billion in total cash and restricted cash as of September 30, 2026, following recent advances from the U.S. Department of Energy and the issuance of subordinated convertible debentures.Basic Materials
- AVAHNov 12, 7:00 AMAveanna Healthcare Holdings reported third-quarter 2026 revenue of $695.5 million, representing an 11.8% increase year-over-year, with net income rising to $45.5 million. Adjusted EBITDA for the quarter reached $100.1 million, a 25.0% increase compared to the prior year period. The company raised its full-year 2026 revenue guidance to greater than $2.695 billion and adjusted EBITDA guidance to greater than $374 million. For the nine-month period ended October 3, 2026, the company generated $157.5 million in net cash from operating activities and $141.2 million in free cash flow.Healthcare
- TCRXNov 12, 7:00 AMTScan Therapeutics announced a strategic reorganization to prioritize its in vivo-engineered TCR-T cell therapy program for solid tumors, advancing candidates targeting PRAME and MAGE-A4 through IND-enabling studies with a goal to dose the first patient in the fourth quarter of 2027. The company paused further enrollment in its Phase 3 ALLOHA-2 study of TSC-101 for heme malignancies due to insufficient capital and is actively seeking strategic partners for both this and its autoimmunity programs. For the third quarter of 2026, TScan reported revenue of $0.6 million and a net loss of $33.1 million, with cash and cash equivalents of $73.0 million expected to fund operations into the fourth quarter of 2027.Healthcare
- FIGRNov 12, 6:47 AMFigure Technology Solutions reported third-quarter 2026 net revenue of $287 million, representing an 84% year-over-year increase, driven by a 135% surge in Loan Marketplace volume to $5.8 billion. The acquisition of Kiavi, completed on September 1, 2026, contributed $677 million to the quarter's volume and expanded the company's presence into Residential Transition Loan and DSCR markets. Adjusted EBITDA rose 91% to $164 million, while the company maintained a cash position of $1.6 billion excluding restricted cash. Looking ahead, the company provided fourth-quarter 2026 guidance projecting Loan Marketplace volume between $6.2 billion and $6.7 billion.Financial Services
- SPBNov 12, 6:46 AMSpectrum Brands Holdings reported fiscal 2026 full-year net sales of $2.85 billion, representing a 1.5% increase, while full-year adjusted EBITDA reached $374.8 million. The company's Global Pet Care and Home and Garden segments drove growth with increases of 5.1% and 3.9% respectively, whereas Home and Personal Care sales declined by 3.0%. Fiscal 2026 fourth quarter net sales decreased 2.8% to $713.2 million, though adjusted EBITDA for the quarter rose 10.3% to $69.9 million. Looking ahead to fiscal 2027, the company forecasts flat to low single-digit growth in both net sales and adjusted EBITDA, excluding the one-time benefit of tariff refunds received in the prior year.Consumer Defensive
- TENov 12, 6:37 AMT1 Energy reported a net loss of $34.7 million for the third quarter of 2026, driven by increased inventory production and higher operating expenses. The company signed nearly 1.6 GW of new offtake contracts following a U.S. Department of Commerce Section 232 proclamation, bringing its total contracted 2027 capacity to over 3.5 GW. T1 raised $50.4 million through a private placement of convertible senior notes and received a waiver to import up to 1.725 GW of solar cells to support manufacturing while its Austin cell fab is under construction. The company has updated its full-year 2026 module production guidance to 4.0–4.2 GW and initiated preliminary 2027 guidance of 5.3 GW based on strong demand.Industrials
- NUAINov 12, 6:35 AMNew Era Energy & Digital, Inc. has contracted up to 207 MW of firm power for the Texas Critical Data Centers Phase 1 project through a 20-year agreement with Luminant, with power availability expected in the third quarter of 2027. The company completed a $64 million PIPE offering to repay borrowings and currently holds $187 million in total cash as of October 31, 2026. Phase 2 plans involve approximately 550 MW of new behind-the-meter generation with Thunderhead Energy Solutions, while the company continues advanced negotiations on lease documentation for both Phase 1 and Phase 2.Energy
- CDNLNov 12, 6:35 AMCardinal Infrastructure Group Inc. reported third-quarter 2026 revenues of $201.9 million, a 65.1% increase from the prior year, driven by organic growth and acquisitions. Despite the revenue surge, the company posted a net loss of $11.0 million and an Adjusted EBITDA margin of 4.2%, significantly below expectations due to project estimate revisions, residential pricing pressure, and rising fuel costs. In response to these performance issues, the company announced a leadership transition to strengthen project execution, postponed a proposed acquisition of Hughes Brothers, and withdrew its full-year 2026 financial guidance. Additionally, the Board authorized a $50 million share repurchase program to support capital allocation while the company focuses on operational discipline.Industrials
- EIKNNov 12, 6:35 AMEikon Therapeutics reported third-quarter 2026 financial results, ending the period with $461.7 million in cash and cash equivalents, projecting an operational runway into the first quarter of 2028. The company advanced its clinical portfolio by dosing the first patient in the registrational TeLuRide-008 trial for EIK1001 in non-small cell lung cancer and submitting an IND application for the novel androgen receptor antagonist EIK1006. Updated clinical data presented at the 2026 ESMO Congress demonstrated strong efficacy for EIK1001 in combination therapies and promising activity for its selective PARP1 inhibitors and WRN helicase inhibitor program. Additionally, the company appointed Ching-Pin Chang as Chief Scientific Officer and reported a net loss of $86.1 million for the quarter.Healthcare
- FPSNov 12, 6:33 AMForgent Power Solutions reported fiscal first quarter 2027 revenues of $479 million, representing a 69% year-over-year increase and the highest quarterly revenue in the company's history. Net income rose 252% to $55 million, while adjusted EBITDA increased 61% to $105 million, driven by strong production ramp execution and higher throughput. Based on robust customer demand and a backlog covering full-year guidance, the company raised its fiscal 2027 outlook to revenues between $2.45 billion and $2.65 billion and adjusted EBITDA between $587 million and $637 million. The company also highlighted significant growth in cash flow from operations, which improved by $130 million year-over-year to $136 million.Industrials
- ANNANov 12, 6:32 AMAleAnna, Inc. reported third-quarter 2026 net income of $6.2 million and revenue of $20.5 million, representing substantial growth compared to the second quarter of 2026. Average daily net sales gas production increased to approximately 274 thousand standard cubic meters per day, driven by robust output at the Longanesi facility and well optimization. The company achieved an Adjusted EBITDA of $12.2 million and an operating income of $9.4 million, supported by stronger realized gas prices and revenue growth that outpaced operating costs. Development progress continued on permanent facilities at Longanesi and construction at the Gradizza project, while Glen Cayley joined the Board of Directors to support the company's growth program.Energy
- WWWNov 12, 6:31 AMWolverine World Wide reported third-quarter 2026 revenue of $505.4 million, representing a 7.5% year-over-year increase, driven by strong performance in its Active Group and Work Group segments. The company achieved a gross margin of 54.6% and an operating margin of 17.7%, significantly improving upon the prior year's figures, with earnings per share rising to $0.78. These results were bolstered by $35.3 million in refunds related to IEEPA tariffs, which contributed approximately $0.31 to diluted earnings per share. Consequently, the company raised its full-year 2026 outlook, projecting revenue between $2.000 billion and $2.010 billion and adjusted diluted earnings per share between $1.95 and $1.99.Consumer Cyclical
- AIRONov 12, 6:30 AMAIRO Group Holdings reported third-quarter 2026 revenue of $17.5 million, representing a 179% increase from the prior-year period, driven by strong growth in its drone segment. The company achieved a gross margin of 57% and an adjusted EBITDA loss of $7.5 million, while maintaining a cash position of $37.8 million with minimal debt. As of November 5, 2026, AIRO's drone backlog stood at $200 million, with a total opportunity pipeline of $1.5 billion across U.S. and allied defense markets. Management expects full-year 2026 revenue growth between 15% and 25% and anticipates the majority of the current backlog will convert to revenue within the next 12 months.Industrials
- VYLRNov 12, 6:23 AMVylor, Inc. reported third-quarter 2026 pro forma net sales of $938 million, a 1% decrease from the prior year, driven by volume declines in both the Americas and Rest of World regions. Despite lower volumes caused by weather impacts and a shift to a licensing model in Brazil, the company achieved a 6% price/mix increase and reaffirmed its full-year 2026 guidance, expecting adjusted pro forma operating EBITDA of approximately $2.8 billion. The company also announced a new $3 billion share repurchase program and a quarterly dividend of $0.13 per share to reinforce its commitment to long-term value creation. Additionally, Vylor highlighted its $19 billion technology pipeline and a 2029 financial framework targeting net sales between $11.2 billion and $11.9 billion.Consumer Defensive
- KPLTNov 12, 6:17 AMKatapult Holdings reported third-quarter 2026 financial results following the August 11, 2026 merger with Aaron's and CCFI, marking its first quarter of combined operations. The company generated $753.9 million in total revenue and $110.4 million in Adjusted EBITDA, while reporting a net loss of $28.0 million driven by interest expenses and acquisition-related costs. Management identified approximately $30 million in annualized cost synergies and outlined a cautious fourth-quarter revenue outlook ranging from $975 million to $1.025 billion. The consolidated balance sheet reflects $1.95 billion in outstanding debt and $261.0 million in cash and cash equivalents as of September 30, 2026.Technology
- ENGNNov 12, 6:14 AMenGene Therapeutics is developing detalimogene voraplasmid, a non-viral gene therapy for high-risk non-muscle invasive bladder cancer (NMIBC) that activates the RIG-I pathway to induce localized immune responses. In the pivotal LEGEND study cohort, detalimogene demonstrated a 56% complete response rate at any time with a favorable safety profile, showing lower rates of treatment discontinuation compared to existing therapies. The company plans to initiate a Biologics License Application filing in the fourth quarter of 2026, with potential approval expected in 2027. Additionally, ongoing research into a surfactant bladder rinse aims to enhance drug transfection, potentially improving efficacy and reducing treatment dwell time from 60 to 30 minutes.Healthcare
- YETINov 12, 6:12 AMYETI Holdings reported third-quarter 2026 net sales of $509.4 million, a 4% increase year-over-year, while adjusted sales rose 6% to $517.9 million. Adjusted earnings per share grew 49% to $0.91, driven by an 180 basis point expansion in gross margin and a 35% increase in adjusted operating income to $90.0 million. The company updated its full-year 2026 outlook, lowering adjusted sales growth expectations to approximately 6% and adjusted EPS guidance to a range of $2.90 to $2.95 due to a cautious consumer environment. Additionally, YETI repurchased approximately 0.5 million shares for $20 million during the quarter and maintains strong liquidity with cash exceeding total debt.Consumer Cyclical
- RMTINov 12, 6:12 AMRockwell Medical reported net sales of $19.1 million for the third quarter of 2026, marking a 20% increase compared to the same period in 2025. Gross profit rose 37% to $3.1 million during the quarter, driven by higher sales volumes, while the company recorded a net loss of $2.3 million. The company announced an agreement to acquire Vantive's hemodialysis business, including manufacturing facilities in Italy, which is projected to generate annual revenue between $400 million and $450 million. Additionally, Rockwell Medical was named to the 2026 Fortune Best Workplaces in Manufacturing & Production list for the third consecutive year.Healthcare
- MRMDNov 12, 6:09 AMMariMed Inc. reported record third-quarter 2026 revenue of $44.2 million, representing a 5.5% sequential increase and an 8.5% year-over-year growth. The company achieved a non-GAAP adjusted EBITDA of $4.7 million, up 18% from the previous quarter, while maintaining a non-GAAP gross margin of 40%. Both wholesale and retail segments contributed to this growth, with wholesale revenue rising 5.2% sequentially and retail transactions increasing 2% sequentially. MariMed ended the quarter with $10.4 million in cash and cash equivalents, marking its strongest cash position in over two years.
- TTEKNov 12, 6:08 AMTetra Tech reported record fourth-quarter earnings per share of $0.51 and fiscal year 2026 adjusted earnings per share of $1.60, driven by strong performance in its global commercial and government businesses. The company achieved fourth-quarter revenue of $1.34 billion and full-year revenue of $5.08 billion, while its backlog grew 13% year-over-year to reach $4.67 billion. Significant contract wins included a $1.4 billion agreement with NASA and multiple awards totaling over $400 million from the U.S. Navy, EPA, and other federal agencies. Additionally, the Board approved an 11% increase in the quarterly dividend to $0.072 per share and repurchased $100 million of common stock during the quarter.Industrials
- EPCNov 12, 6:07 AMEdgewell Personal Care reported fourth-quarter fiscal 2026 net sales of $484.1 million, representing a 3.0% increase over the prior year, while full-year net sales reached $1,996.5 million, up 1.8%. The company posted adjusted earnings per share of $0.78 for the quarter and $1.93 for the full fiscal year, both showing significant growth compared to the previous period. Despite incurring $101.8 million in pre-tax restructuring costs for the year, the company maintained positive adjusted operating income and EBITDA. Edgewell declared a quarterly cash dividend of $0.15 per share and provided a fiscal 2027 outlook projecting adjusted EPS between $1.85 and $2.15.Consumer Defensive
- ENSNov 12, 6:06 AMEnerSys reported second-quarter fiscal 2027 net sales of $949.9 million, matching the prior year period, while achieving a gross margin of 29.9% and diluted earnings per share of $2.42. The company returned $140 million to shareholders through share repurchases and dividends, resulting in a net leverage ratio of 0.8 times EBITDA. EnerSys announced a proposed acquisition of Ultralife to expand its defense power portfolio, with the transaction expected to close in the fourth fiscal quarter of 2027. For the full year, the company expects capital expenditures of approximately $70 million and provided third-quarter net sales guidance between $935 million and $975 million.Industrials
- PXLWNov 12, 6:06 AMPixelworks, Inc. reported net income of $75.013 million for the nine months ended September 30, 2026, driven by a significant gain from discontinued operations, while net loss from continuing operations totaled $10.14 million. For the third quarter alone, the company recorded a net loss of $2.775 million with revenue of $378,000. The company announced a multi-year device certification agreement with Meta to integrate TrueCut Motion technology into Meta's VR devices. Additionally, Pixelworks repurchased $1.2 million of its common stock and ended the quarter with approximately $50 million in cash, cash equivalents, and short-term marketable securities.Technology
- EYENov 12, 6:05 AMNational Vision Holdings, Inc. reported third-quarter 2026 net revenue of $510.5 million, representing a 4.8% increase year-over-year, driven by comparable store sales growth of 3.6% and the addition of new stores. The company achieved significant margin expansion, with adjusted operating income rising to $37.1 million and adjusted diluted earnings per share more than doubling to $0.30. Management updated its full-year 2026 outlook to reflect current market conditions, projecting adjusted comparable store sales growth between 2.0% and 3.0% and adjusted diluted EPS between $0.95 and $1.03. Additionally, the company announced a new $100 million share repurchase authorization and reported a cash balance of $60.0 million as of October 3, 2026.Consumer Cyclical
- BTBTNov 12, 6:05 AMBit Digital, Inc. reported third-quarter 2026 total revenue of $27.1 million, driven by a 232% year-over-year increase in colocation services and a return to positive GAAP earnings of $28.5 million. The company's strategic focus has shifted toward Ethereum and AI infrastructure, resulting in a 19% sequential rise in colocation revenue and a 14% increase in native ETH staking revenue. As of September 30, 2026, Bit Digital held approximately 163,726 ETH valued at $439.4 million and maintained a 59.7% ownership stake in WhiteFiber Inc. with an implied value of $487 million. Concurrently, the company continued to wind down its Bitcoin mining operations, which saw revenue decline 63% year-over-year, while reducing debt through repayments totaling $60 million in the quarter.Financial Services
- XENov 12, 6:04 AMX-energy reported third-quarter 2026 revenues and grant income of $66.3 million, a 118% increase from the prior year period, driven by expanded activities under the U.S. Department of Energy's Advanced Reactor Demonstration Program. The company received a Construction Permit from the Nuclear Regulatory Commission for Dow's Long Mott project in Texas ahead of schedule and selected Fluor Corporation to advance engineering for a second Xe-100 small modular reactor project. Operational milestones included the completion of vertical construction at the TX-1 fuel fabrication facility, the acceptance of the Xe-100 reactor into the United Kingdom's Generic Design Assessment process, and the execution of the first procurement order for steam generator components. X-energy maintained a strong balance sheet with $1.8 billion in total liquidity and zero debt outstanding as of September 30, 2026.Industrials
- TISINov 12, 6:04 AMTeam, Inc. reported a net loss of $11.1 million for the third quarter of 2026, representing a slight improvement from the $11.4 million loss in the same period the previous year. Revenue for the quarter decreased by 2.0% to $220.4 million, driven by lower activity in the United States and Canada's mechanical services segment, which was partially offset by growth in international markets. Despite the revenue decline, the company achieved an Adjusted EBITDA of $15.7 million, an 8.2% increase from the prior year, supported by structural cost reductions and commercial diversification efforts. Management has updated its full-year 2026 guidance, projecting revenue between $870 million and $890 million and Adjusted EBITDA between $56 million and $59 million, citing deferred turnaround activities and Middle East conflicts as key factors influencing the outlook.Industrials
- EZPWNov 12, 6:03 AMEZCORP, Inc. reported record fourth-quarter fiscal 2026 results with net income attributable to the company rising 28% to $34.3 million and total revenues increasing 33% to $447.1 million. The company expanded its store footprint by 41 locations during the quarter, bringing the total number of stores to 1,590 across 15 countries, and completed the acquisition of the remaining interest in SMG to make it wholly owned. Core pawn revenue grew 27% to $383.4 million, driven by a 31% increase in pawn loans outstanding to $402.8 million and higher merchandise sales margins. For the full fiscal year, net income increased 51% to $165.9 million, while diluted earnings per share rose 46% to $2.07, reflecting strong operational performance across U.S., Latin American, and SMG segments.Financial Services
- AERTNov 12, 6:03 AMAeries Technology reported second-quarter fiscal 2027 revenue of $18.1 million, representing a 4.5% increase year over year, with net income rising to $1.3 million. For the first half of the fiscal year, revenue grew 23% to $40.1 million, while operating cash flow increased approximately 98% to $4.7 million. The company reaffirmed its full-year fiscal 2027 guidance, projecting revenue between $80 million and $84 million and Adjusted EBITDA between $10 million and $12 million.Industrials
- SUNSNov 10, 5:30 PMSunrise Realty Trust, Inc. reported a GAAP net income of $2.9 million, or $0.21 per share, and Distributable Earnings of $3.2 million, or $0.24 per share, for the third quarter of 2026. The company completed its merger with Southern Realty Trust on November 5, 2026, creating a larger platform with enhanced balance sheet flexibility. During the quarter, the company paid a cash dividend of $0.30 per share, totaling $4.1 million, while Distributable Earnings per share were $0.24. For the first nine months of 2026, Distributable Earnings totaled $0.89 per share compared to $0.90 per share in declared dividends.Financial Services
- AHTNov 10, 5:28 PMAshford Hospitality Trust reported a net income of $2.5 million for the third quarter of 2026, a significant turnaround from the $69.0 million loss in the prior-year period. Comparable RevPAR increased 7.3% to $140.80, driven by a 6.1% rise in Average Daily Rate and a 1.2% increase in occupancy. The company reduced its total debt to $1.9 billion through the sale of four hotels and refinancing activities, while also securing a $17 million waiver of advisory fees from Ashford Inc.Real Estate
- ASNSNov 10, 5:17 PMActelis Networks reported third-quarter 2026 revenue of $1.1 million, representing a 68% year-over-year increase driven by federal and intelligent transportation sector deliveries. The company achieved a gross margin of 40%, up from 28% in the prior-year quarter, while operating expenses decreased by 13% to $1.9 million. Net loss for the quarter narrowed by 37% to $1.2 million, or $0.04 per share, compared to $2.0 million in the same period of 2025. Additionally, the company's cash and cash equivalents rose to $4.8 million as of September 30, 2026, reflecting continued growth in North American and Asia-Pacific markets.Technology
- SNWVNov 10, 5:09 PMSanuwave Health reported third-quarter 2026 revenues of $8.6 million, representing a 24% decline from the $11.3 million recorded in the same period of 2025. The company sold 40 Ultramist systems during the quarter, a significant drop from 155 units sold in the prior year, while gross margin remained stable at 77.3%. GAAP operating results shifted to a loss of $1.1 million compared to an operating income of $0.9 million in the previous year, driven by the absence of non-recurring gains recognized in 2025. Adjusted EBITDA for the quarter was $0.7 million, down from $3.2 million in the prior year, as the company navigated market challenges related to CMS proposed reimbursement rules.Healthcare
- CPIXNov 10, 5:06 PMCumberland Pharmaceuticals reported a net income of $77.8 million for the third quarter of 2026, driven primarily by an $81.1 million gain from its strategic transaction with Apotex Health which closed on July 1, 2026. Following the transaction, the company has shifted its focus to a development-only model, retaining $80.6 million in cash and cash equivalents while integrating its commercial brands into Apotex's U.S. business. Cumberland announced plans to submit a New Drug Application to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy, supported by positive Phase 2 trial data showing improved left ventricular ejection fraction. Additionally, the company released top-line results from a Phase 2a trial for ifetroban in systemic sclerosis, noting the drug was well-tolerated with no treatment-related serious adverse events.Healthcare
- LVONov 10, 5:00 PMLiveOne reported preliminary H1 Fiscal 2027 revenue of $37.3 million and record Audio Adjusted EBITDA of $7.8 million, representing a 619% year-over-year increase. The company revised its full Fiscal 2027 guidance to $70–$75 million in revenue and over $10 million in Adjusted EBITDA, while issuing first-time Fiscal 2028 guidance of $100 million or more. PodcastOne, a LiveOne subsidiary, achieved record first-half revenue of $31.5 million and Adjusted EBITDA of $3.0 million. Additionally, LiveOne has extinguished $25 million in debt and other liabilities since February 2026, reducing its senior debt balance to $9 million.Communication Services
- EMLNov 10, 5:00 PMThe Eastern Company reported third-quarter 2026 net sales of $75.0 million, representing a 36% year-over-year increase driven by higher shipments of truck mirror assemblies, returnable transport packaging, and the first full quarter of contribution from acquired Sungear and Crown Precision businesses. Operating profit more than tripled to $5.6 million, or 7.4% of net sales, while net income from continuing operations rose to $3.4 million, or $0.57 per diluted share. The company repaid $2 million of debt during the quarter, ending with $61 million in revolver availability, and saw its backlog increase 70% year-over-year to $126.1 million.Industrials
- DLPNNov 10, 4:59 PMDolphin Entertainment reported record third-quarter 2026 revenue of $16.0 million, an 8.3% increase year-over-year, driven by organic growth across its marketing and content production divisions. The company achieved net income of $0.2 million for the quarter, a significant turnaround from a $0.4 million loss in the same period last year, while adjusted EBITDA rose 42.9% to $1.6 million. Dolphin anticipates launching four new ventures in 2027, with the first expected in the first quarter, and highlighted upcoming film production and strategic lease expirations expected to enhance future free cash flow.Communication Services
- GOSSNov 10, 4:50 PMGossamer Bio submitted its first New Drug Application for seralutinib to treat pulmonary arterial hypertension to the U.S. FDA in September 2026. The company completed a 1-for-80 reverse stock split in September 2026 and reacquired worldwide rights to seralutinib from Chiesi in July 2026. A structured private placement provided $25 million in upfront capital with the potential for an additional $125 million upon FDA acceptance of the application. For the third quarter ended September 30, 2026, the company reported $51.2 million in cash, cash equivalents, and marketable securities, alongside a net loss of $48.1 million.Healthcare
- AZTANov 10, 4:46 PMAzenta reported fourth-quarter fiscal 2026 revenue of $167 million, representing a 5% year-over-year increase, while full-year revenue reached $622 million, also up 5%. The company posted a net loss from continuing operations of $157.9 million for the full year, primarily driven by a $149 million non-cash goodwill impairment charge, though adjusted diluted EPS for the period was $0.48. Looking ahead to fiscal 2027, Azenta forecasts total revenue between $648 million and $660 million, with adjusted EBITDA margins expected to expand by 200 to 250 basis points. Recent strategic moves include the acquisition of SynPlexity and a technology agreement with Elegen to enhance gene synthesis capabilities.Healthcare
- HYLNNov 10, 4:46 PMHyliion Holdings reported third-quarter 2026 revenue of $7.5 million, a significant increase from $0.8 million in the same period of 2025, driven by accelerated progress on military research and development services. The company delivered an additional KARNO Power Module to the U.S. Navy and initiated equipment movement to its first commercial customer site while raising its full-year 2026 revenue guidance to approximately $18 million. Anticipated military contract awards totaling $8 million before year-end would bring total new military awards for 2026 to roughly $50 million, with $45.5 million in remaining authorized funding under existing contracts. Hyliion ended the quarter with $121.4 million in cash and investments, maintaining a net loss of $11.1 million for the quarter as it consolidates manufacturing operations in Texas and advances additive manufacturing improvements.Consumer Cyclical
- INMNov 10, 4:45 PMMentari Therapeutics and InMed completed a merger on November 6, 2026, resulting in InMed being renamed Mentari Therapeutics, Inc., with the combined entity focusing on migraine prevention therapies. The transaction was structured as a reverse recapitalization where Mentari stockholders received approximately 99% of the combined company's common stock following a pre-closing financing that raised $490 million. Pro forma financial statements for the six months ended June 30, 2026, show a combined net loss of $37.3 million, while the year ended December 31, 2025, reflects a combined net loss of $26.9 million. The merger involved the conversion of Mentari's preferred stock and options into InMed securities and the elimination of InMed's legacy assets, which are now subject to a contingent value rights agreement.Healthcare
- TLFNov 10, 4:44 PMTandy Leather Factory reported third-quarter 2026 revenues of $18.5 million, representing a 7.3% increase from the prior year. The company generated an operating income of $0.6 million and a net income of $0.5 million, contrasting with a net loss of $1.4 million in the same period of 2025. Gross margin improved to 62.4% from 58.9% in the previous year, driven by operational enhancements and sales growth across retail and e-commerce channels. As of September 30, 2026, the company held $5.7 million in cash and cash equivalents following dividend payments and investments in new store locations and inventory.Consumer Cyclical
- KRMDNov 10, 4:43 PMKORU Medical Systems reported third-quarter 2026 net revenues of $11.6 million, an 11% increase from the prior year, driven by a 31.6% growth in domestic core sales. The company achieved its second consecutive quarter of positive net income, recording $0.2 million in profit and $1.3 million in adjusted EBITDA. Gross margin improved to 65.2% due to lower manufacturing costs and favorable customer mix, while total operating expenses rose slightly to $7.4 million. Consequently, the company revised its full-year 2026 revenue guidance upward to a range of $48.0 to $48.5 million and reiterated its expectation for positive adjusted EBITDA for the year.Healthcare
- EPMNov 10, 4:36 PMEvolution Petroleum reported a net loss of $3.0 million for the fiscal first quarter ended September 30, 2026, driven by unrealized losses on derivative contracts despite a 6% increase in oil, natural gas, and NGL revenues to $22.6 million. Average production for the quarter was 6,978 barrels of oil equivalent per day, with realized equivalent prices rising 11% to $35.13 per BOE due to higher oil and NGL prices. The company declared a $0.12 per share cash dividend for the second quarter, marking its 53rd consecutive quarterly payment, while returning $4.9 million to shareholders in the first quarter. Additionally, Evolution completed a farm-out of 636 net acres in the Williston Basin for approximately $2.5 million and continues to integrate recently acquired Permian Minerals assets which have exceeded production expectations.Energy
- IBIONov 10, 4:36 PMiBio, Inc. reported revenues of approximately $1.1 million for the first quarter of fiscal year 2027, ending September 30, 2026, representing a significant increase from the previous year. The company advanced its clinical pipeline by completing dosing in the single ascending dose portion of the Phase 1 trial for IBIO-600 and presenting new preclinical data showing that IBIO-610 combined with semaglutide resulted in 93% of weight loss coming from fat in non-human primates. Operating expenses rose to $9.4 million due to increased spending on consultants, outside services, and personnel costs associated with advancing multiple programs. As of September 30, 2026, iBio held $76.7 million in cash, cash equivalents, and investments in debt securities while reporting a net loss of $7.6 million for the quarter.Healthcare
- DTCXNov 10, 4:35 PMDatacentrex reported a positive third-quarter 2026 Adjusted EBITDA of $1.3 million, driven by $2.2 million in net gains from digital assets despite a GAAP net loss of $2.6 million. The company completed a $30 million investment in Eagle LNG, securing a 10.5% equity interest in the operating energy business. As of September 30, 2026, Datacentrex held approximately $29.3 million in combined cash and digital assets with no outstanding debt. Additionally, the firm began energizing a prepaid expansion of its mining fleet, which is projected to increase online hashrate by approximately 21% upon full deployment.Communication Services
- ANGXNov 10, 4:35 PMAngel reported third-quarter 2026 total revenue of $159.0 million, representing a 107.7% year-over-year increase, driven by Guild revenue growth of 95.3% to $115.6 million. The company's paying Guild membership expanded to 2.94 million, adding approximately 335,000 new members during the quarter while reducing its net loss to $5.2 million from $38.5 million in the prior year period. Angel generated positive operating cash flow of $10.3 million for the quarter and reiterated its full-year 2026 guidance for an Adjusted EBITDA loss of less than $25 million.
- SWAGNov 10, 4:35 PMStran & Company reported a 32.4% year-over-year increase in third-quarter 2026 gross profit to $9.4 million, driven by a gross margin expansion to 33.3%. The company achieved net income of $35,000 for the quarter, a significant turnaround from a $1.2 million net loss in the prior-year period. For the nine months ended September 30, 2026, total sales reached $92.7 million, resulting in a net income of $1.1 million compared to a net loss of approximately $1.0 million in the same period last year. Additionally, the Stran Loyalty Solutions segment saw its gross profit nearly double to $3.0 million in the third quarter, reflecting improved customer mix and cost management.Communication Services
- FTCONov 10, 4:34 PMFortitude Gold Corporation reported third-quarter 2026 net sales of $10.3 million and net income of $2.0 million, or $0.07 per share. The company produced a total of 2,139 gold ounces across its Isabella Pearl and County Line mines, resulting in a cash balance of $8.5 million as of September 30, 2026. During the quarter, Fortitude paid $0.9 million in cash dividends to shareholders and incurred $3.9 million in exploration expenses. The company continues to advance permitting for its Golden Mile property, targeting construction in 2027.
- UONENov 10, 4:31 PMUrban One, Inc. reported a net loss of approximately $119.2 million for the third quarter of 2026, driven by a $128.9 million impairment charge on goodwill and intangible assets. Net revenue for the period declined 5.0% to $88.0 million, with significant decreases in digital and cable television advertising revenue offset partially by political revenue and station acquisitions. The company recorded an adjusted EBITDA of $12.3 million, down from $14.2 million in the prior year, and revised its full-year 2026 adjusted EBITDA guidance to $40.0 million. Management cited adverse market conditions and weak demand in the cable TV scatter market as primary factors, while noting a focus on achieving at least $20.0 million in annualized cost savings.Communication Services
- MRDNNov 10, 4:30 PMMeridian Holdings reported a third-quarter 2026 revenue of $46.0 million and a net loss attributable to the company of $13.3 million, which included $11.5 million in non-cash impairment charges. These charges consisted of a $5.5 million write-off of the Brazilian gaming license following the country's prohibition of fixed-odds betting and a $5.9 million goodwill impairment related to the RKings and Classics for a Cause reporting unit. Despite the quarterly loss, the company achieved nine-month revenue growth of 10% to $146.3 million and generated $17.7 million in operating cash flow, enabling a 47% reduction in total debt to $24.1 million. The company has updated its full-year 2026 revenue outlook to a range of $195 million to $198 million, reflecting the suspension of operations in Brazil and lower expected revenue from its Australian segments.Communication Services
- NRTNov 10, 4:30 PMNorth European Oil Royalty Trust announced a fourth-quarter fiscal 2026 distribution of $0.20 per unit, payable on November 30, 2026, to shareholders of record as of November 17, 2026. This amount represents a decrease from the $0.31 per unit distributed in the fourth quarter of fiscal 2025 and the $0.26 per unit distributed in the third quarter of fiscal 2026. A maintenance shutdown of the de-sulfurization plant caused an overpayment of royalties during the quarter, creating a negative carry-over that is expected to reduce the first fiscal quarter of 2027 distribution. The cumulative 12-month distribution total reached $0.90 per unit, which is $0.09 higher than the previous 12-month period.
- INBSNov 10, 4:30 PMIntelligent Bio Solutions Inc. reported record fiscal first quarter 2027 revenue of $1.39 million, representing a 25% year-over-year increase and marking the third consecutive quarter of revenue exceeding $1 million. Cartridge sales, which constitute higher-margin recurring revenue, grew 32% year-over-year to account for 61% of total revenue, contributing to an expanded gross profit margin of 54.5%. During the quarter, the company submitted its FDA 510(k) premarket notification for its Intelligent Fingerprinting Drug Screening System and completed its associated clinical program. The company ended the period with $5.93 million in cash and cash equivalents while maintaining an installed base of 1,978 reader units across 516 active customer accounts.Healthcare
- NRGVNov 10, 4:30 PMEnergy Vault reported third-quarter 2026 revenue of $13.1 million, matching consensus estimates, while its contract backlog grew 147% year-over-year to reach $2.3 billion. The company achieved a GAAP gross margin of 71.0% and an adjusted gross margin of 81.1%, with total cash reserves increasing to $236 million. Strategic milestones included the acquisition of 2.3 GW of U.S. battery energy storage projects from Goshe Energy Storage and securing grid interconnection approval for the Stoney Creek project in Australia. Energy Vault affirmed its full-year 2026 revenue guidance of $290–310 million and provided preliminary 2027 guidance projecting revenue between $600–700 million and adjusted EBITDA between $40–50 million.Utilities
Research Reports
Technology →Sep 29, 2026 to Nov 13, 2026 · 388 companies
Technology Earnings Report — 2026-09-29 to 2026-11-13
Report generated: 2026-11-13 00:06:24 EST
Overview
Companies reported: 388 (2026-09-29 - 2026-11-13). Technology sector results were overwhelmingly driven by surging demand for AI infrastructure, which fueled record revenue and order backlogs across semiconductor equipment, chipmakers, and data center providers. While AI-exposed segments delivered double-digit growth and margin expansion, a clear divergence emerged as traditional consumer electronics faced headwinds from soft smartphone demand and inventory corrections. This dynamic was exemplified by massive revenue surges for companies like CoreWeave (CRWV) and Applied Materials (AMAT), contrasting sharply with distressed outliers such as GoPro (GPRO) and Spruce Power (SPRU).
Leaderboard
Top 5 by Revenue Growth (YoY)
| # | Company | Ticker | Revenue Growth YoY | Revenue |
|---|---|---|---|---|
| 1 | Boost Run Inc. | BRUN | 496% | $39.9 million |
| 2 | CoreWeave Inc. | CRWV | 168% | $3.66 billion |
| 3 | Energous Corp. | WATT | 167% | $3.4 million |
| 4 | Netlist Inc. | NLST | 149% | $105.1 million |
| 5 | GCT Semiconductor Holding Inc. | GCTS | 148.6% | $1.1 million |
Note: CoreWeave (CRWV) reported a net loss of $709 million despite the revenue surge.
Top 5 by Net Income Growth (YoY)
| # | Company | Ticker | Net Income Growth YoY | Net Income |
|---|---|---|---|---|
| 1 | Strategy Inc | MSTR | 599.6% | $19.53 billion |
| 2 | Sandisk Corp | SNDK | n/a | $8.101 billion |
| 3 | Netlist Inc | NLST | n/a | $85.4 million |
| 4 | Core Scientific Inc | CORZ | n/a | $1.2 billion |
| 5 | KULR Technology Group Inc | KULR | n/a | $4.47 million |
Net income growth rates for Sandisk, Netlist, Core Scientific, and KULR are not explicitly stated as percentages in the summaries; values are derived from reported current and prior year figures where available or noted as n/a where only current figures or non-comparable prior periods (e.g., one-time gains) are provided without a stated growth rate.
Themes
- AI infrastructure demand is the primary growth driver across the sector, fueling record revenue and order backlogs for semiconductor equipment (Applied Materials, Onto Innovation, KLA), chipmakers (AMD, Marvell, Astera Labs), and data center infrastructure providers (CoreWeave, Cerebras, Core Scientific).
- Hyperscalers and cloud providers are accelerating capital expenditure on high-performance computing, leading to significant revenue surges for networking and optical components suppliers (Cisco, Arista, Lumentum, Applied Optoelectronics) and AI-specific hardware vendors (Super Micro Computer, NVIDIA ecosystem partners).
- Strong demand in automotive and industrial sectors is supporting growth for power management and connectivity specialists (Diodes, onsemi, Infineon partners, TE Connectivity), with many companies citing double-digit growth in these end markets.
- Software and infrastructure companies are seeing accelerated adoption of AI-native platforms and agentic workflows, resulting in higher net dollar retention and ARR growth for firms like Datadog, ServiceNow, Palantir, and Fortinet.
- A divergence in performance is evident between AI-exposed segments and traditional consumer electronics, with the latter facing headwinds from smartphone softness and inventory corrections, while AI-related segments post record performance.
- Supply chain constraints, particularly regarding advanced packaging capacity and power availability, are emerging as key bottlenecks, leading to extended lead times and capacity expansions for equipment makers and data center operators.
- Pricing power remains robust for companies with differentiated AI and high-performance computing solutions, allowing for margin expansion despite rising input costs for memory and logistics in other segments.
- Strategic capital allocation is shifting toward aggressive share repurchases and dividends for cash-rich leaders (Apple, Microsoft, Broadcom, Cisco), while growth-stage AI companies are prioritizing debt financing and equity raises to fund massive infrastructure build-outs.
- M&A activity is concentrated in AI and cybersecurity, with companies acquiring specialized IP and talent to enhance their AI capabilities and secure sovereign environments, though some transactions face regulatory scrutiny.
- Cost discipline and operational efficiency are critical themes for mature software and IT services firms, with many executing restructuring plans to improve margins and redirect resources toward high-growth AI initiatives.
Market Outlook & Trends
- Revenue growth is being driven primarily by AI infrastructure buildouts, with hyperscalers and data center demand offsetting softness in consumer electronics; companies like Cerebras (CBRS), CoreWeave (CRWV), and Nvidia ecosystem partners (e.g., Applied Materials (AMAT), Marvell (MRVL)) report record bookings and multi-year contracts, while others like Diodes (DIOD) and Silicon Labs (SLAB) cite strong automotive and industrial segments.
- Backlog levels are reaching historic highs across the sector, with Cisco (CSCO) noting the "very early stages of a multi-year networking supercycle," Cerebras (CBRS) reporting $26.1 billion in remaining performance obligations, and Avnet (AVT) and TE Connectivity (TEL) seeing order surges driven by AI and connectivity solutions.
- Capacity constraints and extended lead times remain a key theme, particularly in semiconductors and equipment; Diodes (DIOD) and Microchip (MCHP) report tight channel inventory and lengthening supply chain lead times, while Applied Optoelectronics (AAOI) and CoreWeave (CRWV) face delays in power availability and construction for new data center campuses.
- Pricing power and margin expansion are evident in high-growth segments, with Cerebras (CBRS) and Netlist (NLST) achieving record gross margins, while others like Diodes (DIOD) and Microchip (MCHP) guide for margin expansion to 37% and 64-65% respectively, though some companies like TransAct (TACT) and Netgear (NTGR) face margin pressure from product mix shifts and component costs.
- Capital allocation is shifting toward aggressive infrastructure investment and M&A to secure supply and technology; CoreWeave (CRWV) raised $4.2 billion in convertible notes and increased capex to $37-39 billion, while companies like Applied Materials (AMAT), AMD (AMD), and Marvell (MRVL) are executing significant acquisitions to bolster AI and semiconductor capabilities.
- Risks identified by management include geopolitical tensions, export control disruptions, and regulatory hurdles; Peraso (PRSO) and Netlist (NLST) highlight risks related to supply chain and patent litigation, while Intel (INTC) and AMD (AMD) note regulatory uncertainties and intense competition impacting returns on AI investments.
- Several companies are pivoting toward recurring revenue models and software-as-a-service to stabilize earnings, with Rekor (REKR), ServiceNow (NOW), and Fortinet (FTNT) reporting strong ARR growth and high retention rates, while others like SoundHound AI (SOUN) and Palantir (PLTR) are transitioning from license deals to hosted structures to improve margin stability.
- Financial guidance is being raised by many leaders reflecting strong demand, with companies like Shopify (SHOP), Datadog (DDOG), and Fortinet (FTNT) increasing revenue and profitability outlooks, while others like TransAct (TACT) and ADI Global Distribution (ADIG) have lowered guidance due to supply chain delays and residential market weakness.
- Liquidity positions are generally strengthening, with many firms raising capital through equity or debt offerings to fund growth; Cerebras (CBRS) secured $7.8 billion in liquidity, while others like Netlist (NLST) and CoreWeave (CRWV) have significantly increased cash reserves to support their expansion plans.
- Strategic consolidation and M&A activity is accelerating, with companies like Broadcom (AVNW), AMD (AMD), and Marvell (MRVL) pursuing acquisitions to expand their AI and semiconductor portfolios, while others like Rackspace (RXT) and Core Scientific (CORZ) are focusing on converting capacity into high-margin operations within the enterprise AI stack.
Key Numbers
- Cisco Systems (CSCO) reported record quarterly revenue of $18.5 billion, up 24% year-over-year, with GAAP net income rising 59% to $4.6 billion.
- Applied Materials (AMAT) posted record Q4 FY2026 revenue of $10.41 billion, a 53% year-over-year increase, and non-GAAP EPS of $4.16, up 92% year-over-year.
- CoreWeave (CRWV) saw revenue surge 168% year-over-year to $3.66 billion, while Adjusted EBITDA rose 169% to $2.26 billion.
- Arista Networks (ANET) reported Q3 2026 revenue of $3.66 billion, a 58.5% year-over-year increase, with non-GAAP diluted EPS rising to $1.20.
- Super Micro Computer (SMCI) recorded net sales of $19.9 billion in Q1 FY2027, a 298% year-over-year increase, with net income reaching $1.594 billion.
- AMD (AMD) achieved record quarterly revenue of $13.4 billion, up 45% year-over-year, driven by a 97% surge in Data Center segment revenue to $8.5 billion.
- Marvell Technology (MRVL) reported preliminary Q3 FY2027 revenue consistent with guidance, while announcing an all-stock acquisition of Lumentum at an enterprise value of $115 billion.
- Palantir Technologies (PLTR) reported total revenue of $2.313 billion, a 96% year-over-year increase, with GAAP net income of $1.128 billion.
- Microsoft (MSFT) posted revenue of $92.3 billion, up 19% year-over-year, with Azure revenue surging 48% and commercial remaining performance obligations increasing 73% to $677 billion.
- Apple (AAPL) reported total quarterly revenue of $114.5 billion, a 12% year-over-year increase, with iPhone revenue reaching a September quarter record of $57.6 billion.
Outliers
- CoreWeave (CRWV) posted the strongest report with Q3 revenue surging 168% year-over-year to $3.66 billion and a record $132.5 billion revenue backlog, driven by aggressive infrastructure expansion and massive demand for AI compute capacity.
- Applied Materials (AMAT) delivered the most robust results among equipment makers, with Q4 FY2026 revenue hitting a record $10.41 billion (up 53% YoY) and non-GAAP EPS doubling to $4.16, fueled by a 64% surge in Semiconductor Systems.
- GoPro (GPRO) issued the weakest report, citing substantial doubt regarding its ability to continue as a going concern, material weaknesses in internal controls, and a 41% contraction in gross margin to 12.7%.
- Spruce Power (SPRU) reported the most concerning financial position with revenue declining 3% year-over-year to $29.7 million while cash reserves plummeted to $630,000, raising immediate liquidity concerns despite a return to net income.
Earnings Call Transcripts
More →- VITRAura Q3 2026 Earnings Call - VITRIA TECHNOLOGY INC 1d ago
- PWRBAIRD 2026 GLOBAL INDUSTRIAL CONFERENCE - QUANTA SERVICES INC 1d ago
- DGIIQ4 2026 Digi International Inc. Earnings Conference Call - DIGI INTERNATIONAL INC 1d ago
- CURICuriosityStream Third Quarter 2026 Financial Results - CURIOSITYSTREAM INC 1d ago
- ZYMESTIFEL 2026 HEALTHCARE CONFERENCE - Zymeworks Inc. 1d ago
- MXCTSTIFEL 2026 HEALTHCARE CONFERENCE - MAXCYTE INC 1d ago
- MXCTSTIFEL 2026 HEALTHCARE CONFERENCE - MAXCYTE INC 1d ago
- XENESTIFEL 2026 HEALTHCARE CONFERENCE - XENON PHARMACEUTICALS INC 1d ago
- ENGNenGene LEGEND Trial Update - ENGENE THERAPEUTICS INC 1d ago
- OPRXOptimizeRx Corporation Third Quarter 2026 Conference Call - OPTIMIZERX CORP 1d ago
- OPRXOptimizeRx Corporation Third Quarter 2026 Conference Call - OPTIMIZERX CORP 1d ago
- OPRXOptimizeRx Corporation Third Quarter 2026 Conference Call - OPTIMIZERX CORP 1d ago
- XAIRBeyond Air Financial Results for the Quarter Ended September 30, 2026 - BEYOND AIR INC 1d ago
- DGIIQ4 2026 Digi International Inc. Earnings Conference Call - DIGI INTERNATIONAL INC 1d ago
- DDIDOUBLEDOWN INTERACTIVE THIRD QUARTER EARNINGS CALL - DOUBLEDOWN INTERACTIVE CO LTD 1d ago
- ICUSeaStar Medical Reports Third Quarter 2026 Financial Results - SEASTAR MEDICAL HOLDING CORP 1d ago
- FOLDBIOMARIN PHARMACEUTICAL INC. STIFEL 2026 HEALTHCARE CONFERENCE - AMICUS THERAPEUTICS INC 1d ago
- TVTXSTIFEL 2026 HEALTHCARE CONFERENCE - TRAVERE THERAPEUTICS INC 1d ago
- BLLNSTIFEL 2026 HEALTHCARE CONFERENCE - BILLIONTOONE INC 1d ago
- BLLNSTIFEL 2026 HEALTHCARE CONFERENCE - BILLIONTOONE INC 1d ago
- OVIDSTIFEL 2026 HEALTHCARE CONFERENCE - OVID THERAPEUTICS INC 1d ago
- GTESBAIRD 2026 GLOBAL INDUSTRIAL CONFERENCE - GATES INDUSTRIAL CORP LTD 1d ago
- PMNSTIFEL 2026 HEALTHCARE CONFERENCE - PROMIS NEUROSCIENCES INC 1d ago
- FLSBAIRD 2026 GLOBAL INDUSTRIAL CONFERENCE - FLOWSERVE CORP 1d ago
- ORICSTIFEL 2026 HEALTHCARE CONFERENCE - ORIC PHARMACEUTICALS INC 1d ago
- EOLSSTIFEL 2026 HEALTHCARE CONFERENCE - EVOLUS INC 1d ago
- IMUXSTIFEL 2026 HEALTHCARE CONFERENCE - IMMUNIC INC 1d ago
- KMTSStifel 2026 Healthcare Conference - KESTRA MEDICAL TECHNOLOGIES LTD 1d ago
- QURESTIFEL 2026 HEALTHCARE CONFERENCE - UNIQURE NV 1d ago
- SRMCBAIRD 2026 GLOBAL INDUSTRIAL CONFERENCE - MSA Safety Incorporated 1d ago
Press Releases
More →- VFSVinFast's Unlimited-Mileage Battery Warranty Rewards the Freedom to Drive PR Newswire · 10m ago
- RCTRedCloud Announces Effective Date of Reverse Share Split GlobeNewswire · 13m ago
- CASTFreeCast Thanks Bill Jennings for His Board Service Business Wire · 17m ago
- VEONVEON’s Mobilink Microfinance Bank Signs Share Purchase Agreement for 82.5% Stake in Apna Microfinance Bank GlobeNewswire · 48m ago
- WVVIWillamette Valley Vineyards Announces Annual Cash Dividend for Series A Redeemable Preferred Stock PR Newswire · 1h ago
- KDPKeurig Dr Pepper Announces Pricing of Public Offering of Common Stock PR Newswire · 2h ago
- GCMGAvatar Capital Partners Secures US$156 Million First Close for Fund II and Forms Strategic Partnership with GCM Grosvenor and Teacher Retirement System of Texas PR Newswire · 3h ago
- WSMWilliams-Sonoma, Inc. announces release date for third quarter results: Thursday, November 19th, 2026 Business Wire · 3h ago
- JAGGFJaguar Mining Reports Third Quarter 2026 Results with 67% Growth in Adjusted Net Income and 46% Higher Adjusted EBITDA ACCESS Newswire · 3h ago
- LUVSOUTHWEST AIRLINES BRINGS LIVE GAMING TO 35,000 FEET, POWERED BY STARLINK PR Newswire · 3h ago
- RVPHReviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire · 4h ago
- DETXLiberty Defense Announces Investor Relations Engagement with Global Impact Advisors LLC GlobeNewswire · 4h ago
- AXREFAmarc to Participate in the Consolidation of AuRORA West ACCESS Newswire · 4h ago
- VIRVir Biotechnology Announces Pricing of Public Offering of Common Stock Business Wire · 4h ago
- SOSouthern Company announces pricing of equity units PR Newswire · 4h ago
- CLLSCellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update GlobeNewswire · 4h ago
- WYWeyerhaeuser Company Declares Dividend on Common Shares PR Newswire · 5h ago
- RAINRAIN and Tensor Networks Sign Definitive Merger Agreement ACCESS Newswire · 5h ago
- MNTNDid You Lose Money Investing in MNTN, Inc.? Robbins LLP is Investigating MNTN for Possible Violations of Securities Laws Business Wire · 5h ago
- TEOTelecom Argentina S.A. announces consolidated results for the nine-month period ("9M26") and third quarter of fiscal year 2026 ("3Q26")(2) PR Newswire · 5h ago
- AFYAAfya Limited Announces Third Quarter and Nine Months 2026 Financial Results Business Wire · 5h ago
- BIIBLEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease GlobeNewswire · 5h ago
- CPACopa Holdings Announces Monthly Traffic Statistics for October 2026 GlobeNewswire · 5h ago
- WWBWindward Bio Announces Pricing of Initial Public Offering GlobeNewswire · 6h ago
- BKDBrookdale to Present at the 2026 Stephens Annual Investment Conference | NASH2026 PR Newswire · 6h ago
- PALProficient Auto Logistics Reports Third Quarter 2026 Financial Results GlobeNewswire · 6h ago
- QUCYQuantum Cyber Reports First Revenue of ~$1.0 Million and Announces $8.0 Million Funding Commitment From Chief Executive Officer David Lazar GlobeNewswire · 6h ago
- HELEHelen of Troy Issues Statement Business Wire · 6h ago
- MXCMexco Energy Corporation Reports Financial Results for First Six Months GlobeNewswire · 6h ago
- RENGFRenegade Gold Announces Bought Deal Private Placement for Gross Proceeds of C$5 Million ACCESS Newswire · 6h ago
BNN Bloomberg
More →- Is it time to sell Nvidia stock? What investors need to know 4h ago
- Supreme Court of Canada dismisses bid to appeal B.C. foreign buyer tax case 4h ago
- PAL Airlines pulls plane out of service after it lost a wheel in two separate flights 5h ago
- FBI says US has seized US$1.2 billion worth of cryptocurrency stolen from Binance 5h ago
- Can a two-year China tariff deal protect P.E.I.’s lobster and crab industry? 6h ago
- Canada and U.S. have spoken ‘within the past few days’ about potential deal: Trade Rep. Greer 7h ago
- Ottawa serves Stellantis notice of default on funding agreement after Roshel deal 8h ago
- Scaling up LNG would have spillover benefits into oilsands, new report says 8h ago
- Hot Picks: Three U.S. biotech stocks to watch 9h ago
- Investor Outlook: Nvidia’s AI demand offers cushion after Huang’s exit 9h ago
- Lobby records show high-level meetings with government officials and Stellantis, Roshel ahead of sale announcement 9h ago
- A deepfake video network is spreading false information about the U.S. trade war: report 9h ago
- NVDANvidia sell-off continues after CEO Jensen Huang steps down 10h ago
- ‘I feel sorry for him’: Minister responds to Poilievre’s comments on immigration plan 10h ago
- Roshel, Stellantis met with PMO, Joly’s office in lead up to Brampton assembly plant deal 10h ago
- Widespread issues reported with Microsoft products: Downdetector 10h ago
- GOOGStan Wong’s Top Picks for Nov. 12, 2026 11h ago
- Champagne says energy investments set the stage for Canada's future economic growth 11h ago
- Canada's agriculture sector divided on Mercosur free trade deal 11h ago
- Apotex reports Q2 profit, raises guidance for revenue growth for the year 11h ago
- NVDAInvestors worry the AI trade might lose Nvidia’s largesse after Huang 11h ago
- S&P/TSX composite down in late-morning trading 12h ago
- B.C. home sales slide 11 per cent in October as Lower Mainland struggles 12h ago
- Democrats’ blue tsunami could be reversing travel turnoff of Canada-U.S. trade war 13h ago
- Canadian Tire courts gift shoppers with price cuts as costs squeeze consumers 13h ago
- NVDAJensen Huang resigns as Nvidia CEO 13h ago
- Small caps starting to gain traction: Brooke Thackray 13h ago
- ANTAdvocacy groups sue AI giants to freeze new models, warning of 'catastrophic' risks 13h ago
- NVDAHow Nvidia’s Jensen Huang got entangled in a China chip and spy scandal 14h ago
- Pelican AI brings 25 years of banking AI to faster, safer global payment screening 14h ago
Earnings Reports
More →- IORIncome Opportunity Realty Investors, Inc. reports Earnings for Quarter Ended September 30, 2026 7h ago
- STNStantec reports third quarter 2026 results with strong net revenue growth and record adjusted EBITDA margin; raises profitability outlook 7h ago
- ARLAmerican Realty Investors, Inc. Reports Earnings for Quarter Ended September 30, 2026 7h ago
- TCITranscontinental Realty Investors, Inc. Reports Earnings for Quarter Ended September 30, 2026 7h ago
- NUNu Holdings Ltd. Reports Third Quarter 2026 Financial Results 7h ago
- YSSYork Space Systems Reports Third Quarter 2026 Results 7h ago
- QXOQXO Reports Third Quarter 2026 Results 8h ago
- SSentinelOne Announces Date of Fiscal Third Quarter 2027 Financial Results Conference Call and Participation in Upcoming Investor Conference 8h ago
- CSCOCISCO REPORTS FIRST QUARTER EARNINGS 8h ago
- WKHSWorkhorse Group Postpones Third Quarter Earnings Release and Conference Call 8h ago
- VINPVINCI COMPASS REPORTS THIRD QUARTER 2026 EARNINGS RESULTS 8h ago
- WSEWise Group plc H1 Results for Fiscal Year 2027 8h ago
- SVBTSVB&T Corporation, Parent Company of Springs Valley Bank & Trust Company, Reports 2026 Third Quarter and Year to Date Earnings 9h ago
- SMIDSmith-Midland to Release Third Quarter 2026 Earnings on Monday, November 16 12h ago
- FBDTFirst Breach Inc. Announces Third Quarter 2026 Earnings Conference Call 15h ago
- VSXYVictoria’s Secret & Co. Invites You to Listen to the Third Quarter 2026 Earnings Call 15h ago
- CAECAE raises earnings forecast for the year even as profits fall 15h ago
- WMTWalmart To Host Third Quarter Earnings Conference Call November 19, 2026 16h ago
- CMCTCreative Media & Community Trust Announces Date for Its Third Quarter 2026 Earnings Release and Conference Call 16h ago
- SAILSailPoint Announces Date of Fiscal Third Quarter 2027 Earnings Conference Call and Participation in Upcoming Investor Conference 16h ago
- SPHSuburban Propane Partners, L.P. Announces Full Year and Fourth Quarter Results 16h ago
- TWSTTwist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results 17h ago
- NBISNebius reports third quarter 2026 financial results 17h ago
- BNBrookfield Corporation Reports 16% Increase in Earnings 17h ago
- DPCDPC Holdings Reports Record Third Quarter 2026 Results 17h ago
- EYENational Vision Holdings, Inc. Reports Third Quarter 2026 Financial Results 18h ago
- CMBTCMB.TECH ANNOUNCES Q3 2026 RESULTS ON 26/11/2026 21h ago
- PROPPrairie Operating Co. Announces Third Quarter 2026 Earnings Release Date and Conference Call 1d ago
- VITRAura Q3 2026 Earnings Call - VITRIA TECHNOLOGY INC 1d ago
- DDSCORRECTION - Dillard’s, Inc. to Report Third Quarter and Year-to-Date Results 1d ago
FDA Approvals
More →- RVPHReviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire · 4h ago
- YDESYD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease GlobeNewswire · 7h ago
- BLSMBlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire · 8h ago
- TLPHTalphera Reports Third Quarter 2026 Financial Results and Provides Business Update PR Newswire · 8h ago
- ERASErasca Reports Third Quarter 2026 Business Updates and Financial Results GlobeNewswire · 8h ago
- PRMEPrime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire · 8h ago
- RCKTRocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress Business Wire · 8h ago
- NTHINeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial GlobeNewswire · 14h ago
- NTHINeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations GlobeNewswire · 14h ago
- TSHATaysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · 16h ago
- NGENNervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury GlobeNewswire · 17h ago
- BBIOA Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End PR Newswire · 17h ago
- NTHIFDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track GlobeNewswire · 1d ago
- NTHINeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 GlobeNewswire · 1d ago
- PYPDPolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results GlobeNewswire · 1d ago
- INOINOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights PR Newswire · 2d ago
- MGXMetagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results GlobeNewswire · 2d ago
- FRNMFreenome Reports Third Quarter 2026 Financial Results GlobeNewswire · 2d ago
- GRAL1780183 - GRAIL INC Earnings Call Transcripts · 2d ago
- OWLTOwlet Expands Into Everyday Family Health With Launch of Smart Thermometer Business Wire · 2d ago
- WATWaters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma PR Newswire · 2d ago
- SRRKScholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights Business Wire · 2d ago
- BDTXBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update GlobeNewswire · 2d ago
- BDTXBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update GlobeNewswire · 2d ago
- NVOFDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound CNBC · 2d ago
- RANIRani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update GlobeNewswire · 3d ago
- LRMRLarimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia GlobeNewswire · 3d ago
- RANIRani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update GlobeNewswire · 3d ago
- TRVITrevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire · 3d ago
- HYPRHyperfine, Inc. Reports Third Quarter 2026 Financial Results Business Wire · 3d ago